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153 Summary: 
1-The  herbal  extract  of  Artemisia  has  been  regarded  to  be  anti-hyperglycaemic 
since  olden  times  and  is  commonly  used  by  diabetics  in  Libya.  The  present  work  was 
designed  to  evaluate,  test  and  determine  which  fraction  or  component  of  the  herb  had 
the  hypoglycaemic  effects  in  normal  and  streptozotocin-induced  diabetic  rats. 
2-The  plant  extract  was  administered  to  the  animals  in  their  drinking  water  and 
body  weight,  food  and  fluid  intake  and  urine  volume  were  all  monitored  daily.  Food  and 
fluid  intake  and  body  weight  gain  in  normal  rats  were  not  altered  by  treatment  with  the 
plant  extract  but  there  was  a  rise  in  the  urine  glucose  in  the  first  six  rats  but  rats  7,8  and 
9  were  not  affected  by  treatment  with  plant.  Urine  volume  was  increased  in  all  rats 
suggesting  Artemisia  jzidaica  is  a  mild  diuretic. 
3-  The  streptozotocin-induced  diabetic  rat  model,  used  in  this  study,  was 
associated  with  the  characteristic  diabetic  symptoms  of  hyperphagia,  hyperglycaemia, 
polydipsia,  weight  loss  and  urinary  glucose  excretion.  When  a  crude  aqueous  extract  of 
Artemisia  was  given  in  their  drinking  water,  it  had  little  effect  on  these  symptoms  after 
10  days  of  treatment.  Urine  glucose  was  reduced  in  the  last  two  days  and  ketones  in  the 
urine  were  abolished  by  this  treatment. 
4-  Diabetes  mellitus  is  known  to  affect  many  and  varied  parameters  in  rat  liver. 
Insulin,  biguanides  and  sulphonylureas  are  known  antidiabetic  diabetic  treatments. 
Artemisia  judaica  extract  was  tested  for  its  effect  on  hepatic  steroid  metabolism  and 
glycogen  phosphorylase  a  activity  in  comparison  with  the  above  drugs.  Clearly 
Artenzisia  does  act  as  an  insulin-mimetic  in  these  assays  by  reversing  all  the  effects 
produced  by  the  administration  of  streptozotocin.  In  particular  the  changes  in  the 
enzyme  activities  of  cytochrome  P-450  (2E1,2B  and  2C)  on  androst-4-ene-3,17-dione 
metabolism  are  all  reversed  by  the  administration  of  Arlemisia  extract  to  diabetic  rats. 
The  addition  of  insulin  and/or  Artemisia  extract  directly  to  normal  rat  hepatocytes, 
however,  did  not  have  any  effect  on  the  metabolism  of  androst-4-ene-3,17-dione.  This  is 
in  contrast  to  the  results  of  Hussin  &  Skett  (1988).  Extracts  of  other  plants,  Anvillea and  Marnibium,  similarly  showed  little  effect  on  steroid  metabolism  in  isolated 
hepatocytes. 
5-  Insulin  is  known  to  inhibit  glycogen  breakdown  by  decreasing  the  activity  of 
glycogen  phosphorylase  a  and  counteracting  the  stimulatory  effect  of  glucagon  (van  de 
Werve  and  Jeanrenaud,  1987).  In  this  study  the  effects  of  insulin  on  glycogen 
phosphorylase  a  activity  were  confirmed  as  was  the  reported  stimulatory  effect  of 
glucagon  on  the  same  enzyme.  All  of  the  plant  extracts  mimicked  insulin  in  decreasing 
glycogen  phosphorylase  a  activity.  Marrubiwn  and  Anvillea  were  more  potent  than 
Artemisia.  Artemisia,  Marrubium  and  Anvillea  when  added  together  with  insulin 
decreased  the  activity  of  glycogen  phosphorylase  a  more  than  extracts  alone  and  they 
antagonised  the  effect  of  glucagon. 
6-  A  start  was  made  in  separating  the  active  ingredient(s)  from  the  Artemisia 
judaica  extract.  From  the  results  of  the  aqueous  and  ethanolic  extracts  of  Artemisia,  it 
is  suggested  that  the  extract  contains  at  least  two  active  ingredients.  One  which 
mimicked  and  enhanced  the  effect  of  insulin  (in  the  water  extract)  and  the  other  (in  the 
ethanol  extract)  which  antagonised  the  effect  of  glucagon. 
7-  The  preliminary  results  of  human  studies  showed  that  Artemisia  judaica  had  a 
potential  use  in  treating  patients  with  diabetes  and  it  is  suggested  that  Artemisia  judaica 
contains  material  capable  of  reducing  an  elevated  blood  sugar  and  improving  diabetic 
symptoms. 
8-  It  can  be  concluded  therefore  from  the  results  of  the  present  study  that 
Artemisia  can  exhibit  significant  anti-diabetic  effects  inn-vivo  and  in-vitro  and  has  an 
insulin-like  action.  Marrubium  and  Anvillecr  when  tested  on  glycogen  phosphorylase  a 
have  the  same  action  as  insulin  but  these  were  not  further  tested  due  to  lack  of  time. 
These  findings  tend  to  endorse  the  wide  use  of  these  plants  in  Arab  folk  medicine  and 
show  a  great  potential  for  the  treatment  of  diabetes. LIST  OF  FIGURES 
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xx INTRODUCTION 1.  BACKGROUND: 
1.1  Diabetes  mellitus  : 
Diabetes  mellitus  may  be  defined  as  a  disorder  of  metabolism  in  which  a  relative 
or  absolute  deficiency  or  lack  of  effect  of  insulin  leads  to  chronic  hyperglycaemia  with 
or  without  glucosuria. 
Diabetes  has  probably  been  known  to  medical  science  longer  than  any  other 
ailment,  yet,  in  many  respects  it  is  still  poorly  understood.  It  is  characterized  by 
hyperglycaemia  (high  blood  glucose)  and  occurs  because  the  liver  and  skeletal  muscle 
cannot  store  glycogen  and  the  tissues  are  unable  to  utilize  glucose. 
There  are  two  main  forms  of  diabetes  mellitus;  type  1  and  type  2. 
Type  1  diabetes,  also  known  as  insulin  dependent  diabetes  (IDDM),  is  due  to  an 
inadequate  insulin  secretion  resulting  from  a  large  decrease  in  the  number  of  beta-cells 
in  the  islets  of  Langerhans  (Eisenbarth,  1986)  and  Type  2  diabetes,  or  non-insulin 
dependent  diabetes  mellitus  (NIDDM),  is  due  to  a  lack  of  insulin  action  in  target  tissues 
(Lillioja  et  al.,  1988)  and  /  or  insulin  resistance  that  leads  to  impaired  tissue  glucose 
uptake  and  impaired  suppression  of  hepatic  glucose  production  (Martin  et  al.,  1991). 
IDDM  is  usually  managed  by  injection  of  insulin  and  NIDDM  may  be  controlled  by 
dietary  means  such  as  weight  loss  and  diet  control,  However,  around  50%  of  NIDDM 
patients  cannot  achieve  satisfactory  control  through  diet  alone  and  require  treatment 
with  a  class  of  drugs  collectively  referred  to  as  oral  hypoglycaemic  agents  (OHA) 
(Kennedy  et  al.,  1988) 
Most  of  the  pathological  conditions  of  diabetes  mellitus  can  be  attributed  to  one 
of  the  following  three  major  effects  of  insulin  lack  (I)-  Decreased  utilization  of  glucose 
by  the  body  cells,  with  a  resultant  increase  in  blood  glucose  concentration  (2)-Markedly 
increased  mobilization  of  fats  from  the  fat  storage  areas  causing  deposition  of  lipids  in 
the  vascular  walls  due  to  abnormal  fat  metabolism  and  resulting  atherosclerosis  and 
abnormal  breakdown  of  fats  leading  to  the  formation  of  ketone  bodies  (3)-  Depletion  of 
protein  in  the  tissues  of  the  body. 
The  overall  effect  is  dehydration  of  the  extracellular  space,  which  then  causes 
dehydration  of  the  intracellular  spaces  as  well  (Bowman  &  Rand,  1983).  Glucose 
i absorbed  into  the  blood  stream  cannot  be  utilized  by  the  body's  cells  due  to  the  lack  of 
insulin,  and  consequently  blood  glucose  levels  rise.  In  an  effort  to  redress  the  situation, 
glucose  flows  out  in  the  urine  as  the  kidney  threshold  for  glucose  is  exceeded  and 
excess  glucose  cannot  be  reabsorbed.  Glucose  acts  as  an  osmotic  diuretic  and  large 
quantities  of  water  are  excreted  as  the  glucosuria  worsens.  This  makes  the  individual 
thirsty  and  the  patient  drinks  large  volumes  of  fluid  (Watkinson  et  al.,  1993).  There  is 
also  an  increased  appetite  without  any  weight  gain  which  is  particularly  evident  in 
IDDM  where  patients  have  a  tendency  to  lose  weight. 
Also,  in  type  1  diabetes,  the  excess  breakdown  of  fat  leads  to  the  formation  of 
ketones  bodies  and  organic  acids  leading  to  acidosis  (Bloom  et  at,  1985).  The  liver  is 
supplied  with  massive  amounts  of  free  fatty  acids  (FFA).  These  are  oxidized  in  the  liver 
to  provide  the  energy  required  for  glucose  synthesis,  simultaneously  releasing  large 
quantities  of  ketone  bodies  into  the  circulation.  At  the  same  time  release  of  amino  acids 
from  breakdown  of  protein  or  lactate  production  in  peripheral  tissues  supplies  the  liver 
with  the  carbon  substrates  essential  for  glucose  formation.  This  process,  which  can  be  a 
useful  source  of  both  glucose  and  ketone  bodies  for  energy  in  times  of  starvation, 
accelerates  hyperglycaemia  and  ketoacidosis  in  severe  insulin  deficiency  of  juvenile 
onset  (type  1)  diabetes.  This  ketoacidosis  only  occurs  in  IDDM  individuals,  where  there 
is  a  severe  insulin  deficiency. 
Acute  deficiency  of  insulin,  therefore  causes  a  metabolic  acidosis  (ketosis)  due 
to  the  shift  from  carbohydrate  to  fat  metabolism  in  diabetes  (due  to  the  absence  of 
insulin  this  occurs  even  normally  between  meals  when  secretion  of  insulin  is  minimal, 
but  it  becomes  extreme  in  diabetes  when  secretion  of  insulin  is  almost  zero  ).  When  the 
body  depends  almost  entirely  on  the  fat  for  energy,  the  level  of  ketone  bodies  in  the 
body  fluid  rises  mainly  derived  from  the  ongoing  activity  of  the  liver,  which  releases 
them  into  the  circulation  for  transport  to  the  heart,  skeletal  muscle,  and  other  tissues  to 
be  used  as  an  energy  source.  In  the  normal  fed  state,  the  concentration  of  ketone  bodies 
is  relatively  low  because  insulin  stimulates  the  synthesis  of  fatty  acids,  a  competing 
pathway  for  the  use  of  acetyl  CoA.  Insulin  also  inhibits  lipolysis,  thereby  decreasing  the 
supply  of  fatty  acids,  which  are  a  major  source  of  acetyl  CoA  in  the  liver.  Thus,  when 
insulin  concentrations  are  decreased,  as  occurs  in  type  I  diabetes  or  fasting,  production 
of  ketone  bodies  is  favoured.  Severe  ketosis  does  not  develop  in  normal  individuals 
2 because  only  a  small  amount  of  insulin  is  needed  to  inhibit  lipolysis  in  adipose  tissue 
(Espinal,  1989) 
NIDDM  usually  develops  after  35  years  of  age  and  most  diabetics  of  this  type 
are  obese,  and  the  hormone  is  often  present  in  plasma  at  near-normal  or  even  above- 
normal  levels,  and  therapy  often  does  not  require  administration  of  insulin  (Luciano, 
1990).  Indeed,  the  presence  of  insulin  and  the  ability  of  sulphonylureas  to  evoke  release 
of  the  hormone  are  indicative  of  NIDDM.  Because  only  a  small  amount  of  insulin  is 
needed  to  prevent  ketone  body  formation,  the  non-insulin-dependent  diabetic  rarely 
develops  ketosis.  In  some  cases  of  NIDDM  the  plasma  insulin  concentrations  are 
actually  higher  than  normal  due  to  hyporesponsiveness  to  insulin,  termed  insulin 
resistance.  This  is  explained  by  the  fact  that  the  target  cells  are  relatively  insensitive  to 
the  hormone.  In  such  resistant  cells,  a  higher  concentration  of  insulin  is  needed  to  elicit 
a  response  than  in  normal  cells.  In  some  cases  of  insulin  resistance  the  concentration  of 
insulin  receptors  appears  to  be  decreased  (Home,  1989). 
The  sequence  of  events  coupling  obesity  to  a  diminished  number  of  insulin 
receptors  is  shown  (Figure  1.1).  Because  insulin  secretion  is  increased  during  food 
absorption,  any  person  diabetic  or  not  who  chronically  overeats  secretes,  an  average, 
increased  amounts  of  insulin.  Over  time,  the  resulting  elevation  of  plasma  insulin  induces 
a  reduction  in  the  number  of  insulin  receptors.  Thus  insulin  itself  is  responsible  for  the 
decrease  in  target-cell  responsiveness  (insulin  resistance),  producing  a  higher  plasma 
glucose  concentration  at  any  given  plasma  insulin  level.  The  tendency  toward  a  higher 
plasma  glucose  concentration  is  small  in  non-diabetic  overeaters  because  the  islet  cells 
respond  by  secreting  enough  additional  insulin  to  get  the  job  done  despite  the  reduction 
in  available  receptors.  In  contrast,  the  diabetes-prone  person  may  also  secrete  additional 
insulin  but  not  enough  to  prevent  significant  hyperglycaemia 
Diabetic  coma  is  rarely  seen  in  non-insulin-dependent  diabetics,  presumably 
because  their  endogenous  insulin  prevents  ketosis.  However,  a  related  condition, 
referred  to  as  hyperosmolar  coma,  can  occur.  It  is  most  often  observed  in  elderly 
individuals  and  is  usually  preceded  by  an  illness  or  other  stressful  situation  that  increases 
the  requirement  for  insulin.  Under  these  circumstances,  the  insulin  present  becomes 
insufficient  to  prevent  glucosuria  and  excess  water  loss  leading  to  a  hyperosmolar 
plasma. 
3 EXCESSIVE  OBESITY 
OOD  INTAKE 
TPLASMA 
GLUCOSE 
Islet  beta-cells 
TINSUUH  SECRETI®N 
PLASMA  INSULIN 
-rGL000SE  UPTAKE  ---  --  ; 
',  'INSULIN  RECEPTORS 
(DOWN  REGULATION) 
''CELL 
RESPONSIVENESS 
TO  INSULIN  --  --! 
(INSULIN  RESISTANCE) 
Figure  1.1  Postulated  mechanisms  by  which  chronic  overeating  leads  to  chronically 
elevated  plasma  insulin  and  diminished  cell  responsiveness  to  insulin  (Luciano,  1986). 
4 Fluid  loss  is  compounded  when  vomiting  is  associated  with  the  precipitating 
illness.  As  dehydration  become  severe,  urinary  output  decreases  in  spite  of  the  high 
urinary  levels  of  glucose.  Thus  renal  excretion  of  glucose  falls,  and  blood  sugar  and 
serum  osmolarity  increase  to  extremely  high  levels,  leading  to  loss  of  consciousness. 
Like  diabetic  coma,  hyperosmolar  coma  is  life  threatening  and  is  a  particular  grave 
condition  in  older  diabetics,  who  may  already  have  compromised  cardiovascular 
function  (Joslin,  1989). 
Diabetes  mellitus  therefore  affects  protein,  lipid  and  carbohydrate  metabolism 
and  reflects  a  state  of  impaired  insulin  function.  The  net  effect  of  insulin  in  the  body  is  to 
increase  metabolic  energy  store  by  promoting  the  storage  of  protein,  lipid  and 
carbohydrates  (Ganong,  1989).  Thus  when  insulin  function  is  impaired,  hyperglycaemia 
results  from  the  reduction  in  glucose  uptake  and  increased  rate  of  gluconeogenesis  and 
hyperlipidaemia  results  from  increased  lipase  activity  and  reduced  deposition  of 
triglycerides.  It  is  these  dysfunctions  that  produce  much  of  the  pathology  associated 
with  diabetes  mellitus.  Diabetics  are  25  times  more  prone  to  blindness,  suffer  from  an 
increased  risk  of  myocardial  infarction  and  increased  incidence  of  peripheral  vascular 
disease  such  as  gangrene.  They  are  also  more  prone  to  renal  failure  and  to  peripheral 
neuropathy  than  non-diabetics. 
1.2  Treatments  of  Diabetes  Mellitus  : 
Type  1  (IDDM)  diabetics  lack  insulin  and  their  treatment  is  hormone 
replacement  therapy  with  insulin.  Type  2  (NIDDM)  diabetics,  however;  often  do  not 
respond  to  insulin  and  require  alternative  drugs  if  dietary  control  is  insufficient. 
There  are  two  main  classes  of  oral  hypoglycaemic  drugs,  the  sulphonylureas 
such  as  tolbutamide  and  glibenclamide,  and  the  biguanides  such  as  phenformin  and 
metformin.  Tolbutamide  and  phenformin  were  introduced  in  clinical  practice  in  1954, 
and  1957  respectively.  Tolbutamide  is  still  widely  used  though  phenformin  has  been 
withdrawn  since  1982  as  a  result  of  the  risk  of  lactic  acidosis,  (Oates  el  a!  1981). 
However  metformin  which  belongs  to  the  same  class  as  phenformin  is  the  drug  of 
choice  in  the  therapy  of  obese  NIDDM  diabetes.  The  use  of  sulphonylureas,  the  other 
S class  of  hypoglycaemic  agents,  is  also  not  without  its  problems  and  side  effects.  They 
have  adverse  effects  including  coma  (Ferner  and  Neil,  1988)  particularly  in  the  elderly 
and  patient  with  impaired  hepatic  or  renal  function  who  are  taking  longer  acting 
sulfonylureas. 
Sulfonylureas  and  metformin  are  valuable  treatments  for  hyperglycaemia  in 
NIDDM,  but  they  are  often  unable  to  lower  glucose  concentrations  to  within  the  normal 
range,  or  to  reinstate  a  normal  pattern  of  glucose  homeostasis  (Lebovitz,  1985;  Bailey 
&  Nattrass,  1988).  Even  insulin  therapy  does  not  reinstate  a  normal  pattern  of  glucose 
homeostasis  in  most  NIDDM  patients,  and  over  vigorous  insulin  treatment  may  carry an 
increased  risk  of  atherogenesis  and  hypoglycaemia  (Peacock  &  Tattarsall,  1984  ). 
As  a  result  of  these  numerous  side  effects  of  oral  hypoglycaemic  drugs,  there  has 
been  an  increase  in  research  of  other  potential  oral  hypoglycaemics  and  renewed  for 
attention  to  alternative  medicines  and  natural  therapies.  This  has  stimulated  a  new  wave 
of  research  in  traditional  practices  and  the  World  Health  Organization  Expert 
Committee  on  Diabetes  has  listed  these  as  one  of  the  treatment  for  diabetes  which 
should  be  further  investigated  (Watt  &  Wood,  1988;  WHO  Expert  Committee,  1980). 
Traditional  oral  hypoglycaemic  plants  might  provide  a  useful  source  of  new  oral 
hypoglycaemic  compounds  for  development  as  pharmaceutical  entities,  or  as  simple 
dietary  adjuncts  to  existing  therapies.  The  known  use  of  plants  for  diabetes  dates  from 
the  Ebers  papyrus  of  about  1550BC  and  many  traditional  plant  treatments  for  diabetes 
are  used  throughout  the  world  (Bailey  &  Day,  1989).  After  the  introduction  of  insulin 
therapy,  the  use  of  traditional  treatments  for  diabetes  greatly  declined  in  societies, 
although  some  plant  extracts  are  still  used  as  prophylactics  and  adjuncts  to  conventional 
medicine. 
For  this  purpose  the  natives  of  Libya  use  a  hot  water  decoction  made  from  the 
whole  plants,  Artemisia  Juidaic 
, 
Anvillea  carcinii  and  Marnubizmt  umgare.  There 
appears  to  be  no  documented  reports  on  the  antidiabetic  activity  of  Artemisia  judaica, 
Marrubium  vulgare,  and  Anvillea  carcinii,  although  there  is  a  report  on  Artemisia 
abyssinia  which  indicates  that  it  has  hypoglycemic  activity  (Mossa,  1985).  Extracts  of 
Artemisia  judaica  have  been  shown  to  have  effects  on  the  heart  (digitalis-like)  (Gala  el 
al.,  1974)  and  on  the  isolated  guinea-pig  ileum  (Abdalla  &  Zarga  1987).  Arlemisia 
herba  alba  has  also  been  used  by  the  local  populations  of  some  Middle  East  countries  as 
6 an  anthelminthic  (Khaffagy  et  at,  1988),  and  also  it  has  antidiabetic  (Husni  &  Al-Badr, 
1988,  Farjou  et  at,  1987,1988,  Al-Kazraji  cat  crl.,  1993)  and  antibacterial  (Hussein- 
Ayuob  1990)  actions.  In  1986,  Abdalla,  found  a  parasympathomimetic  compound  in  a 
crude  extract  of  Arlemisia  judaica  which  stimulated  muscarinic  receptors  and  also 
certain  anticancer  agents  have  been  found  (Alwan  et  at,  1989).  Artemisinin,  santonin, 
judaicin,  and  cirsimaritin  have  been  isolated  from  Artenrisia  sp  (Khaffagy  &  Tosson, 
1968). 
In  this  study  the  anti-diabetic  properties  of  the  plants  Artemisia  judaica, 
Anvillea  carcinii  and  Marrubirmr  vulgare  L  are  investigated.  These  plants  will  be 
discussed  in  detail  later.  It  is  the  aim  of  the  project  to  validate  scientifically  the  use  of 
these  plants  in  the  treatment  of  diabetes.  These  plants  have  been  used  successfully  in  the 
treatments  of  diabetes  in  Libya  as  well  as  other  Arabic  speaking  countries  but  they  have 
not  received  much  in  the  way  of  medical  or  scientific  scrutiny. 
1.3  Glycogen  Phosphorylase 
1.3.1  Function  and  Regulation: 
Glycogen  phosphorylase  plays  a  central  role  in  the  mobilization  of  carbohydrate 
in  a  wide  variety  of  organisms  including  bacteria,  fungi,  plants  and  insects.  It  catalyses 
the  first  step  of  the  intracellular  degradation  of  glycogen,  where  inorganic  phosphate 
(Pi)  is  used  in  the  cleavage  of  an  [al-+4]  glucosidic  bond  to  yield  glucose  I-phosphate 
according  to  the  equation. 
(a-1,4-glucoside)n  +  P144(a-1,4-glucose),, 
_  j+  a-D-glucose  1-phosphate 
(G1c1P) 
Glycogen  phosphorylase  catalyses  both  the  forward  and  the  reverse  reaction.  Under  in- 
vivo  conditions  the  phosphate  concentration  is  usually  so  high  that  the  catalyzed 
reaction  is  in  the  direction  of  glycogen  degradation. 
7 Glycogen  phosphorylase  can  exist  in  two  forms,  a  and  b.  Inactive  phosphorylase 
b  can  be  activated  in  two  ways,  namely  (a)  by  covalent  alteration  through 
phosphorylation  of  ser-14  at  its  terminal  tail  (giving  glycogen  phosphorylase  a  ;  GPHa) 
in  response  to  hormone  and  neural  signals,  and  (b)  allosteric  binding  to  the  activator 
AMP. 
1.3.2  Role  of  Insulin  and  Glucagon  in  control  of  glycogen  metabolism: 
In  the  transition  between  the  fed  state  and  periods  of  short  fasting,  the  net 
hepatic  glucose  output  is  determined  by  the  reciprocal  activities  of  glycogen  synthase 
and  glycogen  phosphorylase.  The  regulation  of  the  activation  and  inactivation  of  both  of 
these  enzymes  has  been  the  object  of  intense  investigation,  particularly  with  regard  to 
the  roles  of  various  hormones,  including  insulin  and  glucagon. 
Insulin  has  also  been  implicated  as  a  major  regulator  of  hepatic  glucose  output. 
Hers  (1976)  demonstrated  that  in  the  isolated  perfused  liver,  insulin  acts  to  decrease 
hepatic  glucose  output.  Miller  and  Larner  (1973)  have  reported  that  insulin  acts  to 
promote  glycogen  synthesis  by  a  direct  activation  of  glycogen  synthase.  Witters  el  al. 
(1978)  found  that  both  glucose  and  insulin  are  major  regulators  of  hepatic  glycogen 
synthase  and  glycogen  phosphorylase  in  hepatocytes  isolated  from  fed  rats.  In  1967, 
Bishop  et  al.  demonstrated  that  insulin  administered  iii-vivo  activates  dog  liver  glycogen 
synthase  and  inactivates  phosphorylase.  Glucagon  reverses  these  changes. 
Several  studies  have  suggested  that  control  of  glycogen  metabolism  in  liver  is 
regulated  by  a  cascade  enzyme  system  that  is  similar  to  the  one  already  established  in 
skeletal  muscle  (Krebs,  1962;  Hers,  1961).  Glucagon  stimulates  the  formation  of  active 
phosphorylase  a  (Sutherland  &  Robinson,  1951)  and  converts  glycogen  synthase  from 
an  active  form  into  an  inactive  form  (Stalman  &  Hers,  1971).  Insulin  on  the  other  hand, 
converts  glycogen  synthase  from  an  inactive  form  into  an  active  form,  both  in-vivo  and 
in-vitro  (Bishop  &  Larner,  1967;  Kreutner  &  Goldberg,  1967;  DeWulf  &  Hers,  1968). 
There  is  general  agreement  that  insulin  antagonizes  the  effect  of  glucagon  on  glycogen 
metabolism  (Beesj  et  al.,  1995).  Miller  and  Larner  (1973)  concluded,  after  examining 
the  effect  of  insulin  on  hepatic  glycogen  synthase  by  use  of  either  diabetic  or  glucagon- 
stimulated  normal  rats,  that  insulin  increases  the  formation  of  glycogen  synthase  with  a 
8 concomitant  decrease  in  cyclic  AMP-dependent  glycogen  synthase  kinase  activity. 
Insulin  appears  to  interfere  with  glucagon  action  by  reducing  the  elevated  levels  of 
cAMP  (Blackmore  et  al  1979). 
1.4  Pancreatic  Hormones: 
1.4.1  Insulin: 
An  increase  in  blood  glucose  signals  the  release  of  insulin  from  the  beta  cells  of 
the  pancreas.  Insulin  circulates  in  the  blood,  serving  as  first  messenger  to  inform  several 
tissues  that  excess  glucose  is  present.  Insulin  receptors,  located  on  the  plasma 
membranes  of  insulin-responsive  cells,  respond  to  insulin  binding  by  producing 
secondary  messengers  that  mediate  insulin  action  and  promote  glucose  use  within  these 
tissues.  The  pancreas  responds  to  a  decrease  in  blood  glucose  with  less  release  of  insulin 
but  greater  release  of  glucagon  (Harris,  1992).  Insulin  increases  glucose  utilization  rates 
in  part  by  promoting  glycogenesis  and  inhibiting  glycogenolysis  in  liver  (Figure  1.2). 
Insulin  promotes  glycogen  accumulation  in  liver  by  activating  glycogen  synthase  and 
inactivating  glycogen  phosphorylase  (Harris,  1992).  Insulin  is  known  to  inhibit  glycogen 
breakdown  by  decreasing  the  activity  of  glycogen  phosphorylase  a  (van  de  Werve  & 
Jeanrenaud,  1987). 
1.4.1.1  Mechanism  of  action  of  insulin 
The  enzymatic  pathway  involved  in  glycogen  synthesis  and  breakdown  has  been 
characterized  in  most  mammalian  tissues.  Glycogen  synthesis  in  liver  is,  at  least 
partially,  controlled  by  the  activity  of  glycogen  synthase,  the  enzyme  responsible  for 
catalyzing  the  incorporation  of  glucose,  via  uridine  diphosphoglucose,  into  glycogen 
(Letoir  &  Cardini,  1957).  The  effect  of  insulin  is  to  promote  the  activation  of  glycogen 
synthase  from  a  glucose-6-P-dependent  to  a  glucose-6-P-independent  form.  Witter  el 
al.  (1978)  have  reported  that  insulin  acts  to  promote  glycogen  synthesis  by  a  direct 
9 activation  of  glycogen  synthase  (Figure  1.2).  It  has  become  widely  accepted  that  insulin 
promotes  the  arrest  of  glycogenolysis  and  the  deposition  of  glycogen  in  the  liver.  A 
partial  inactivation  of  glycogen  phosphorylase  has  been  observed,  although 
inconsistently,  in  anaesthetized  rats  (Stalmans  el  al.,  1974)  and  much  more 
systematically  in  rhesus  monkeys  (Curnow  el  al.,  1975  ). 
Thus  by  measurement  of  glycogen  alone,  it  appears  that  the  current  concepts  of 
insulin  action  at  the  biochemical  level  are  unable  to  explain  all  of  the  effects  observed  In- 
vivo.  Insulin  could  act  by  lowering  the  hepatic  concentration  of  cyclic  AMP.  Such  an 
effect  can  be  readily  demonstrated  with  isolated  liver  preparations  when  the 
concentration  of  the  nucleotide  has,  been  previously  increased  by  glucagon  or  adrenaline 
(Exton  el  al.,  1971).  Whereas  the  inactivation  of  phosphorylase  was  a  constant  feature 
following  the  administration  of  insulin,  the  activation  of  glycogen  synthase  occurred 
only  occasionally.  The  activation  of  synthase  was  only  observed  when  phosphorylase 
activity  had  reached  a  very  low  value  (Stalmans  e1  al.,  1975).  The  activity  of  glycogen 
phosphorylase  and  synthase  is  controlled  to  a  great  extent  by  phosphorylation,  which  in 
turn  is  catalysed  by  the  cAMP-dependent  protein  kinase  (protein  kinase  A).  Thus 
changes  in  the  level  of  cAMP  by  insulin  may  have  a  marked  effect  on  the  activity  of  the 
glycogen  phosphorylase  and  synthase.  The  same  pattern  of  reciprocal  changes  in 
phosphorylase  and  synthase  has  been  noted  in  a  study  with  anaesthetized  mice  treated 
with  glucose  (Stalmans.  et  al.,  1974).  Insulin  has  also  been  implicated  as  a  major 
regulator  of  hepatic  glucose  output.  The  studies  of  Witter  &  Avrub  (1978) 
demonstrated  that,  in  the  isolated  perfused  liver,  insulin  acts  to  decrease  hepatic  glucose 
output.  Glycogen  phosphorylase  activity  may,  therefore,  be  a  better  measure  for 
insulin-like  activity  than  glycogen  synthase  or  glycogen  concentration  alone. 
1.4.2  Glucagon 
Even  though  insulin  plays  a  central  role  in  controlling  the  metabolic  adjustments 
between  the  absorptive  and  post-absorptive  states,  the  secreted  product  of  pancreatic 
islet  A-cells,  glucagon,  is  also  very  important.  It  seems  that  glucagon  secreting  A-cells 
and  insulin  secreting  ß-cells,  as  a  coupled  endocrine  system,  is  a  major  factor  in  the 
regulation  of  fuel  metabolites. 
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Figure  1.2  Insulin  acts  via  secondary  mediators  of  its  action  to  inhibit  glycogenolysis 
and  promote  glycogen  synthesis  in  liver  (adapted  from  Harris,  1992). 
11 Glucagon  has  many  effects  on  the  same  metabolic  processes  that  are  influenced  by 
insulin.  It  has  the  opposite  effect  to  insulin  and  again  the  liver  is  the  major  site  of  action 
of  glucagon. 
1.4.2.1  Mechanism  of  action  of  glucagon 
Glucagon  is  released  from  the  A-cells  of  the  pancreas  in  response  to  low  glucose 
levels  in  the  blood.  One  of  glucagon's  primary  jobs  during  periods  of  low  food  intake 
(fasting  or  starvation)  is  to  mobilize  liver  glycogen,  that  is,  stimulate  glycogenolysis,  in 
order  to  ensure  that  adequate  blood  glucose  is  available  to  meet  the  needs  of  glucose- 
dependent  tissues.  Glucagon  circulates  in  the  blood  until  it  interacts  with  glucagon 
receptors  such  as  those  located  on  the  plasma  membrane  of  liver  cells  (Figure  1.3). 
Binding  of  glucagon  to  these  receptors  activates  adenylate  cyclase  and  triggers  the 
cascades  that  result  in  activation  of  glycogen  phosphorylase  and  inactivation  of 
glycogen  synthase  (Harris,  1992). 
1.5  Cytochrome  P-450: 
Cytochrome  P-450  initially  was  reported  in  1958  by  Klingenberg  &  Garfinkel. 
They  noticed  the  presence  of  a  carbon  monoxide-binding  pigment  in  rat  liver 
microsomes.  The  pigment  displayed  a  maximal  absorbance  at  a  wavelength  of  450  nm 
upon  bubbling  carbon  monoxide  into  a  dithionite  reduced  rat  liver  microsomal 
suspension  and  thus,  it  was  called  P(pigment)-450.  In  1964  Omura  &  Sato  published 
spectral  evidence  that  this  pigment  was  a  haemoprotein,  a  new  b-type  cytochrome. 
Cytochrome  P-450  plays  an  important  role  in  the  metabolism  of  endogenous  substrates, 
as  well  as  exogenous  xenobiotics.  The  biological  effectiveness  is  responsible  for  the 
hydroxylation  or  oxidative  dealkylation  of  various  drugs  by  liver  microsomes  (Cooper  et 
al..  1965). 
The  cytochromes  P-450  are  a  group  of  haemoproteins  and  are  located  in  almost 
every  tissue,  and  in  many  subcellular  membrane  fractions  including  the 
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Figure  1.3  Glucagon  acts  via  secondary  mediators  of  its  action  to  activate 
glycogenolysis  and  inhibit  glycogen  synthesis  in  liver  (  adapted  from  Harris,  1992) 
13 endoplasmic  reticulum  (Brodie  et  al.,  1955)  and  the  mitochondria  of  the  adrenal  gland 
(Harding  et  al.,  1964). 
In  mammals,  cytochrome  P-450  is  found  at  varying  concentration  in  microsomes 
from  liver,  kidney,  small  intestine,  lung,  adrenal  cortex,  skin,  testis,  placenta,  and  other 
tissues  (Omura  &  Sato  1964).  The  parenchymal  cells  of  liver  (hepatocytes)  contain  the 
highest  concentration  of  cytochrome  P-450  although  it  has  also  been  demonstrated  that 
the  non  parenchymal  cells  of  the  liver  also  have  the  capacity,  though  lower  than  the 
parenchymal  cells,  to  metabolize  a  wide  range  of  drugs  and  chemicals  (Steinberg  et  al., 
1976).  Hepatocytes  contain  different  constitutive  forms  of  cytochrome  P.  450,  some  of 
these  forms  of  cytochrome  P-450  varying  in  content  on  challenge  of  the  animal  with 
xenobiotics.  Other  forms  appear  to  respond  to  homeostatic  control  signals  varying  with 
conditions  in  the  body,  from  developmental  changes  to  sexual  development,  and  in 
response  to  pathophysiological  conditions  such  as  starvation,  diabetes  and  hypertension. 
These  changes  all  result  in  differential  abilities  of  the  animal  to  metabolize  drug  and 
xenobiotic  chemicals  as  well  as  endogenous  compounds  such  as  fatty  acids  and  steroids 
(Schenkman,  1990).  The  cytochrome  P-450  mono-oxygenases  play  a  central  role  in  the 
biotransformation  of  xenobiotics  (including  drugs,  insecticides,  pesticides,  food 
additives,  products  in  smoke  and  pyrolysis  products  produced  by  cooking)  into  more 
water  soluble  products  that  permit  detoxication  and  removal  from  the  body  and 
metabolism  of  certain  xenobiotics  such  as  benzene,  acetoaminophen,  halothane  and 
nitrosamines,  to  more  reactive  products  that  are  toxic  and  /  or  carcinogenic  (Defeng  et 
at,  1993). 
The  finding  of  the  successful  stabilization  of  cytochrome  P-450  by  glycerol 
(Ichikawa  &  Yamano,  1967)  permitted  solubilization  and  purification  experiments  on 
cytochrome  P-450  leading  to  the  understanding  that  there  is  a  large  family  of  these 
proteins  with  different  substrate  specificity.  The  metabolism  of  xenobiotics  is  affected  by 
many  factors  (Paine,  1981,  Gibson  &  Skett,  1994),  one  of  them  being  hormones.  It  has 
been  established  that  the  alteration  in  drug  and  steroid  metabolism  may  be  attributed  to 
endocrinological  disorders  and  the  pancreas  is  one  whose  secretions  affect  xenobiotic 
metabolism. 
14 Insulin  and  glucagon  secreted  by  the  islets  of  Langerhans  in  the  pancreas  have 
been  demonstrated  to  affect  xenobiotic  metabolism  in  experimental  animals  (see  next 
section). 
1.5.1  Liver,  Cytochrome  P-450  and  Diabetes  Mellitus: 
The  first  report  suggesting  that  diabetes  mellitus  may  affect  drug  metabolism 
(Dixon  et  at,  1963)  showed  an  overall  decreased  hepatic  microsomal  metabolism 
following  acute  treatment  with  the  ß-cell  toxin,  alloxan,  and  that  this  effect  was 
suppressed  by  insulin.  It  was  reported  that  activities  of  drug-metabolizing  enzymes  in 
liver  microsomes,  such  as  hexobarbitone  hydroxylation  were  markedly  decreased  by 
alloxan-induced  diabetes  in  male  rats.  A  later  study  by  Kato  et  at,  (1971)  demonstrated 
that  the  magnitude  of  the  difference  spectum  of  cytochrome  P-450  induced  by 
hexobarbital  and  aminopyrine  was  markedly  decreased  in  male  but  not  in  female  alloxan- 
treated  rats.  This  suggests  that  the  binding  capacities  of  cytochrome  P-450  for 
hexobarbital  and  aminopyrine,  which  are  normally  stimulated  by  androgen  (Schenkman 
et  al.,  1990)  are  decreased  in  the  microsomes  of  diabetic  male  rats  but  not  in  female  rats 
and  this  was  confirmed  by  other  workers  (Kato  &  Gillette,  1965;  Weiner  et  al,  1972  ). 
However,  studies  have  shown  that  diabetes  produces  an  increase  in  the  hepatic  levels  of 
cytochrome  P-450  2E1,  responsible  for  the  increase  in  the  microsomal  metabolism  of 
aniline  in  rats  (Favreau  &  Shenkman  1987)  which  means  the  effect  of  diabetes  is  not 
always  to  decrease  drug  metabolism  as  documented  by  Dixon  et  al.,  (1963).  There  is  an 
increase  in  the  oxidation  of  aniline  which  is  known  to  be  an  effective  substrate  for 
cytochrome  P-4502E1  (Defeng  et  at,  1993).  Although  the  microsomal  metabolism  of 
androgenic  hormones,  testosterone  and  androst-4-ene-3,17-dione,  has  been  studied  in 
several  laboratories.  (Conney  et  al.,  1973  Einarsson  el  al.,  1974),  Reinke  et  al.  (1978) 
were  the  first  to  report  alterations  in  hepatic  steroid  metabolism  in  streptozotocin- 
diabetic  male  rats.  The  diabetic  state  resulted  in  an  overall  decrease  in  the  rate  of 
microsomal  metabolism  of  androst-4-ene-3,17-d  ione  compared  to  the  control.  This  was 
confirmed  by  Skett  et  al.  (1980).  Changes  in  androst-4-ene-3,17-dione  metabolism  can 
be  reversed  by  insulin  treatment.  If  insulin  action  on  steroid  metabolism  is  investigated 
in  isolated  hepatocytes,  it  is  found  that  steroid  metabolism  is  increased  by  insulin 
15 (Hussin  &  Skett,  1987).  Metabolism  of  androst-4-ene-3,17-dione  metabolism  can,  thus, 
be  used  a  measure  of  insulin-like  activity. 
1.6  Plants  used  as  herbal  treatment: 
1.6.1  ARTEMISIA  JUDAICA  (Family  Compositae) 
The  desert  plant  Artemisia  judaica  L.  is  widely  used  in  folk  medicine  in  the 
Arabian  region  especially  in  Libya.  It  is  commonly  known  by  the  Arabic  name'Shih'  and 
is  a  popular  folk  remedy  for  the  treatment  of  diabetes  mellitus  in  Libya.  It  is  a  genus  of 
aromatic  and  bitter  plants  of  the  family  Compositae.  About  400  species  have  been 
cultivated  or  used  by  man.  It  is  a  genus  with  alleviating  properties  for  gastrointestinal 
colics,  diarrhoea  and  gastrointestinal  disorders  and  it  is  a  popular  medicine  in  use  for  a 
long  time  to  treat  diabetic  symptoms  and  is  sold  in  many  markets  in  Tripoli,  Libya. 
Other  uses  for  this  plant  have  also  been  reported  (Khafagy  &  Tosson,  1968).  It  has  a 
protective  effect  against  carbon  tetrachloride-induced  hepatotoxicity  (Kiso  et  al.,  1984). 
Judaicin  and  cirsimaritin  were  isolated  from  Arkmisia  judaica  (Abdalla  &  Zarga,  1987, 
Khafagy  &  Tosson,  1968).  Artemisia  sp.  is  also  known  to  be  used  by  local  populations 
as  an  anthelminthic  (Khafagy  e1  al.,  1971).  It  has  been  found  to  have  anti- 
arteriosclerosis  &  anti-thrombosis  effects  (Kaji  el  al.,  1990).  Judaicin  is  a  new 
sesquiterpene  ketolactone,  recently  found  to  have  a  cardiotonic  effect  which  did  not 
deviate  from  the  general  frame  of  digitoxin  action  (Khafagy  et  a/.,  1976). 
Some  of  the  biological  effects  of  cirsimaritin  have  been  studied  besides  its 
antiviral  and  antibacterial  activities,  cirsimaritin  has  been  shown  to  inhibit  beef  heart 
cyclic  AMP  phosphodiesterase,  but  no  information  is  available  on  the  biological  effects 
of  cirsimaritin  at  the  tissue  level  (Abdalla,  &  Zarga,  1987). 
1.6.2  AN117LLEA  CARCINI  (Family.  Compositae) 
Anvillea  carcinlii  is  a  woody  desert  plant  with  the  aspect  of  Aslericus 
graveolvns.  It  contain  hydroxyparthenelide,  astriseinolide,  kaempferol  and  quericitine 
(Elgadi,  1989).  but  no  scientific  work  has  been  done  on  the  pharmacology  of  this  plant. 
16 1.6.3  MARRUBIUM  VULGARE  L  (Family.  Labiatae) 
The  genus  Marrrubium  is  represented  by  97  species  which  are  widely  spread  over 
the  temperate  and  warm  regions.  Two  species  have  been  identified  namely,  Marrubium 
alysson  and  Marrubium  vulgar.  Many  Marrribiurn  species  are  reported  in  the  literature 
to  be  used  in  folk  medicine  (Watt,  1962  ).  It  is  used  in  the  form  of  a  decoction  as  a 
remedy  for  diabetes,  anaemia  and  as  a  diuretic.  Marrubium  sp.  contain  marrubiin, 
tannin,  resin,  volatile  oil,  and  vitamins  (Elgadi,  1990).  In  north  Africa,  the  tops  are  used 
as  a  flavouring  agent  (Lewis,  1977  ). 
1.7  Experimental  Models  of  Diabetes  mellitus: 
Insulin-dependent  diabetes  is  a  pathological  state  that  affects  endogenous 
metabolism  and  also  the  pathways  of  metabolism  and  disposition  of  drugs  as  discussed 
above.  Chemical  compounds  that  specifically  damage  the  pancreatic  islet  ß-cells 
constitute  a  class  of  diabetogenic  agents.  Among  such  compounds,  alloxan  and 
streptozotocin  exhibit  this  characteristic  and  are  widely  used  to  induce  experimental 
diabetes,  which  closely  resembles  insulin-dependent  diabetes  mellitus  (Agrawal,  1995). 
The  earlier  extensive  use  of  alloxan  has  more  recently  been  replaced  by  the 
streptozotocin-induced  diabetes  model  because  streptozotocin  is  a  more  selective  ß-cell 
toxin  (Hoftiezer  and  Carpenter,  1973)  and  because  its  effect  on  the  liver  has  been  shown 
to  be  due  to  its  diabetogenic  action  since  treatment  with  insulin  could  reverse  the  effects 
seen  (Favreau  and  Schenkman,  1987).  On  the  other  hand,  alloxan  has  been  criticized  for 
its  overt  toxicity  (Hoftiezer  and  Carpenter  1973)  which  indicates  that  this  may  not  be  a 
good  model  of  diabetes.  The  dose  of  STZ  which  was  used  was  65mg/kg  because  it  has 
previously  been  shown  in  this  laboratory  to  induce  hyperglycaemia  and  hyperlipidaemia 
in  adult  rats  (Skett,  1986). 
Selecting  an  appropriate  model  for  testing  the  anti-hyperglycaemic  effects  of 
drugs  is  complicated  by  the  heterogeneity  of  the  diabetic  condition  and  the  fact  that  no 
17 single  model  is  entirely  representative  of  a  particular  type  of  human  diabetes  (Bailey  & 
Flatt,  1990). 
Diabetes  mellitus  could  be  induced  in  experimental  animals  by  administering  to 
the  animals  streptozotocin.  STZ  is  transported  into  pancreatic  beta-cells  through 
glucose  transporters  in  the  cell  membranes  and  attacks  mitochondria.  Mitochondrial 
ATP  generation  is  inhibited  and  the  resulting  high  concentration  of  intracellular  ADP 
causes  its  degradation  providing  hypoxanthine,  a  substrate  of  xanthine  oxidase  (XOD) 
whose  activity  is  intrinsically  very  high  in  the  beta-cell.  The  XOD-catalyzed  reaction 
produces  uric  acid  and  oxygen  radicals,  but  beta-cells  are  inefficient  in  scavenging  these 
radicals  because  of  their  extremely  low  activity  of  superoxide  dismutase.  On  the  other 
hand,  STZ  directly  activates  XOD  and  enhances  oxygen  radical  generation. 
Consequently,  the  pancreatic  B-cells  are  subjected  to  a  high  concentration  of  oxygen 
radicals  when  exposed  to  STZ  (Kawad,  1992)  and,  thus,  leading  to  cellular  toxicity.  The 
STZ-diabetic  rat  model  was,  thus  chosen  to  represent  typel  diabetes  mellitus. 
18 1.8  Aims  of  the  Project: 
1-  In  1988,  Hussin  et  al.,  showed  the  role  of  insulin  in  the  regulation  of  hepatic 
steroid  and  drug  metabolism.  It  was  found  that  addition  of  insulin  to  cultures  of  adult  rat 
hepatocytes  caused  a  general  increase  in  the  steroid  metabolizing  activity  of  the  cells. 
We  wished  to  use  this  as  a  test  system  for  the  possible  insulin-like  effects  of  extracts  of 
Artemisia  judaica,  Marrubium  vulgar,  &  Auvillea  carcinü.  We  also  wished  to  examine 
if  extracts  of  Artemisia  judaica,  Marnibium,  &  Anvillca  can  enhance  insulin  action  on 
isolated  liver  cells.  If  we  could  demonstrate  such  effects  we  would  continue  by  trying  to 
purify  the  active  ingredients  from  the  extracts. 
2-  To  examine  the  effects  of  Arlc'misia  judaica,  Anvilk'a  carcinil  L.  and 
Marrubiunm  vtilgare  on  some  hepatic  functions  that  are  responsible  for  regulating 
glucose  output.  In  particular,  we  wish  to  examine  the  ability  of  Arlemisia  jrudaica, 
Anvillea  carcinü  L.  and  Marrtibium  vulgare  to  mimic  insulin  and  attenuate  glucagon 
action  on  the  liver  by  measuring  the  activity  of  glycogen  phosphorylase  a  in  normal  and 
diabetic  rat  hepatocytes. 
3-  To  test  the  effects  of  Artemis/a  juduica  extract  in  normal  and  diabetic  rats 
in-vivo  by  giving  it  in  their  drinking  water  on  diabetic  related  parameters  i.  e.  body 
weight,  food  intake,  water  intake,  urine  production,  faeces  production  and  urinary 
glucose  concentration. 
4-  To  investigate  the  effects  of  Arlenri.  sicr  judaica  on  internal  parameters  (e.  g 
liver  weight,  liver  protein  content,  enzymatic  activities  of  cytochrome  P-450  and  liver 
microsomal  metabolism  of  androst-4-ene-3,17-dione. 
5-  To  investigate  the  effects  of  Arlemisia  judaicn  extract  on  blood  glucose  in 
non-insulin-dependent  and  insulin-dependent  diabetic  patients,  and  any  potential  side 
effects. 
19 METHODS  AND  MATERIALS 2.  MATERIALS  AND  METHODS 
2.1  Preparation  of  Artemisia  judaica  extract 
Artemisia  judaica  was  collected  in  the  spring  from  the  Huon  desert  region  of 
Libya  and  air-dried  before  transport  to  Glasgow.  A  voucher  specimen  of  the  plant  was 
identified  by  Dr.  J.  H.  Dickson,  Department  of  Botany,  University  of  Glasgow.  The  dried 
whole  plant  was  kept  in  the  dark  in  dry  conditions  until  extracted.  Marrubium  vulgare 
and  Anvillea  carcinii  were  bought  from  markets  in  Libya  and  a  voucher  specimen 
similarly  identified  by  Dr.  Dickson. 
2.1.1  Preparation  of  crude  extract 
The  whole  plant  (aerial  parts)  was  crushed  in  a  grinding  machine  to  a  fine 
powder  and  was  kept  in  nylon  bags  at  room  temperature  until  used.  The  powder  (100g) 
was  mixed  with  500m1  of  distilled  water  and  allowed  to  extract  overnight  at  room 
temperature.  The  resultant  dark  green-brown  mixture  was  filtered  through  filter  paper 
(Whatman  No.  1)  and  the  filtrate  was  evaporated  to  dryness  at  40°C  under  reduced 
pressure  in  a  Buchi  Rotavapor-R  rotary  evaporator.  The  resultant  brown  powder 
weighed  16g.  The  residue  was  redissolved  in  distilled  water  at  a  concentration  of 
0.2g/ml  and  kept  frozen  in  lml  aliquots  at  -20°C  until  required  (see  Figure  2.1) 
This  was  termed  the  crude  extract.  The  same  method  was  used  for  the 
preparation  of  the  crude  extracts  ofMarrubiurn  vulgar'  and  Aiwi  lea  carcinil. 
2.1.2  Preparation  of  the  aqueous  and  ethanolic  extract  ofArtemisia  judaica 
The  dried  crude  extract  (14g),  produced  as  above,  was  mixed  with  absolute 
ethanol  (  80  ml)  and  allowed  to  stand  overnight  in  a  dark  place.  The  resultant  light 
green-brown  mixture  was  then  filtered  and  the  filtrate  was  evaporated  to  dryness  at 
40°C  under  reduced  pressure.  2g  of  dry  material  was  found  and  redissloved  in  absolute 
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Figure  2.1  Extraction  procedure  for  Arrlemisia  jlidaica  (Crude,  Aqueous  and  ethanolic) 
21 ethanol  (0.2g/ml).  This  was  termed  the  "ethanolic  extract".  The  residue  from  the 
extraction  was  redissolved  in  distilled  water  (0.2g  ml  )  (Figure  2.1). 
2.2  IN  VIVO  STUDIES 
2.2.1  EXPERIMENTAL  ANIMALS 
Mature  male  Wistar  rats  of  approximately  250g  were  used  throughout  the  study. 
The  animals  were  bred  in  the  department  and  housed  in  light  (lights  on  0800-2000hrs) 
and  temperature  (19°C  ±  1°C)  controlled  conditions.  The  animals  had  free  access  to 
food  (CRM  Nuts,  Labsure,  Croyden)  and  tap  water  throughout  the  experiments  except 
where  noted. 
2.2.2  Induction  of  diabetes  mellitus 
Diabetes  mellitus  could  be  induced  in  experimental  animals  by  administering  to 
the  animals  streptozotocin  (STZ).  It  is  considered  that  STZ  may  provide  a  better  model 
for  type  1  (insulin-dependent)  diabetes  than  alloxan  because  of  its  more  selective  beta- 
cell  toxicity  (Hoftiezer  &  Carpenter,  1973).  Since  STZ  is  unstable  in  solution,  it  was 
dissolved  in  distilled  water  (at  65mg/ml.  )  immediately  before  use  and  then  injected 
intravenously  (65mg/kg)  into  the  tail  vein  of  the  rat  under  halothane/nitrous  oxide 
anaesthesia.  The  animals  were  replaced  in  ordinary  cages  and  left  for  three  days  for 
recovery  and  development  of  the  symptoms  of  diabetes  mellitus  before  use. 
2.2.3  METABOLIC  CAGES 
The  metabolism  cages  were  supplied  by  Jencons  of  Hemel  Hempstead  and  were 
of  glass  construction  with  wire  mesh  floor  and  roof.  The  cages  were  set-up  in  the  animal 
house  to  keep  the  animals  in  the  same  light  and  temperature  conditions  that  they  were 
previously  accustomed  to.  The  cage  design  allows  the  animals  easy  access  to  measured 
quantities  of  food  and  fluid  with  a  facility  to  collect  any  crumbs  or  drips  to  allow 
22 accurate  measurement  of  the  animals'  consumption.  The  wire  floor  allows  faeces  to  fall 
throughout  the  living  area  to  facilitate  collection.  Urine  either  falls  or  is  deflected  onto 
the  walls  of  the  chamber  below  the  living  area,  and  runs  down  the  glass  to  be  collected 
in  a  flask.  Each  cage  was  initially  provided  with  l00g  of  food  and  100mis  of  water 
which  were  refreshed  and  replenished  as  required. 
2.2.4  EXPERIMENTAL  PROCEDURES 
Normal,  healthy  male  rats  or  rats  made  diabetic  by  treatment  with  STZ  as 
described  above  were  used  in  experiments  lasting  up  to  27  days  in  total.  At  no  time 
were  animals  in  the  metabolic  cages  for  more  than  7  days  continuously.  The  actual 
experimental  protocols  are  outlined  in  Figures  2.2  -  2.4.  Each  animal  acted  as  its  own 
control  being  tested  as  control,  after  induction  of  diabetes  (if  appropriate)  and  after 
treatment  with  the  respective  extracts. 
2.2.5  Experimental  protocol: 
Every  24  hours  the  following  parameters  were  measured: 
1.  Body  weight 
2.  Food  intake 
3.  Fluid  intake 
4.  Urine  volume 
5.  Faeces  weight 
A  urine  sample  was  collected  and  frozen  until  assayed  for  glucose  and  ketones 
as  described  later. 
The  animals  were  removed  from  their  cages  for  a  period  not  exceeding  5 
minutes  to  facilitate  collection  and  measurement  of  the  required  parameters.  Although 
the  animals  did  urinate  and  defaecate  during  this  period  the  quantities  involved  were  not 
significant  compared  to  the  daily  collection. 
23 2.2.6  Normal  rat  treated  with  Artemisia  (17  Day  experimental  run  ): 
Animals  were  weighed  (  starting  weight:  250-300g)  and  placed  in  the  metabolic 
cages.  The  animals  were  allowed  a  24hr  run-in  period  to  adjust  to  their  new 
surroundings  after  which  the  experimental  run  began.  Each  animal  was  then  tested  under 
control  conditions  for  7  days.  The  animal  was  then  removed  from  the  metabolic  cage 
and  allowed  to  recover  for  3  days  in  an  ordinary  animal  cage. 
On  day  11  (for  animals  1-3)  or  day  7  (for  animals  4-9)  animals  were  supplied  with  the 
plant  extract  as  a  decoction  in  their  drinking  water  -  5ml  of  Arlemisia  crude  extract  as 
prepared  above  in  200m1  tap  water  (Figure  2.2). 
2.2.7  Diabetic  rat  (17  Day  experimental  run): 
The  animals  were  selected  and  run  as  controls  in  the  metabolic  cages  for  7  days 
to  ensure  they  exhibited  a  normal  pattern  of  measured  parameters.  Diabetes  mellitus  was 
induced  on  day  7  by  administration  of  STZ  as  described  in  Section  2.2.2,  after  which  the 
animals  were  kept  for  three  days  in  a  conventional  cage  to  allow  recovery  and  onset  of 
diabetes.  On  day  11  the  animals  were  replaced  in  the  metabolic  cages  and  the 
experiment  continued  for  a  further  7  days  (Figure  2.3). 
2.2.8  Diabetic  rats  treated  with  Artemisia  extract  (27  day  experimental 
run): 
The  animals  were  selected  and  run  as  controls  in  the  metabolic  cages  for  7  days 
to  ensure  they  exhibited  a  normal  pattern  of  measured  parameters.  Diabetes  mellitus  was 
induced  on  day  8  by  administration  of  STZ  as  described  above,  after  which  the  animals 
were  kept  for  three  days  in  a  conventional  cage  to  allow  recovery  and  onset  of  diabetes. 
On  day  11  the  animals  were  replaced  in  the  metabolic  cages  and  the  experiment 
continued  for  a  further  7  days.  The  animals  were  removed  from  the  metabolic  cage  and 
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Figure  2.2  Normal  rat  treated  with  Artemisici  extract  (10  days). 
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Figure  2.4  Diabetic  rat  treated  with  Artemisia  extract  (10  days). 
27 kept  in  a  conventional  cage  for  3  days  during  which  time  they  were  treated  with 
Artemisia  extract  (concentration  as  given  above).  The  bitter  taste  of  Artemisia  extract 
meant  that  the  animals  did  not  drink  it,  so,  in  these  cases,  a  more  dilute  solution  was 
used  for  day  19,  (1  or  2ml  of  Artemisia  extract  in  200m1  of  tap  water)  followed  by  a 
more  concentrated  solution  on  day  20  (2.5  or  3m1  of  Artemisia  extract  in  200m1  tap 
water)  and  then  to  the  normal  concentration  of  extract  on  day  21  and  on  day  21  the 
animals  were  returned  to  the  metabolic  cage  for  a  final  period  of  7  days  (Figure  2.4). 
2.3  Assays 
2.3.1  Glucose  Assay 
Urine  samples  were  assayed  for  glucose  using  the  assay  kit  supplied  by  the 
Sigma  Chemical  Co.  Ltd.  which  is  based  on  a  procedure  similar  to  that  described  by 
Carrol,  et  a!.,  (1970)  based  on  the  following  reactions: 
Hexokinase 
Glucose  +  ATP  ->  G-6-P  +  ADP 
G-6-PDH 
G-6-P  +  NADP+  -* 
NADPH  +  PMS  -> 
6-PG  +  NADPH 
NADP++  PMSH 
PMSH  +  INT  -+  PMS+INTH 
The  analysis  is  based  on  the  hexokinase  (1-1K)  catalyzed  conversion  of  glucose  to 
glucose-6-phosphate  (G-6"P).  This  reaction  is  coupled  to  the  subsequent  reduction  of 
28 nicotinamide  adenine  dinucleotide  phosphate  (NADP)  to  NADPH  by  the  action  of 
glucose-6-phosphate  dehydrogenase  (G-6-PDH).  In  the  presence  of  NADPH,  phenazine 
methosulphate  (PMS)  is  reduced.  The  PMSH  generated  is  then  responsible  for  the 
reduction  of  iodonitrotetrazolium  chloride  (INT)  forming  INTH,  which  is  measured 
colourimetrically  at  520nm.  The  colourimetric  response  is  proportional  to  the  glucose 
concentration.  The  absorbance  of  the  sample  was  thus  measured  at  520nm  in  a 
Shimadazu  UV-240  spectrophotometer  and  the  glucose  concentration  calculated  from 
standards  supplied  by  Sigma 
2.3.2  Urine  ketones  and  glucose 
The  presence  of  ketones  in  the  urine  was  assayed  using  Keto-Diabur  5000  strips 
supplied  by  Boehringer,  Mannheim,  Germany  which  produce  a  colour  change  in  the 
presence  of  ketones. 
2.4  MEASUREMENT  OF  OTHER  PARAMETERS 
After  the  various  treatments,  described  above,  the  animals  were  sacrificed  by 
carbon  dioxide  asphyxiation,  and  their  necks  were  broken.  Immediately  after  cervical 
dislocation,  the  throat  was  cut  and  blood  was  collected  by  using  a  10ml  syringe.  5ml  of 
blood  was  transferred  to  a  lithium  heparin  bottle  containing  100µI  of  Trasylol.  The  livers 
were  quickly  removed  from  the  animal  as  soon  as  possible,  rinsed  in  ice  cold  phosphate 
buffer  (pH  7.4,0.01  M  with  1.15%  potassium  chloride  added)  to  remove  any  excess 
blood  and  other  foreign  material  , 
blotted  dry  on  filter  paper  and  weighed.  At  the  end  of 
each  experiment,  therefore,  there  was  urine,  blood  and  liver  material  to  be  assayed.  The 
urine  was  assayed  for  glucose  and  ketones  (see  section  2.3.2),  the  blood  for  insulin  and 
glucagon  and  the  liver  was  assayed  for  protein  content,  cytochrome  P-450  content, 
29 activity  and  the  metabolism  of  androst-4-ene-3,17-dione,  aniline  and  aminopyrine.  All  of 
these  assays  are  described  below. 
2.4.1  Preparation  of  liver  microsomes 
In  order  to  measure  the  liver  parameters,  subcellular  fractions  needed  to  be 
prepared.  It  is  essential  to  keep  the  liver  as  cool  as  possible  and  to  get  the  microsomes 
prepared  and  frozen  as  quickly  as  possible  to  prevent  damage  to  the  tissue  and  its 
enzymes. 
The  liver  was  homogenized  in  five  times  its  weight  of  phosphate  buffer 
containing  1.15%  potassium  chloride  (see  section  2.20.1),  in  a  Potter-Elvehjem 
homogenizer  with  a  Teflon  pestle  (for  1g  of  liver  use  5m1  of  buffer).  The  homogenate 
was  then  centrifuged  in  a  Sorvall  refrigerated  centrifuge  for  15  minutes  at  12500xg  to 
sediment  the  mitochondria  and  nuclei.  The  post-mitochondrial  supernatant  then  had 
calcium  chloride  (1M)  added  to  it  to  bring  the  supernatant  to  8mM  with  respect  to 
calcium  chloride  (i.  e.  0.1  ml  of  1M  calcium  chloride  (BDH  Chemicals)  for  every  12.5  ml 
of  supernatant).  The  solution  was  then  mixed  and  left  to  stand  on  ice  for  5  minutes.  The 
supernatant  was  then  centrifuged  again  this  time  at  28000xg  for  20  minutes  to  sediment 
out  the  microsomes.  The  supernatant  was  poured  off  and  the  pellet  resuspended  in  the 
phosphate  buffer.  For  every  50  volumes  of  the  original  homogenate,  the  sediment  was 
resuspended  in  20m1  buffer  and  5nm1  glycerol.  The  microsomes  were  then  frozen  at  about 
-70°C.  The  microsomes  were  used  to  measure  the  hepatic  parameters  discussed  above 
and  described  in  detail  below.  All  assays  have  previously  been  tested  for  linearity  with 
respect  to  time  and  concentration  of  measured  compound  in  the  range  used  in  this 
study.  Enzyme  assays  have  also  been  previously  tested  to  be  within  the  linear  range  for 
protein  concentration. 
30 2.4.2  Protein  determination 
The  method  described  by  Lowry  et  al  (1951)  was  used  to  determine  the  protein 
content  of  the  microsomes.  A  sample  of  the  prepared  microsomes  was  diluted  (1:  100) 
with  distilled  water.  A  reagent  was  made  by  mixing  50  parts  of  4%  (weight  /  volume) 
sodium  carbonate  dissolved  in  0.1  N  sodium  hydroxide  (Fisons),  1  part  1%  (weight  / 
volume)  potassium  tartrate  (BDH  Chemicals)  and  1  part  0.5%  (weight  /  volume  ) 
CuSO4.  H20  (Glasgow  University  Chemistry  Department).  This  reagent  must  be  freshly 
made  as  it  only  lasts  3-4  hours.  2ml  of  this  reagent  was  then  added  to  lml  of  diluted 
microsomes,  mixed  and  left  to  stand  for  10  minutes.  Then  0.3  ml  of  IN  Folin  Ciocalteu 
reagent  (BDH  Chemicals)  was  added,  mixed  and  allowed  to  stand  for  30  minutes  at 
room  temperature.  A  coloured  complex  was  formed  between  the  alkaline  copper-phenol 
reagent  and  tyrosine  and  tryptophan  residue  of  the  protein.  The  optical  density  at  750nm 
was  determined  on  a  Shimadzu  UV-240  spectrophotometer.  A  standard  curve  was  also 
prepared  using  0.2  to  I  ml  aliquots  of  crystalline  bovine  serum  albumin  (200pg/ml, 
Sigma  BSA  fraction  IV)  made  up  to  Iml  with  distilled  water.  By  comparing  the  optical 
density  of  the  sample  to  the  standard  curve,  a  measure  of  the  protein  content  was 
established. 
2.4.3  CYTOCHROME  P-450  ENZYME  ACTIVITIES 
2.4.3.1  ASSAY  OF  ANILINE  4-HYDROXYLASE  ACTIVITY 
This  assay  acts  as  a  measure  predominantly  of  the  enzyme  activity  of 
cytochrome  P4502E1,  (aniline  is  hydroxylated  to  4-aminophenol  )  as  follows  (Gibson  & 
Skett,  1994)  (Figure  2.5). 
31 NH2  NH2 
O  Cytochrome  P450 
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OH 
Figure  2.5  The  hydroxylation  of  aniline 
The  following  was  added  to  each  test  tube  : 
Microsome  preparation  ................................................................ 
I  ml 
0.  IM  Magnesium  Chloride  (BDH  Chemicals) 
.............................. 
0.1  ml 
0.5M  Nicotinamide  (Sigma  Chemical  Co.  Ltd.  ) 
............................. 
0.1ml 
Tris  buffer  pH  7.4  0.05M 
....................................................... 
0.59ml 
0.05M  Aniline  (BDH  Chemicals) 
.................................................. 
0.  lml 
Co-factor  mixture  ........................................................................ 
0.11  ml 
(to  start  reaction.  see  reagent  section  2.20  at  the  end) 
The  above  were  incubated  at  37°C  for  30  minutes  in  a  shaking  water  bath  before 
the  reaction  was  stopped  by  adding  1  nil  of  20%  trichloroacetic  acid  (DDH  Chemicals), 
which  precipitated  the  protein  present  in  each  incubation.  This  was  mixed  well  and 
allowed  to  stand  for  5  minutes  at  4°C.  The  precipitate  was  then  spun  down  in  a  bench 
centrifuge  for  15  minutes.  lml  of  the  supernatant  was  then  taken  to  be  assayed  for  4- 
aminophenol.  To  the  lml  supernatant  was  added  lml  of  1%  phenol  in  0.5M  sodium 
hydroxide  solution  (Fison)  and  mixed  with  Inil  of  sodium  carbonate  (4%  w/v)  solution 
(Hopkin  and  Williams).  The  solution  was  then  mixed  and  the  resultant  solution  was  left 
to  stand  for  30  minutes  at  room  temperature  before  the  optical  density  was  measured  at 
630nm  in  a  Shimadzu  UV240  spectrophotometer.  The  measurement  obtained  was 
compared  to  the  standard  curve  to  find  the  concentration  of  4-aminophenol  formed  per 
minute  per  mg  protein  (see  calculations  in  Section  2.11) 
The  standard  curve  was  prepared  by  using  0.2  to  lml  aliquots  of  fresh  4- 
aminophenol  solution  (10µM)  (BDH  Chemicals)  made  up  to  Iml  with  distilled  water. 
32 Again  the  optical  density  was  measured  at  630nm  and  a  standard  curve  was  drawn  from 
the  values  obtained. 
2.4.3.2  ASSAY  OF  AMINOPYRINE  N-DEMETHYLASE  ACTIVITY 
This  assay  is  considered  to  act  as  a  general  measure  of  the  enzyme  activity  of 
cytochromes  P450  of  the  2B  and  2C  subfamilies. 
N-demethylation  of  drugs  is  a  common  metabolic  pathway  and  is  thought  to 
proceed  by  initial  hydroxylation  at  the  alpha-carbon  atom  and  subsequent  breakdown  of 
the  carbinolamine  intermediate  liberating  formaldehyde  (Gibson  &  Skett,  1994)  (Figure 
2.6). 
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Figure  2.6  N-Demethylation  of  aminopyrine. 
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33 The  following  were  added  to  each  test  tube  : 
Microsome  preparation  ............................................................................  1.00ml 
0.  IM  Magnesium  chloride  (BDH  Chemicals) 
............................................. 
0.1Oml 
0.5M  Nicotinamide  (Sigma  Chemical  Co.  Ltd) 
............................................ 
0.1  Oml 
450mM  Semicarbazide  (Sigma  Chemical  Co.  Ltd.  ) 
..................................... 
0.1  Oml 
0.5M  phosphate  Buffer  pH  7.4 
.................................................................. 
0.49m1 
50mM  Aminopyrine  (Sigma  Chemical  Co.  Ltd.  ) 
........................................ 
0.1Oml 
Co-factor  Mixture 
..................................................................................... 
0.11  ml 
(to  start  the  reaction,  see  reagent  section  2.20  at  the  end) 
The  above  mixture  was  incubated  at  37°C  for  30  minutes  in  a  shaking  water  bath 
before  the  reaction  was  stopped  with  1ml  20%  zinc  sulphate  (Hopkin  and  Williams), 
which  precipitates  the  protein  present  in  each  incubation.  This  was  then  mixed  well  and 
left  for  5  minutes.  lml  of  saturated  barium  hydroxide  (Hopkin  and  Williams)  solution 
was  then  added  to  precipitate  out  the  zinc  sulfate.  Again  this  was  mixed  and  left  to  stand 
for  5  minutes.  The  precipitate  was  then  spun  down  in  a  bench  centrifuge  for  15  minutes. 
2m1  of  the  supernatant  was  added  to  1  ml  of  Nash  reagent  (see  reagent  section  2.20.2) 
for  the  assay  of  formaldehyde.  The  supernatant  /  Nash  reagent  mixture  was  incubated 
for  30  minutes  at  60°C  in  a  water  bath,  using  a  glass  marble  to  close  the  mouth  of  tube 
to  cut  down  on  evaporation.  The  optical  density  was  measured  at  415nm  against 
distilled  water  as  'a  blank.  The  measurement  obtained  was  compared  to  the  standard 
curve  obtained  using  a  standard  formaldehyde  solution  to  find  the  concentration  of 
formaldehyde  formed  per  minute  per  mg  protein  (see  calculations  in  section  2.11) 
2.4.3.3  ASSAY  OF  STEROID  (ANDROST-4-ENE-3,17-DIONE) 
METABOLISM 
The  activity  of  several  enzymes  upon  the  substrate  androst-4-ene-3,17-dione 
was  studied  using  a  technique  outlined  by  Berg  and  Gustafsson  in  1973.  These  enzymes 
being  7a-,  16a-  and  60-hydroxylases,  17-oxosteroid  oxidoreductase  and  5a-reductase. 
They  act  on  the  steroid  substrate  to  produce  the  various  products  shown  in  (Figure  2.8 
and  2.9).  A  co-factor  mixture  was  prepared  in  the  same  way  as  that  for  the  assay  of 
34 aniline  4-hydroxylase  activity.  It  was  preincubated  at  37°C  for  2  minutes  to  allow  the 
formation  of  NADPH.  1.9ml  of  phosphate  buffer  pH  7.4,1  nil  microsomes,  500µg  of  [4- 
14C]-androst-4-ene-3,17-dione  (containing  0.1  tCi,  dissolved  in  50µl  of  acetone)  were 
then  added  and  incubated  in  a  shaking  water  bath  at  37°C  for  10  minutes.  The 
metabolites  formed  were  extracted  and  quantitated  as  described  later  (see  Section  2.16). 
2.5  HUMAN  STUDIES 
2.5.1  Preparation  of  Artemisia  judaica  extract 
500g  ofAriemisia  judaica  containing  stems  and  leaflets  were  added  to  2  litres  of 
tap  water  and  were  boiled  for  a  period  of  30min.  After  cooling  to  room  temperature  the 
extract  was  sieved  to  remove  stems  and  leaflets  and  stored  in  a  refrigerator  (4°C).  Each 
patient  drank  a  half  glass  (approx.  I  00ml)  each  eight  hours. 
2.5.2  Subject  Descriptions 
Patient  (1):  was  a  man  of  43  years  with  mild  diabetes  of  5  years  duration.  This  patient 
had  undergone  therapy  with  Arlemisia  jzidciira  and  Mari*ubiuni  vu/gare  with  a 
controlled  diet  for  approximately  three  years.  The  patient  was  asked  to  stop  the 
treatment  with  Artemisia  jridaica  and  Mari-iibiiun  wilgctl-e  extract  for  the  period  of  the 
study. 
Patient  (2):  was  a  man  of  20  years  who  had  been  treated  with  insulin  injection  (40  i.  u. 
once  daily).  The  patient  was  then  given  Ar"lemisiu  judo  ica  extract  as  described  three 
times  daily  together  with  the  pre-existing  insulin  therapy. 
Patient  (3):  was  a  man  of  17  years.  Since  being  a  juvenile  he  had  been  treated  with 
plants  extracts  one  of  them  being  Aricmisia  judaica.  He  had  stopped  using  the 
Artenzisia  because  when  he  took  it  lie  suffered  from  bradycardia.  He  had  asked  the 
35 doctor  to  replace  his  treatment  with  lente  insulin  injection.  We  asked  the  patient  to  use 
Artemisia  judaica  with  insulin.  The  patient  had  polyuria,  polydipsia  and  polyphagia  with 
insulin  treatment. 
Patient  (4):  was  a  man  aged  24  years  with  diabetes  of  one  year  duration,  he  was  treated 
with  diet  restriction  and  insulin  (  30  i.  u.  a.  m.  and  20  Lu.  p.  m.  ).  This  was  the  first  time  he 
had  used  Artemisia  extract  but  he  knew  that  the  plant  is  widely  used  by  diabetics. 
Patient  (5):  was  a  woman  of  55  years  with  diabetes  mellitus  of  eight  years  duration,  she 
used  hypoglycaemic  agents  and  Artcinisia  and  other  plants  at  some  times.  This  patient 
was  asked  to  stop  the  use  of  these  plants 
Patient  G:  was  a  man  of  60  years  with  mild  diabetes  of  20  years  duration.  He  had  used 
this  plant  for  a  long  time  but  at  irregular  intervals  and  he  did  not  feel  any  side  effects. 
Some  history  was  taken  as  described  in  the  results  section. 
Z6  IN-VITRO  EXPERIMENTS  (ISOLATED  HEPATOCYTES): 
2.6.1  Preparation  of  isolated  hepatocytes 
Hepatocytes  were  isolated  from  male  rats  (weight  250  -  350  g)  by  the 
collagenase  perfusion  method  of  Seglen  (1976).  The  reservoir,  kept  at  45  °C  by  means 
of  a  heated  water  jacket,  was  filled  with  Ca2+-free  butler  (see  Section  2.21.1)  which 
was  oxygenated  with  a  slow  flow  of  pure  oxygen  through  the  apparatus.  The  rat  was 
anaesthetised  (4%  halothane,  800  mUmin  N20,800  ml/min  02  using  a  Mini  Boyle 
anaesthetic  machine),  the  abdomen  cut  open  and  the  portal  vein  freed  of  any  fat.  A 
thread  was  inserted  under  the  portal  vein  and  was  loosely  tied.  The  cannula  (size  20 
GAX  32mm  length)  was  inserted  into  the  hepatic  portal  vein  at  a  position  just  before  the 
vein  branches  into  the  liver  and  the  thread  tied  tightly  around  the  cannula.  The  needle 
was  removed  from  the  plastic  cannula  and  the  blood  was  allowed  to  flow  back  up  the 
cannula.  The  inferior  vena  cava  was  cut  to  reduce  back  pressure  on  the  liver  and  the 
36 cannula  was  attached  via  a  silicon  rubber  tube  to  a  pump  providing  a  continuous  flow  of 
warmed  buffer  (37°C).  The  thorax  was  opened  and  the  superior  vena  cava  was  cut  close 
to  the  heart  to  further  reduce  back  pressure  on  the  liver  (Figure  2.7).  The  Cat+-  free 
Krebs-Henseleit  buffer  was  allowed  to  pass  through  the  liver  for  at  least  12  min  as 
necessary  for  disruption  of  the  tight  junctions,  which  intimately  connect  the  parenchymal 
cells  (500m1  at  40m1/min).  The  Ca  2+  free  buffer  was  then  changed  to  the  Ca2+  free 
buffer  (without  EGTA  100ml  see  section  2.21.2)  and  then  Ca  2+  free  buffer  without 
EDTA  containing  collagenase  (120  ml  at  a  concentration  of  432  units  of  collagenase/ml 
and  4.2mM  CaC12  (see  section  2.21.3)  and  this  buffer  was  allowed  to  run  through  for  1 
min  to  wash  the  first  buffer  out  of  the  system  and  then  the  collagenase  buffer  was 
recycled  for  12  -  15  min  at  a  rate  of  40mUmin.  By  this  method  of  collagenase  perfusion 
it  is  possible  to  convert  the  whole  liver  to  a  suspension  of  intact  cells.  At  the  end  of  the 
second  perfusion  with  collagenase  the  liver  should  look  as  if  it  is  falling  apart  and  gentle 
pressure  on  the  lobes  should  release  the  cells.  At  this  stage  the  perfusion  was  stopped 
and  the  liver  removed  from  the  animal.  The  liver  capsule  was  removed  and  the  cells 
were  stroked  out  into  Ca2+-free  Krebs-Henseleit  butler 
. 
The  suspension  of  cells  was 
filtered  through  gauze  (Snow  flake  absorbent  gauze)  to  separate  connective  tissues  and 
undigested  liver.  The  cells  were  centrifuged  in  a  Damon-IEC  refrigerated  centrifuge  at  a 
speed  of  less  than  200  rpm  (50  g)  for  2  min  at  a  temperature  of  5°C.  The  cells  were 
washed  3  times  in  the  same  buffer  and  the  upper  layer  was  removed  by  suction  after 
centrifugation  on  each  occasion.  After  the  last  wash  the  cells  were  resuspended  in 
washing  buffer  (see  Section  2.21.4)  and  left  on  ice  for  lh.  The  number  of  cells  was 
estimated  in  a  haemocytometer.  Viability  was  estimated  by  microscopic  examination,  the 
cells  which  are  highly  refractive  are  live  cells  and  cells  with  a  viability  above  90%  were 
used  in  the  experiments.  The  preparation  was  diluted  to  10  million  live  cells  /  ml  before 
subsequent  incubation  at  37°C  under  95%  air  and  5%  C02  in  a  humidified  incubator 
(Forma  Scientific  Model  3028)  for  about  30  min  to  equilibrate  the  cells. 
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Figure  2.7:.  Diagram  of  the  liver.  pedusion  (Adapted  from  Berry  et  al.,  1991). 2.7  Hepatocyte  culture 
Into  separate  9  cm  diameter  sterile  plastic  petri-dishes  (Nunclon,  Denmark)  were 
placed  107  cells  and  6  ml  Ham's  F-10  medium  containing  0.1%  bovine  serum  albumin 
plus  0.05  ml  of  a  penicillin  /  streptomycin  mix  (100u  /100  pg  /  ml).  This  procedure  was 
carried  out  under  sterile  conditions.  The  petri-dishes  were  incubated  at  37°C,  under 
5%C02;  95%  air  for  up  to  72  hours  prior  to  enzyme  assay. 
2.8  Addition  of  test  materials 
2.8.1  Pre-incubation  for  androst-4-ene  3,17-dione  metabolism  assay: 
To  prepare  these  cultured  cells  for  assay,  the  contents  of  the  plates  were 
scraped  into  separate  glass  test  tubes  and  centrifuged  at  a  speed  of  less  than  200  rpm 
(50g)  for  2  min.  at  a  temperature  of  5°C  in  a  Damon-IEC  refrigerated  centrifuge.  The 
intact  hepatocytes  sedimented  to  the  bottom  of  the  tubes  and  the  excess  medium  was 
removed  using  a  pasteur  pipette.  To  each  tube  was  added  I  ml  of  Ham's  F-10  or 
Williams'  E  medium  (containing  0.1%  BSA) 
. 
The  cells  are  then  ready  for  the  addition 
of  the  various  extracts.  If  the  cells  were  to  be  used  directly  after  preparation,  they  were 
then  suspended  in  medium  following  the  third  wash  (see  Section  2.6.1  Preparation  of 
Hepatocytes)  and  used  as  such. 
To  107  cells  in  1  ml  of  Ham's  F-10  or  Williams'  E  medium  as  prepared  above 
was  added  one  or  more  of  the  following: 
1.10  µl  insulin  10-7  M  dissolved  in  0.1M  hydrochloric  acid  (giving  final  conc.  of 
10  -9  M). 
39 2.10  µl  insulin  10-4  M  dissolved  in  0.  IM  hydrochloric  acid  (giving  final  conc.  of 
10-6  M). 
3.10  µl  crude  extract  (as  prepared  or  diluted  with  solvent  to  varying  degrees.  ). 
4.1OpI  of  vehicle  (0.1M  HCI,  ethanol  or  water  ;  to  act  as  control) 
The  cells  were  left  in  the  presence  of  the  test  material  for  30  min.  at  37°C  in  a 
humidified  incubator  in  an  atmosphere  of  5%  CO2  and  95%  air.  After  the  preincubation 
period  of  30  min.,  the  cells  were  centrifuged  at  a  speed  of  less  than  200  rpm  (50g)  for  2 
min  at  a  temperature  of  5°C  in  a  Damon-IEC  refrigerated  centrifuge  and  the  medium 
was  removed  using  a  pasteur  pipette. 
2.8.1.1  Assay  of  steroid  metabolism 
For  the  assay  of  steroid  metabolism,  cells,  as  prepared  above,  were  resuspended 
in  1  ml  of  fresh  Ham's  F-10  medium  or  William's  E  followed  by  the  steroid  substrate,  4- 
[4-14C]-androstene-3,17-dione  (100  µg;  0.1  pCi  in  17  tl  of  acetone).  The  cells  were 
incubated  in  the  C02  incubator  for  30  min  at  37°C.  The  incubations  were  terminated 
by  the  addition  of  0.5  ml  of  0.9%  NaCl  (to  increase  the  ionic  strength),  5  ml  of  Folch 
solution  (CHC13  (to  extract  steroid)  and  MeOH  (to  precipitate  protein);  2:  1  v/v)  and 
500  µg  of  unlabelled  androst-4-ene-3,17  dione  (dissolved  in  50µI  of  acetone;  to  act  as 
carrier).  The  tubes  were  mixed  on  a  rotary  mixer  and  left  to  stand  overnight  for  phase 
separation.  After  24  hours  some  tubes  did  not  show  phase  separation  and  these  were 
centrifuged  at  1000  rpm  for  5  min  at  a  temperature  of  5°C  in  a  Danon-IEC  refrigerated 
centrifuge  for  complete  separation  between  the  aqueous  and  organic  phases.  The  lower 
40 organic  layer  was  transferred  to  another  tube  and  dried  at  50°C  under  oxygen-free 
nitrogen  (to  prevent  degradation  of  the  metabolites  by  atmospheric  oxygen)  using  a 
Techne  dry-block.  The  extract  was  redissolved  in  three  drops  of  chloroform  using  an 
ultra-sonic  water  bath  for  at  least  20  seconds  and  then  spotted  onto  silica  gel  thin  layer 
chromatography  plate  (Merck  F-254;  20  cm  x  10  cm.  Individual  substrate  and 
metabolite  bands  were  roughly  visualized  by  U.  V.  light  to  make  sure  of  adequate 
separation  (Figure  2.9).  The  accurate  bands  were  located  by  autoradiography.  This 
step  needs  complete  darkness  so  the  plates  were  put  in  a  black  bag  in  a  closed  cupboard 
for  about  one  week  in  contact  with  X-ray  film  X-Omat  film  (Kodak,  France).  The 
radio-labeled  bands  were  located  by  developing  the  film  in  X-ray  developer  (DX-24)  ( 
200m1  added  to  1000ml  tap  water)  and  then  fixing  in  FX-40  solution  (100ml  added  to 
1000ml  of  tap  water)  for  a  few  minutes.  The  film  was  then  washed  for  1  hour  in  cold 
running  water  and  dried.  The  developed  X-ray  film  was  then  aligned  with  the  T.  L.  C 
plate  (Figure  2.9)  and  the  radioactive  bands,  which  have  previously  been  identified  using 
authentic  standards  and  verified  by  GC-MS  (Gustafsson  &  Stenberg,  1974),  were 
scraped  into  polythene  scintillation  vials  and  suspended  in  Ecoscint  liquid  scintillant. 
Radioactivity  in  each  sample  was  measured  in  a  Packard  Tri-carb  Model  2000  (A) 
scintillation  counter  and  the  various  enzyme  activities  expressed  as  pmol  metabolite 
formed  per  min.  per  mg  of  protein  was  determined  using  the  formula  for  calculations 
and  statistics  (section  2.19)  from  the  d.  p.  m.  in  each  band  using  a  custom-made 
computer  programme. 
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42 Figure  2.9  Laser  scan  of  androstene-4-ene-3,17-dione  metabolites  separation  by  one- 
dimensional  thin  layer  chromatography. 
- 
Il-i  Ft 
5a-Androstane-3,17-dione 
Androst-4-ene-3,17-dione 
(unchanged  substrate) 
5a-Androstane-3cx((i)-oI-17-one 
Testosterone/Epitestosterone 
Androst-4-ene-  16cx-o1-3,17-d  inne 
Androst-4-ene-6(3-o1-3,17-dione 
Androst-4-ene-7cx-o1-3,17-dionc 
Start  band 
43 It  is  apparent  from  Figure  2.8  that  there  are  six  main  metabolites  of  androst-4- 
ene-3,17-dione  which  can  be  separated  by  this  method.  However,  it  has  been  shown  that 
3a/0-oxosteroid  oxidoreductase  does  not  metabolize  the  parent  compound,  but  that 
metabolism  by  this  enzyme  occurs  subsequent  to  metabolism  by  5a-reductase.  Hence, 
for  the  purpose  of  this  study,  only  the  activities  of  the  enzymes  metabolizing  the  parent 
molecule  were  evaluated  and  hence  the  amount  of  metabolite  produced  by  subsequent 
metabolism  of  5a-androstane-3,17-dione  was  not  determined  separately  but  the  amount 
of  metabolite  produced  by  this  enzyme  was  added  to  the  amount  of  unchanged  Sa- 
androstane-3,17-dione  to  determine  the  total  amount  of  metabolite  produced  by  the 
activity  of  5a-reductase. 
2.8.2  Pre-incubation  for  glycogen  phosphorylase  a  activity  assay. 
Cells  prepared  as  outlined  in  Section  2.6.1  were  resuspended  in  Krebs-Henseleit 
solution  (see  Section  2.21.4)  at  a  concentration  of  2-3  x  106  cells/ml.  2m1  aliquots  of 
the  hepatocyte  suspension  were  then  placed  in  20  ml  plastic  scintillation  vials,  gassed 
with  oxygen/carbon  dioxide  mixture  (95:  5)  for  approximately  15  seconds  and  incubated 
for  30  minutes  at  37°C  under  95%  air  and  5%  CO2  in  an  incubator  (Forma  Scientific 
Model  3028),  prior  to  the  addition  of  test  substances. 
After  the  pre-incubation  described  above,  450  pl  aliquots  of  cells  were 
transferred  to  lml  microcentrifuge  tubes  containing  50  pl  of  drugs  at  various 
concentrations  (glucagon,  insulin  at  10-10  -  10-6  M  dissolved  in  0.1  M  HCI;  test 
compounds  and  crude  extracts,  Artemisia  judaica,  Marrubium  ti7ilgare  and  Anvillea 
carcinii  at  various  concentrations  from  2x10-1  -2  x10-5  g/  ml  H2O  or  vehicle 
(control))  and  incubated  at  37°C  in  a  dry  heating  block  (Genesys  Instruments)  (Figure 
2.10).  The  incubations  were  terminated  after  3  minutes  by  dropping  the  tubes  in  liquid 
nitrogen  (for  overall  assay  procedure  see  Figure  2.10.  The  tubes  were  then  stored 
frozen  at  -70°C  until  they  were  assayed  for  enzyme  activity  as  described  below  (section 
2.8.2.1).  Duplicate  incubations  were  made  for  each  concentration  of  test  substance. 
44 2.8.2.1  Glycogen  phosphorylase  a  assay 
Phosphorylase  a  activity  was  determined  by  the  filter  paper  assay  method  of 
Thomas  et  al  (1968)  as  modified  by  Stalman  and  Hers  (1975).  The  method  assays 
glycogen  phosphorylase  a  in  the  'unphysiological'  direction  i.  e.,  employing  the  reaction 
between  D-glucose-1-phosphate  (Glc-1-P)  and  glycogen  (i.  e.  in  the  direction  of 
glycogen  synthesis.  The  principle  involves  the  incorporation  of  [14C]glucose  from 
glucose-  I  -phosphate  into  glycogen.  Caffeine  is  added  to  the  assay  mixture  to  make  the 
assay  specific  for  phosphorylase  a.  Sodium  fluoride  and  disodium  edetate  are  added  to 
the  disruption  buffer  to  inhibit  phosphorylase  activity. 
An  equal  volume  (500µl)  of  ice-cold  disruption  buffer  (see  Section  2.21.5.1) 
was  added  to  the  frozen  samples  and  allowed  to  thaw  on  ice  and  then  shaken  for  about 
60  seconds  in  an  ultrasonic  bath  to  disrupt  the  cells.  The  mixture  was  then  centrifuged  at 
2,500g  at  4°C  for  10  min.  in  a  Damon-IEC  centrifuge  (see  Figure  2.10).  50µI  of  the 
supernatant  was  added  to  50µl  of  assay  mixture  (for  composition  of  assay  mixture  see 
below)  in  a  microcentrifuge  tube,  mixed  by  means  of  a  rotary  mixer  and  incubated  in  a 
water  bath  at  37°C  for  20  mins.  The  reaction  was  stopped  by  removing  30µI  aliquots  of 
the  mixture  and  spotting  on  paper  pieces  (Whatman  3MM  chromatography  paper, 
10mm2),  previously  marked  with  the  sample  number  in  pencil,  and  dropped  in  a  beaker 
containing  66%  (v/v)  ethanol  in  water.  Blank  samples  were  prepared  by  mixing  50µl  of 
disruption  buffer  with  50µl  of  assay  mixture. 
The  filter  paper  squares  were  subsequently  washed  three  times  for  40  min  each 
in  the  66%  ethanol  on  a  magnetic  stirrer,  replacing  the  ethanol  with  a  fresh  mixture  after 
each  wash.  The  stirring  bar  was  screened  with  an  aluminium  mesh  to  prevent 
disintegration  of  the  filter  papers.  After  the  final  wash,  the  ethanol  was  decanted  and  the 
papers  washed  for  1  minute  in  acetone.  The  papers  were  allowed  to  dry  in  air  and  the 
radioactivity  of  each  paper  measured  in  a  Tri-Carb  2000CA  scintillation  counter 
(Packard,  Berks.,  England),  by  placing  the  filter  papers  in  20ml-plastic  scintillation  vials 
with  2  ml  of  Ecoscint  scintillation  fluid  (National  Diagnostics,  Manville,  NJ,  USA).  (  for 
method  flowchart  see  Figure  2.10) 
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46 The  total  amount  of  radioactivity  present  in  the  assay  mixture  was  measured  by 
spotting  50µl  of  assay  mixture  onto  a  filter  paper,  allowing  to  dry  and  counting  as 
above. 
2.9  Protein  assay 
The  amount  of  protein  present  in  the  supernatant  of  freeze  thawed  cells  was 
measured  by  the  Folin-phenol  method  (Lowry,  1951)  with  bovine  serum  albumin  as  a 
standard  (as  described  in  section  2.4.2). 
2.10  CALCULATIONS  AND  STATISTICS: 
An  outline  of  each  calculation  used  in  the  Results  is  given  below.  Some  are 
taken  from  Gibson  and  Skett,  (1994). 
2.1  1  Cytochrome  P450-Dependent  Enzyme  Activities 
The  amount  of  metabolite  formed  can  be  calculated  by  direct  reference  to  the 
standard  curve. 
Amount  of  product  in  incubation  =X  nmoles 
incubation  time  =  30  minutes 
Protein  content  =Y  mg  protein 
Enzyme  activity  =X  /30Y  nmoles/min.  /mg  protein 
47 2.12  How  to  calculate  the  volume  of  the  buffer  for  microsome 
preparation 
liver  weight  (g)  x5  ml  of  buffer 
2.13  Total  Protein  (mg) 
=  volume  of  buffer  x  Protein  concentration 
2.14  Protein  (mg/g  ) 
=Total  Protein  /  Liver  weight 
2.15  Liver  weight  as  %  of  Body  weight 
=  Liver  weight  x  100  /  Body  weight 
2.16  Steroid  metabolising  enzyme  activities 
The  amount  of  each  metabolite  of  androst-4-dione-3,17-dione  expressed  as 
pmole  metabolite  formed  per  minute  per  106  cell  or  mg  protein  was  determined  using 
the  formula  shown  below: 
pmol  metabolite  /  min.  /106  cell  or  mg  of  protein=  Sx  (Cm/Ct)  x  (1/t)  x  (1/n)  x 
(1/N 
Where 
48 S=  amount  of  substrate  added  (µg) 
Cm  =  d.  p.  m.  metabolite 
Ct  =  d.  p.  m.  total 
MW  =  molecular  weight  of  substrate  (286) 
t=  incubation  time  (minutes) 
n=  number  of  cells  (divided  by  106) 
this  gives  activity  in  nmoles  product  /  min.  /  million  cells 
2.17  Counting  number  of  cells  /  Iml  (in  steroid  metabolism) 
Using  the  haemocytometer: 
if  there  are  20  cells  in  one  large  square  and  the  viability  is  80%  then  viable  cells  = 
20  x  0.8  =  16  million  cells/ml 
If  the  total  volume  of  cell  suspension  is  30m1,  then 
..  Total  number  of  cells  =  30x  16  =  480  million  viable  cells 
:.  make  up  to  48m1,  to  give 
The  final  concentration  =  480=48  =  10  million  cells/lml 
2.18  Calculations  of  glycogen  phosphorylase  a  activity 
The  activity  of  glycogen  phosphorylase  a  in  a  given  sample  was  measured  as  the 
amount  of  14C-glucose  incorporated  into  glycogen  after  subtraction  of  the  blank  values. 
49 Enzyme  activity  is  expressed  as  nmol  of  14C-glucose  1-phosphate  into 
glycogen/min.  /mg  of  protein. 
ENZYME  ACTIVTY=(DPMS-DPMB)/DPMTX  [S]  X  (1/P)  X  (1/t)  X  (10,000/3) 
where, 
DPMS,  DPMB,  DPMT  are  the  disintegrations/min.  for  the  sample,  blank  and  total 
amount  of  radioactivity  in  the  assay  respectively. 
[S]  =  substrate  (GIcIP)  concentration  (50mM  in  all  the  assays) 
P=  protein  conc.  of  the  supernatant 
t=  incubation  time  (min) 
Results  were  expressed  as  percentage  increase  in  phosphorylase  a  activity  of 
appropriate  control  values. 
2.19  STATISTICS 
The  means  and  standard  deviation  were  calculated  where  appropriate.  Statistical 
differences  were  determined  by  the  ANOVA  followed  by  Dunnet's  test  and  the  level  of 
significance  set  at  P<0.05.  In  many  cases  results  were  calculated  as  percentage  of 
relevant  control  values  (as  the  control  values  could  vary  between  cell  preparations  and 
between  experiments)  to  make  understanding  of  the  results  easier.  In  these  cases 
statistics  were  performed  on  the  untransformed  data  and  these  statistics  given. 
50 2.20  REAGENTS  USED 
2.20.1  BUFFERS 
To  make  1  Molar  phosphate  Buffer  pH  7.4 
Make  the  following  solutions: 
Solution  A:  9.08g  ofKH2PO4  (BDH  Chemicals)  dissolved  in  1  liter  of  distilled  water 
Solution  B:  11.88g  of  Na2HPO4.2H20  (Hopkin  and  Williams)  dissolved  in  1  liter  of 
distilled  water 
0.1M  solution  was  prepared  by  adding  19.6ml  of  solution  A  to  80.4ml  of  solution  B  and 
diluting  to  I  litre.  pH  =  7.4 
100m1  of  0.1M  buffer  was  diluted  to  1  litre  and  11.5g  of  potassium  chloride  was  added 
to  give  0.01M  buffer  (pH=7.4)  for  use  in  microsome  preparation. 
2.20.2  NASH  reagent: 
75g  of  ammonium  acetate  (BDH  Chemicals)  was  dissolved  in  500mI  distilled 
water.  1.5m1  glacial.  acetic  acid  (M&B)  and  lml  acetylacetone  (Sigma  Chemical 
Co.  Ltd.  )  was  added.  This  reagent  is  made  just  before  it  is  used  as  it  is  unstable. 
51 2.20.3  CO-FACTOR  MIXTURE  FOR  ENZYME  ASSAYS 
For  each  incubation 
3mg  NADP+  (Sigma  Chemical  Co.  Ltd.  ) 
3.9  mg  Trisodium  Isocitrate  (Sigma  Chemical  Co.  Ltd.  ) 
dissolved  in  1001il  MnC12  solution  (6mg/l00m1)  (BDH  Chemicals) 
Add  I  Oµl  Isocitrate  Dehydrogenase  (Boehringer  Mannheim). 
Isocitrate  +  NADP+  -+  a-ketoglutarate+  NADPH+H+  +  CO2 
2.21  Buffers  and  physiological  solutions: 
Perfusion  buffers  were  prepared  from  a  5xstock  solution  containing  the 
ingredients  listed  in  500ml  of  distilled  water. 
NaCl 
............................................ 
17.  lg 
NaHCO3 
....................................... 
5.25g 
HEPES 
.......................................... 
6.50g 
Glucose 
......................................... 
5.00g 
KCl(10%  w/v  soln)  ..................... 
8.75m1 
MgSO4.7H2o 
................................. 
7.25m1 
KH2PO4 
........................................ 
4.00m1 
The  stock  solution  was  stored  at  2  to  4°C  and  was  not  used  if  more  than  a  week  old. 
52 2.21.1  Ca2+-Free  Krebs-Henseleit  solution  (with  EGTA)  -1500m11 
Ca2+-Free  buffer  was  prepared  by  dissolving  1.9g  EGTA  in  100ml  of  the  stock 
solution  that  has  been  diluted  to  450m1  with  distilled  water.  The  pH  was  adjusted  to  7.4 
with  0.1  M  NaOH  and  the  volume  made  up  to  500ml  with  distilled  water. 
2.21.2  Ca2+  free  Buffer  (with  out  EGTA)  [100mJJ: 
Dilute  20m1  of  stock  solution  to  100m1  with  distilled  water.  Adjust  pH  to  7.4 
with  0.  IM  NaOH. 
2.21.3  Collagenase  buffer  [100mi]: 
As  above  (section  2.21.2)  but  containing  4.2  mM  CaC12  (0.42m1  of  a  IM  CaC12 
stock  solution  /  100  ml  of  buffer)  and  the  pH  adjusted  to  7.6.  Due  to  the  high 
concentration  of  Ca2+  precipitation  of  calcium  salts  may  occur  in  the  collagenase  buffer. 
This  is  undesirable  and  to  avoid  precipitation,  the  CaC12  solution  was  added  gradually  to 
the  solution  while  stirring. 
2.21.4  Washing  buffer 
As  in  (section  2.21.2)  without  EGTA  and  containing  1.5  mM  CaCI2  (0.75  ml  of 
IM  CaC12in  500m1),  adjusted  at  pH  7.4. 
53 2.21.5  Buffer  and  radioactive  mixture  for  glycogen  phosphorylase  a  assay 
2.21.5.1  MOPS  Buffer 
(g  /100m1) 
MOPS 
........................................  2.09 
NaF 
........................................... 
0,84 
NaEDTA 
..................................... 
1.12 
Dithiothreitol  (DTT) 
................... 
0.154 
Dist.  water  ..............  to  .............. 
100m1 
Adjust  pH  to  6.5  with  0.1M  KOH.  Store  at  2  to  4  °C.  Discard  if  more  than  a  week  old. 
2.21.5.2  Radioactive  assay  mixture 
(mg/l  Omi) 
Caffeine 
.................................................... 
1.00mM 
Glycogen 
...:.............................................. 
2.00% 
a-D-Glucose-1  phosphate  .......................... 
336.3mg 
a-D-[U-14Glucose-1  phosphate  .................... 
25.0µl 
Distilled  water  ........................................ 
10.  Oml 
-  Dissolve  the  glycogen,  caffeine,  and  unlabelled  GIc1P  in  diluted  MOPS  buffer  (1:  1) 
with  GENTLE  shaking. 
-  Adjust  pH  to  6.5  with  0.1  N  HCL,  the  labeled  G1c1P  added  and  mixed  thoroughly. 
Transfer  1-ml  aliquots  to  microcentrifuge  tubes  and  store  at  -20  °C.  (will  keep  for  6 
months). 
54 2.22  -  SOURCES  OF  HORMONES,  DRUGS  AND  REAGENTS 
Hormones,  chemical  and  reagents  are  listed  according  to  the  manufacturer. 
Sigma  Chemical  Co.  Ltd..  St  Louis  MO.  USA: 
MOPS 
DL-dithiothreitol 
Caffeine 
Rabbit  liver  glycogen  type111 
HEPES 
Insulin  (porcine) 
EGTA 
Streptozotocin 
Bovine  serum  albumin  (Fraction  V) 
4-Androstene-3,17-dione 
a-D-Glucose-I  -phosphate 
Glucose  Assay  Kit 
Glucose  /  Urea  Nitrogen 
combined  standards  set 
Glucagon 
Insulin  Bovine 
CuSO4.  H2O 
Nicotinamide 
Semicarbazide 
Aminopyrine 
Hopkins  &  Williams.  Essex.  England: 
Sodium  fluoride 
Disodium  EDTA 
British  Drug  Houses.  Poole.  Enl  and 
Folin-Ciocalteu'  phenol  reagent 
glycine 
55 Potassium  Tartrate 
Sodium  Hydrosuiphite 
Magnesium  Chloride 
Aniline 
Trichloroacetic  Acid 
4-Aminophenol 
Zinc  Sulphate 
Calcium  Chloride 
Amersham  International  p.  l.  c..  Bucks.  England: 
[U-14C]-D-Glucose-1  phosphate 
Potassium  salt 
[4-14C]  androst-4-ene-3,17-dione 
Boehringer.  Mannheim.  Germany: 
Collagenase  A  from  Clostridium  histolyticum 
Keto-Diabur  Test  5000  strips 
GIBCO  BRL  Limited 
Ham's  F-10  Culture  medium 
Williams'  E  medium 
Penicillin  /  Streptomycin 
Fisons.  Loughborough.  England 
NaCl,  NaOH,  KCI,  MgSO4,  NaHC03,  KH2P04,  Glucose 
Kodak.  France 
X  Ray  film  (X-Omat) 
Devleloper  (DX  24) 
Fixer  (FX-40) 
56 RESULTS  AND  DISCUSSIONS 3.  IN-VIVO  EXPERIMENTS 
The  tables  and  figures  represent  the  results  which  were  collected  from  each 
experimental  run  and  the  statistical  analysis  of  the  results  were  from  9  normal,  healthy 
rats  treated  with  Artemisia  extract,  6  diabetic  rats  and  6  diabetic  rats  treated  with 
Artemisia  extract.  The  results,  in  general,  are  presented  for  individual  rats  as  each 
animal  acted  as  its  own  control  during  the  experiments. 
3.1  Normal  Rats  treated  with  Artemisia  (17  days): 
This  experiment  was  to  see  if  Artemisia  extract  had  any  observable  effects  on 
healthy  rats  such  as  changes  in  body  weight,  food  and  fluid  intake,  urine  volume,  urine 
glucose  concentrations  and  faeces  output.  The  results  of  this  experiment  are  shown  for 
normal  rats  treated  with  Artenzisia  extract  as  follows: 
All  9  rats  showed  normal  growth  rate.  In  summary,  body  weight  increased  over 
a  7-days  period  at  a  fairly  constant  rate  of  27.2  f  7.1g  before  treatment  and  28.2  ± 
6.9g  after  treatment  (Figure  3.1).  Faeces  output  was  not  significantly  different  (p>0.05) 
-  9.69  ±  4.74g  before  treatment  and  6.99  ±  1.96g  after  treatment  (Table  3.1).  Food 
intake  did  not  alter  significantly  after  introduction  of  the  Artemisia  extract  except  for 
rats  3  and  9,  which  appeared  to  have  a  low  food  intake  temporarily  upon  being  in  giving 
the  Artemisia  extract  but  the  feeding  habit  became  normal  after  1-2  days.  Overall, 
Artemisia  had  no  measurable  effect  on  food  intake  -  19.5  ±  6.75g  before  treatment  and 
22.3  ±  5.86g  after  treatment  (Figure  3.2).  Fluid  intake  in  all  9  rats  was  unchanged  by 
treatment  except  in  rats  4,5  and  6  where  it  was  reduced  slightly  in  the  presence  of 
Artemisia  extract  on  the  first  day  of  giving  Artemisia.  This  is  probably  due  to  a  taste 
factor  -  Artemisia  extract  is  bitter.  Overall,  however,  Artenzisia  extract  had  no  effect  on 
fluid  intake  -  22.4  ±  6.2ml  before  treatment  and  24.89  ±  5.77m1  after  treatment  (Figure 
3.3). 
Urine  volume  significantly  increased  from  7.11  ±  3.16  ml  to  9.3  ±  3.05ml  (p<0.05)  after 
treatment  with  Artemfsia  extract  (Figure  3.4).  This  was  seen  in  all  rats  but  is  particularly 
apparent  in  rats  1-6  with  little  change  in  rats  7  and  8.  Despite  the  unchanged  intake  of 
fluid  as  seen  above,  it  is  seen  that  Artemisia  extract  appeared  to  act 
57 Figure  3.1  The  effect  ofArtenzisia  judaica  extract  on  body  weight  of  control  male  rats. 
(T  )=  Start  of  Arlemisia  treatment  (note  :  treatment  started  on  day  11  in 
experiment  1,  (a)  and  day  7  in  experiments  2&3,  (b,  c)). 
Results  for  individual  rats  are  shown. 
(o  )=  rat  (1,4,7);  (")  =  rat  (2,5,8);  (V)=  rat  (3,6,9) 
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in  experiment  1  and  in  day  7  in  experiment  2&3,  (n.  d.  =  not  determined) 
DAY  RATZ  RATZ  RAT3  RAT4  RAT5  RAT6  RAT7  RATS  RAT9 
1  3.42  4.98  2.87  4.10  7.3  8.00  9.30  2.88  3.48 
2  5.40  4.30  2.50  5.80  7.60  6.40  12.25  8.30  3.92 
3  4.48  5.42  5.59  5.90  9.50  6.50  12.0  8.61  10.0 
4  3.46  4.22  4.13  7.80  9.20  6.20  8.40  10.3  10.01 
5  5.73  3.66  7.32  6.50  6.60  6.70  11.33  9.60  9.90 
6  5.43  4.72  5.68  8.90  9.40  9.60  10.43  8.96  9.34 
7  4.01  4.02  4.29  n.  d.  n.  d.  n.  d.  n.  d.  n.  d.  n.  d. 
11  5.62  6.84  6.62  4.00  5.50  5.00  8.22  12.5  12.1 
12  5.13  7.86  5.30  5.50  6.50  7.00  12.7  8.61  10.0 
13  5.04  7.05  5.17  4.50  5.00  7.10  5.92  6.57  8.57 
14  5.14  6.8  5.22  8.4  7.4  8.5  9.95  9.03  9.73 
15  5.14  6.80  5.22  5.90  5.40  8.80  6.89  7.72  6.24 
16  6.08  6.29  4.87  5.50  7.30  7.50  8.65  6.87  7.79 
17  4.20  6.80  4.83  n.  d.  n.  d.  n.  d.  10.0  8.65  6.89 
63 'as  a  mild  diuretic  There  were  no  detectable  ketones  in  the  urine  of  any  of  the  animals 
whereas  urine  glucose  concentrations  were  significantly  increased  in  rats  1-6  (p<0.05) 
but  not  in  rats  7-9  (Figure  3.5). 
Arlemisia  extract,  therefore,  has  little  effect  on  normal  animals  except  for  a 
slight  diuresis.  This  is  probably  related  to  the  apparent  appearance  of  glucose  in  the 
urine  of  rats  treated  with  the  extract.  Analysis  of  a  sample  of  Artemisia  extract  showed 
that  it  did  indeed  contain  substances  giving  a  positive  reaction  in  the  glucose  assay 
(results  not  shown  ).  This  is  unlikely  to  be  glucose  itself  as  this  would  be  retained  in  the 
body  and  used  as  an  energy  source  but,  perhaps,  a  non-metabolisable  sugar  derivative 
which  is  directly  excreted  in  the  urine  and,  thus,  acts  as  an  osmotic  diuretic  (e.  g. 
mannitol). 
3.2  Diabetic  Rats  (17  days): 
Before  testing  the  effect  of  the  Artemisia  extract  on  diabetic  rats  an  experiment 
was  carried  out  to  determine  any  changes  in  the  measured  parameters  in  rats  suffering 
from  diabetes  mellitus.  Animals  were  monitored  for  a7  day  period  before  being  made 
diabetic  so  that  each  animal  acted  as  its  own  control. 
On  administration  of  STZ  a  pronounced  decrease  in  body  weight  of  all  rats  was 
seen  especially  in  rat  2  (around  20g  weight  loss)  and  rat  6  (30g  weight  loss)  (Figure 
3.6).  Despite  this  weight  loss  all  rats  had  an  increased  food  intake  (hyperphagia) 
(18.93±7.92g)  in  control  animals  and  37.20±8.47g  in  treated  animals  (p<0.05))  (Figure 
3.7).  Fluid  intake  significantly  increased  in  all  rats  after  induction  of  diabetes  from 
21.05±9.10ml  to  244.40±50.84ml  (p<0.05)  after  treatment  with  STZ  (Figure  3.8)  and 
urine  volume  also  showed  a  large  increase  in  all  rats  from  6.21±3.18ml  to  200.0±39.  Oml 
(p<0.05)  after  treatment  with  STZ  (Figure  3.9).  Faeces  weight  only  showed  an  increase 
from  6.48±2.30g  to  14.65±3.19g  (p<0.05)  after  induction  of  diabetes  (Table  3.2).  All 
urine  samples  showed  glycosuria  (Figure  3.10)  and  all  tested  positive  for  ketones  after 
induction  of  diabetes. 
64 Figure  3.6  The  effect  of  STZ-induced  diabetes  on  body  weight. 
(T  )=  Treatment  with  STZ  (65mg  /  kg). 
Results  for  individual  rats  are  shown  in  graphs  a  and  b  as. 
o=  rat  (1,4);  9=  rat  (2,5);  V=  rat  (3,6)  from  two  separate 
experiments  (  ab) 
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0  14 Table  3.2  Faeces  (g)  of  diabetic  rat  on  day  7  STZ  was  given  (n.  d.  =  not  determined). 
DAYS  RATZ  RAT2  RAT3  RAT4  RAT5  RAT6 
1  11.2  3.40  1.50  5.00  2.20  2.40 
2  7.40  7.00  4.20  7.10  9.50  13.5 
3  10.5  7.50  7.00  7.50  4.00  6.00 
4  5.50  6.50  4.00  8.50  4.00  2.50 
5  7.50  7.50  8.10  10.0  4.00  2.50 
6  11.5  5.50  9.20  8.80  4.90  7.30 
7  5.50  6.90  8.00  n.  d  5.00  5.00 
11  11.9  11.0  14.6  n.  d.  n.  d.  n.  d. 
12  10.3  15.0  16.6  14.0  12.3  18.3 
13  6.00  17.0  20.0  13.5  14.0  n.  d 
14  13.0  13.0  14.0  21.0  16.0  13.0 
15  11.0  13.5  18.5  18.0  n.  d.  14.0 
16  16.5  n.  d.  20.0  13.4  15.0  15.0 
17  18.5  n.  d.  11.5  14.0  n.  d.  n.  d. 
70 3.3  Diabetic  Rat  treated  with  Artemisia  (27  day  experiment): 
This  experiment  was  designed  to  try  and  established  the  beneficial  effect,  if  any, 
of  Artemisia  judaica  in  diabetic  rats. 
Induction  of  diabetes  caused  the  same  rate  of  weight  change  as  seen  in  the 
previous  experiment  (26.12±12.45g  in  control  animals  and  -2.6±7.31g  in  diabetic 
animals)  (p<0.05) 
. 
This  was  associated  with  the  other  characteristics  of  diabetes 
mellitus  (i.  e.  polydipsia  ,  polyuria  (Figure  3.14)  and  hyperphagia.  All  animals  showed 
clear  glycosuria  and  significant  signs  of  ketosis  after  induction  of  diabetes. 
Replacement  of  the  drinking  water  by  a  crude  extract  of  Artemisia  judaica  on 
day  17  following  induction  of  diabetes,  led  to  a  marked  inhibition  of  all  six  rats  to  drink 
any  extract  solution  and  this  led  to  dehydration  see  (Figure  3.11)  and,  thus,  a  marked 
decrease  in  body  weight.  This  weight  loss  was  so  severe  that  rat  6  was  sacrificed  early. 
On  day  19  the  plant  extract  was  replaced  by  water  for  24  hours  and  then  the  dose  of 
extract  was  gradually  increased  to  allow  body  weight  to  stabilize  while  continuing 
treatment  with  Artemisia  extract.  Overall  a  small  though  non-significant  reversal  of  the 
weight  loss  caused  by  diabetes  was  seen  (before  treatment  26.014.5g,  after  treatment 
with  STZ  -2.6±7.30g  and  after  treatment  with  Artemisia  extract  (4.0±12.5g)  (Figure 
3.11).  There  was  no  improvement  in  food  intake  (before  treatment  with  Arlemisia  ; 
23.2±5.84g,  after  treatment  with  STZ  ;  33.27±  9.52g  and  after  treatment  with  Artemisia 
;  41.86±7.1g)  and,  indeed,  food  intake  increased  further  (Figure  3.12).  Urine  volume 
was  also  unchanged  by  Artemisia  treatment  (7.4812.60ml  in  control  animals, 
191.97±39.41ml  after  treatment  with  STZ  and  199.57±29.21m1  with  Artemisia  extract 
(Figure  3.14)  as  was  the  fluid  intake  (Figure  3.13)  and  faeces  weight  (Table  3.4). 
Significant  results  were  found  for  urine  glucose  and  ketone  levels.  Glucose  levels  were 
reduced  on  the  last  2  days  of  Artemisia  treatment  (Figure  3.15)  often  the  urine  tested 
negative  for  ketones  in  the  animals  treated  with  Artemisia  extract  (Table  3.3). 
71 Figure  3.11  The  effect  of  STZ-induced  diabetes  and  Ariemisia  judaica  extract 
treatment  on  body  weight. 
(1)  =  Treatment  with  STZ  (65mg  /  kg) 
. 
(2)  =  Start  of  treatment  with  Artemisia  extract  in  a  and  b  as. 
o=  rat  (1,4);  "=  rat  (2,5);  V=  rat  (3,6) 
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DAYS Figure  3.12  The  effect  of  STZ-induced  diabetes  and  Ariemisia  judaica  treatment  on 
food  intake 
(1)  =  Treatment  with  STZ  (65mg  /  kg). 
(2)  =  Start  of  treatment  with  Artemisia  extract  in  a  and  b  as. 
o=  rat  (1,4);  "=  rat  (2,5);  V=  rat  (3,6) 
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14  21  28 Figure  3.13  The  effect  of  STZ-induced  diabetes  and  Artemisiajudaica  treatment  on 
fluid  intake. 
(1)  =  Treatment  with  STZ  (65mg  /  kg). 
(2)  =  Start  of  treatment  with  Artemisia  extract  in  a  and  b  as. 
o=  rat  (1,4);  "=  rat  (2,5);  V=  rat  (3,6) 
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U/I4LI  cU Figure  3.14  The  effect  of  STZ-induced  diabetes  and  Artemisia  judaica  extract 
treatment  on  urine  volume. 
(1)  =  Treatment  with  STZ  (65mg  /  kg). 
(2)  =  Start  of  treatment  with  Artemisia  extract  in  a  and  b  as. 
o=  rat  (1,4);  9=  rat  (2,5);  V=  rat  (3,6) 
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07  i4  41  LU Figure  3.15  The  effect  of  STZ-induced  diabetes  and  Artemisiajudaica  extract 
treatment  on  urine  glucose. 
(1)  =  Treatment  with  STZ  (65mg  /  kg). 
(2)  =  Start  of  treatment  with  Artemisia  extract  in  a  and  b  as. 
5.  b=  rat  2;  c=  rat  3;  d=  rat  4&e=  rat 
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01  .1 Table  3.3:  Urine  ketone  of  diabetic  rats  treated  with  Artemisia  judaica  (  STZ  was  given 
on  day  7  and  treatment  begun  on  day  17.  &  n.  d  =  not  determined) 
Urine 
Ketone  DAYS  RATZ  RAT2  RAT3  RAT4  RAT5  RAT6 
1  -ve  -ve  -ve  -ve  -ve  -ve 
2  -ve  -ve  -ve  -ve  -ve  -ve 
3  -ve  -ve  -ve  -ve  -ve  -ve 
4  -ve  -ve  -ve  -ve  -ve  -ve 
5  -ve  -ve  -ve  -ve  -ve  -ve 
6  -ve  -ve  -ve  -ve  -ve  -ve 
7  -ve  -ve  -ve  -ve  -ve  -ve 
11  ++  ++  +  n.  d.  +++  +++ 
12  +++  ++  +  +++  +++  +++ 
13  +++  +++  ++  ++  +++  ++ 
14  +++  +++  +++  +++  +++  +++ 
15  +++  +++  +++  +++  +++  +++ 
16  ++  ++  +++  +++  +++  +++ 
17  +++  +++  ++  +++  +++  +++ 
21  +  ++  ++  ++  ++  n.  d. 
22  ++  +  +  -ve  +  n.  d. 
23  -ve  +  +  -ve  ++  n.  d. 
24  -ve  -ve  -ve  ++  -ve  n.  d. 
25  +  -ve  -ve  -ve  -ve  n.  d. 
26  +  -ve  -ve  -ve  +  n.  d. 
77 Table  3.4:  Faeces  (g)  weight  of  diabetic  rat  treated  with  Arlemisia  judaica  (  STZ  was 
given  on  day  7  and  treatment  begun  on  day  17.  &  n.  d  =  not  determined) 
Faeces 
Weight(g  DAYS  RATZ  RAT2  RAT3  RAT4  RAT5 
1  3.30  6.31  4.91  8.50  4.91 
2  6.50  9.90  5.780  7.80  5.60 
3  7.50  11.4  11.1  6.20  7.40 
4  6.50  6.50  5.50  12.0  7.50 
5  9.00  9.50  11.0  7.50  5.90 
6  8.50  7.50  6.00  n.  d  n.  d 
7  8.50  7.50  6.00  n.  d  n.  d 
11  10.5  16.0  10.0  13.5  20.0 
12  15.0  5.50  7.50  14.0  10.5 
13  10.0  9.30  13.5  20.0  18.0 
14  15.0  10.4  12.5  17.0  14.0 
15  14.2  14.43  10.0  15.0  10.5 
16  18.5  16.5  17.0  16.0  13.5 
17  n.  d  n.  d  n.  d  n.  d.  n.  d. 
21  n.  d.  16.0  18.5  19.0  n.  d. 
22  n.  d.  11.5  14.0  15.1  n.  d. 
23  n.  d.  11.5  13.5  13.5  n.  d. 
24  n.  d.  16.5  15.5  16.5  n.  d. 
25  n.  d.  19.0  16.5  17.0  n.  d. 
26  n.  d.  16.0  24.4  14.0  n.  d. 
78 3.4  Discussion: 
Before  discussing  the  results  obtained  from  the  in-vivo  experiments,  a  few 
general  comments  concerning  the  overall  results  need  to  be  made.  One  problem 
experienced  during  this  project,  which  is  common  to  all  in-vivo  experimentation,  is 
subject  individuality  which  can  possibly  cause  a  wide  range  of  variance  between 
experimental  groups  and  individual  animals  within  an  experimental  group.  We  tried  to 
minimise  this  problem  by  using  each  animal  as  its  own  control  -  i.  e.  the  same  animal 
was  assessed  before  treatment,  after  induction  of  diabetes  and  during  Artemisia 
treatment,  as  and  where  appropriate.  One  other  biological  variation  has  to  be 
considered,  however,  and  that  is  the  plant.  The  site  from  which  the  plant  was  collected 
and  the  time  of  plant  collection  as  well  as  the  maturity  of  the  plant  at  collection  time 
can  lead  to  variance  and  different  in  the  results.  Where  possible  a  full  set  of  experiments 
was  performed  with  a  single  extraction  of  the  plant  material. 
Another  significant  limitation  on  the  project  directly  related  to  the  in-vivo 
experiments  was  that  the  fluid  intake  in  all  diabetic  animals  was  significantly  reduced  in 
the  presence  ofArtemisia  extract  due  to  the  bitter  taste.  This  led  to  dehydration  of  the 
animals  which  caused  a  significant  decrease  in  the  body  weight  in  5  rats  and,  indeed,  one 
of  the  rats  (rat  6)  was  sacrificed  due  to  excessive  weight  loss.  This  led  to  a  modification 
of  the  experimental  schedule  as  described  above. 
One  of  the  first  observations  made  early  on  in  the  experiments  was  that  the 
animals  suffered  from  stress  upon  entry  into  the  metabolic  cages.  This  was  manifested  as 
agitated  behaviour,  increased  urine  volume  and  glucose  content  (stress  polyuria  and 
glycosuria),  reductions  in  food  and  fluid  intake  which  increased  the  apparent  weight  loss 
in  the  rats  during  the  first  24  hours.  This  problem  was  overcome  by  not  taking 
measurements  from  the  rats  until  they  had  been  in  the  metabolic  cages  for  24  hours. 
This  meant  most  animals  had  re-established  a  normal  food  and  fluid  consumption 
patterns  by  the  start  of  the  recording  period. 
The  induction  of  diabetes  with  STZ  was  followed  by  a  three  day  recovery  period 
to  reduce  the  chance  that  any  experimental  compounds  were  producing  seemingly 
beneficial  effects  simply  by  acting  as  radical  scavengers  and  preventing  or  reducing  the 
effects  of  STZ.  The  diabetogenic  effect  of  STZ  seen  in  the  present  study  is  in  agreement 
79 with  those  who  have  previously  reported  a  severe  hyperglycaemia  and  glucosuria  in  rats 
(Bone,  1990,  Salhanick  et  al.,  1983). 
The  initial  investigation  ofArtemisia  judaica  extract  in  normal  animals  produced 
interesting  results.  Urine  volume  was  found  to  increase  substantially  despite  fluid  intake 
remaining  at  a  constant  level.  This  would  suggest  that  Artemisia  judaica  is  itself  acting 
as  a  mild  diuretic.  We  were  concerned  about  the  apparent  presence  of  glucose  in  the 
urine  of  normal  animals  following  exposure  to  Artemisia  extract  in  the  first  6  rats.  A 
possible  explanation  for  this  may  be  the  presence  of  a  substance  in  the  Artemisia  extract 
that  reacts  in  the  glucose  assay  but  which  is  not  re-absorbed  through  the  kidney.  Indeed, 
assay  of  the  Artemisia  extract  itself  revealed  that  there  is  a  cross-reacting  substance  in 
the  extract,  the  nature  of  which  is  unknown  at  present  (giving  an  apparent  glucose 
reading  of  3.49  g/l).  Some  preliminary  ideas  about  the  contents  of  the  extract  are 
discussed  later.  The  effect  noted  may  be  similar  to  an  osmotic  diuretic  (e.  g.  mannitol). 
The  effect  of  Artemisia  extract  on  the  STZ  diabetic  animals  was  fairly  small  but 
included  a  decrease  in  glucose  urine  level  in  the  last  2  days  of  treatment  and  a  decrease 
in  the  presence  of  ketones  from  the  urine  within  72  hours  of  the  extract  first  being 
administered.  This  reduced  incidence  and  severity  of  ketosis  would  suggest  that  there  is 
an  improvement  in  the  handling  or  catabolism  of  lipids,  both  of  which  would  be 
beneficial  in  diabetes.  There  is,  thus,  some  indication  that  a  crude  extract  of  Arlemisia 
judaica  can  alleviate  some  of  the  symptoms  of  diabetes  mellitus.  The  overall  lack  of 
dramatic  effect  of  treatment  with  Artemisia  extract  in  the  in-vivo  experiments  could  be 
due  to  an  inadequate  dose  of  Artemisia  or  to  the  relatively  short  treatment  period. 
These  experiments  will  need  to  be  repeated  with  larger  doses  ofArtemisia  extract  (if  the 
animals  will  drink  it)  and  /  or  longer  periods  of  treatment. 
80 4.  Post  In-Vivo  liver  parameters 
At  the  end  of  the  in-vivo  experiments  described  above,  the  animals  were 
sacrificed,  the  liver  removed  and  washed  and  microsomes  prepared  as  described  in 
Materials  &  Methods.  The  following  results  were  obtained: 
4.1  Liver  weight  as  percentage  (%)  of  body  weight 
The  effect  of  streptozotocin-diabetes  and  treatment  with  Artemisia  extract  on 
liver  weight  (as  %  of  body  weight)  are  shown  in  Figure  4.1.  The  administration  of 
streptozotocin  caused  a  significant  decrease  in  liver  weight  (expressed  as  %  of  body 
weight)  as  compared  to  normal  livers  (p<0.05).  An  extract  of  Artemisia  given  to 
streptozotocin-induced  diabetic  rats  caused  the  liver  weights  to  return  to  normal  and,  in 
some  instances,  above  normal.  The  same  observation  was  seen  when  Arlemisia  extract 
was  given  to  normal  rats. 
4.2  Liver  protein  content: 
The  effect  of  streptozotocin  on  hepatic  microsomal  protein  content  in  normal 
rats  and  the  effects  of  Artemisia  extract  in  diabetic  rats  is  shown  in  Figure  4.2.  The 
administration  of  streptozotocin  induced  a  significant  increase  in  protein  content 
(p<0.05)  whereas  the  extract  of  Artemisia  given  to  normal  rats  caused  a  decrease  in 
protein  content.  To  make  sure  this  was  an  effect  of  Artemisia  extract  in-vivo  and  not 
something  interfering  with  the  protein  assay,  the  extract  was  added  to  microsomes  in 
vitro  and  caused  no  change  in  protein  content. 
4.3  Aniline  4-hydroxylase  activity: 
The  effect  of  streptozotocin-induced  diabetes  and  treatment  with  Artemisia 
extract  on  aniline  4-hydroxylase  activity  (expressed  as  nmol  product/min/mg  protein)  is 
shown  in  Figure  4.3.  The  administration  of  streptozotocin  caused  a  significant  increase 
(p<0.01)  in  the  enzyme  activity.  This  increase  was  partially  reversed  by  the 
administration  of  Artemisia  extract  to  the  diabetic  rats  but  there  was  no  significant 
effect  on  the  enzyme 
81 Figure  4.1  The  effect  of  diabetes  and  Artemisia  extract  treatment  on  liver  weight  as 
percentage  (%)  of  body  weight. 
Control  =  untreated;  NOR  +  ART(VIVO)  =  normal  rat  treated  with  Artemisiajudaica 
in-vivo;  DIA  +  ART(VIVO)  =  diabetic  rat  treated  with  Artemisia  judaica  in-vivo,  *=  p< 
0.05  compared  to  control 
Results  expressed  as  mean  ±  s.  d.  (for  normal  n=9  and  diabetic  and  diabetic  treated  with 
Arlemisla  judaica  n=  6) 
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%  OF  BODY  WEIGHT Figure  4.2  The  effect  of  diabetes  and  Artemisia  extract  treatment  on  liver  protein 
content. 
Control  =  untreated;  NOR  +  ART.  (VITRO)  =  normal  rat  treated  with  Artemisia  judaica 
in-vitro;  NOR  +  ART(VIVO)  =  normal  rat  treated  with  Artemisiajudaica  in-vivo;  DIA 
+  ART(VIVO)  =  diabetic  rat  treated  with  Artemisia  judaica  in-vivo,  *=  p<  0.05 
compared  to  control. 
Results  expressed  as  mean  ±  s.  d.  (for  normal  n=9  and  diabetic  and  diabetic  treated  with 
Ar/emisia  judaica  n=  6). 
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10  15  20 
PROTEIN  CONTENT  (nmol/min/mg  prot.  ) Figure  4.3  The  effect  of  diabetes  and  Artemisia  extract  treatment  on  aniline  4- 
hydroxylase. 
Control  =  untreated;  NOR  +  ART.  (VITRO)  =  normal  rat  treated  with  Artemisia  judaica 
in-vitro;  NOR  +  ART(VIVO)  =  normal  rat  treated  with  Artemisia  judaica  in-vivo;  DIA 
+  ART(VIVO)  =  diabetic  rat  treated  with  Artemisia  judaica  in-vivo,  **  =  p<  0.01 
compared  to  control  rat  &t=  p<0.05 compared  to  diabetic  rat. 
Results  expressed  as  mean  ±  s.  d.  (for  normal  n=9  and  diabetic  and  diabetic  treated  with 
Arlemisia  judaica  n=  6). 
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ENZYME  ACTIVITY  (nmol/min/mg) activity  when  Artemisia  was  added  directly  to  normal  microsomes  (in-vitro).  Normal 
rats  treated  with  Artemisia  extract  showed  little  decrease  in  the  enzyme  activity. 
4.4  Aminopyrine  N-demethylase  activity: 
The  effect  of  streptozotocin-induced  diabetes  and  Artemisia  extract  treatment  of 
normal  and  diabetic  rats  on  aminopyrine  N-demethylase  activity  is  shown  in  Figure  4.4. 
The  administration  of  streptozotocin  caused  a  significant  decrease  in  enzyme  activity 
(p<0.01).  This  decrease  was  reversed  by  the  administration  of  Artemisia  extract  to 
diabetic  rats.  The  administration  of  Artemisia  to  normal  rats  showed  no  significant 
effect  on  the  enzyme  activity  where  as  the  addition  of  Artemisia  extract  directly  to 
normal  microsomes  gave  a  significant  increase  in  enzyme  activity  (p<0.05). 
4.5  Liver  steroid  metabolism  : 
The  effects  of  streptozotocin-induced  diabetes  and  treatment  with  Arlemisia 
extract  on  the  five  enzymes  which  metabolize  the  steroid  androst-4-ene-3,17-dione  are 
shown  in  Figures  4.5-4.9.  The  administration  of  streptozotocin  induced  a  decrease  in  all 
of  the  enzyme  activities  except  the  7a-hydroxylase,  but  when  Artemisia  extract  was 
given  to  diabetic  rats  a  significant  increase  in  all  enzyme  activities  was  seen,  especially 
the  7a-  and  60-hydroxylases  (p<0.001)  and  the  5a-reductase  (p<0.05).  The  addition  of 
Artemisia  extract  directly  to  normal  microsomes  caused  a  significant  change  in  all 
enzyme  activities  except  the  16a-hydroxylase  whereas  the  administration  of  Artemisia 
extract  to  normal  rats  caused  a  significant  decrease  in  17-oxosteroid  oxidoreductase  and 
16a-hydroxylase  activities  but  no  significant  change  in  7a-hydroxylase  and  5et- 
reductase  activities. 
85 Figure  4.4  The  effect  of  diabetes  and  Arlemisia  extract  treatment  on  aminopyrine  N- 
demethylase  activity. 
Control  =  untreated;  NOR  +  ART.  (VITRO)  =  normal  rat  treated  with  Artemisia  judaica 
in-vitro;  NOR  +  ART(VIVO)  =  normal  rat  treated  with  Artemisiajudaica  in-vivo;  DIA 
+  ART(VIVO)  =  diabetic  rat  treated  with  Artemisiajudaica  in-vivo,  *=  p<0.05,  **_ 
p<  0.01  compared  to  control  rat  &  ttt  =  p<0.05  compared  to  diabetic  rat. 
Results  expressed  as  mean  ±  s.  d.  (for  normal  n=9  and  diabetic  and  diabetic  treated  with 
Artemisia  judaica  n=  6). 
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ENZYME  ACTIVITY  (nmol/min/mg) Figure  4.5  The  effect  of  diabetes  and  Artemisia  extract  treatment  on  liver  steroid 
metabolism  (7(x-hydroxylation  of  androst-4-ene-3,17-dione)  by  liver  microsomes. 
Control  =  untreated;  NOR  +  ART.  (VITRO)  =  normal  rat  treated  with  Artemisiajudaica 
in-vitro;  NOR  +  ART(VIVO)  =  normal  rat  treated  with  Artemisia  judaica  in-vivo;  DIA 
+  ART(VIVO)  =diabetic  rat  treated  with  Artemisia  judaica  in-vivo.  **  =  p<  0.01,  ** 
=  p<0.001  compared  to  control  rat  &  ttt  =  p<0.001  compared  to  diabetic  rat. 
Results  expressed  as  mean  ±  s.  d.  (for  normal  n=9  and  diabetic  and  diabetic  treated  with 
Artemisia  judaica  n=  6). 
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ENZYME  ACTIVITY  (AS  %  OF  CONTROL) Figure  4.6  The  effect  of  diabetes  and  Artemisia  extract  treatment  on  liver  steroid 
metabolism  (160-hydroxylation  of  androst-4-ene-3,17-dione)  by  liver  microsomes. 
Control  =  untreated;  NOR  +  ART.  (VITRO)  =  normal  rat  treated  with  Artemisia  judaica 
in-vitro;  NOR  +  ART(VIVO)  =  normal  rat  treated  with  Artemisia  judaica  in-vivo;  DIA 
+  ART(VIVO)  =  diabetic  rat  treated  with  Artemisia  judaica  in-vivo,  *=  p<  0.05 
compared  to  control. 
Results  expressed  as  mean  ±  s.  d.  (for  normal  n=9  and  diabetic  and  diabetic  treated  with 
Arlemisia  judaica  n=  6). 
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ENZYME  ACTIVITY  (AS  %  OF  CONTROL) Figure  4.7  The  effect  of  diabetes  and  Artemisia  extract  treatment  on  (60-hydroxylation 
of  androst-4-ene-3,17-dione  by  rat  liver  microsomes. 
Control  =  untreated;  NOR  +  ART.  (VITRO)  =  normal  rat  treated  with  Artemisia  judaica 
in-vitro;  NOR  +  ART(VIVO)  =  normal  rat  treated  with  Artemisiajudaica  in-vivo;  DIA 
+  ART(VIVO)  =  diabetic  rat  treated  with  Artemisia  judaica  in-vivo,  *=  p<o.  o5,  **  = 
p<  0.01  compared  to  control  rat  &  ttt  =  p<0.001  compared  to  diabetic  rat. 
Results  expressed  as  mean  ±  s.  d.  (for  normal  n=9  and  diabetic  and  diabetic  treated  with 
Artemisia  judaica  n=  6). 
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ENZYME  ACTIVITY  (%  of  control) Figure  4.8  The  effect  of  diabetes  and  Artemisia  extract  treatment  on  17a(ß)- 
hydroxysteroid  dehydrogenase  of  androst-4-ene3,17-dione  by  rat  liver  microsomes. 
Control  =  untreated;  NOR  +  ART.  (VITRO)  =  normal  rat  treated  with  Artemisia  judaica 
in-vitro;  NOR  +  ART(VIVO)  =  normal  rat  treated  with  Artemisiajudaica  in-vivo;  DIA 
+  ART(VIVO)  =  diabetic  rat  treated  with  Artemisiajudaica  in-vivo,  *=  p<o.  o5,  **  _ 
p<  0.01  compared  to  control  rat  &  ttt  =  p<0.001  compared  to  diabetic  rat... 
Results  expressed  as  mean  ±  s.  d.  (for  normal  n=9  and  diabetic  and  diabetic  treated  with 
Artemisia  judaica  n=  6). 
90 NORMAL 
NOR+ART(VITRO) 
NOR+ART(VIVO) 
DIABETIC  *** 
DIA+ART(VIVO)  **  ttt 
50  100  150  200 
ENZYME  ACTIVITY  (AS  %  OF  CONTROL) Figure  4.9  The  effect  of  diabetes  and  Artemisia  extract  treatment  on  5a-reductase  of 
androst-4-ene3,17-dione  by  rat  liver  microsomes. 
Control  =  untreated;  NOR  +  ART.  (VITRO)  =  normal  rat  treated  with  Artemisia  judaica 
in-vitro;  NOR  +  ART(VIVO)  =  normal  rat  treated  with  Artemisia  judaica  in-vivo;  DIA 
+  ART(VIVO)  =  diabetic  rat  treated  with  Artemisia  judaica  in-vivo,  *=  p<0.05,  **  _ 
p<  0.01  compared  to  control  rat  &  ttt  =  p<0.001  compared  to  diabetic  rat.. 
Results  expressed  as  mean  ±  s.  d.  (for  normal  n=9  and  diabetic  and  diabetic  treated  with 
Artemisia  judaica  n=  6) 
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ENZYME  ACTIVITY  (AS  %  OF  CONTROL)) 4.6  Discussion  of  Results  for  Liver  Parameters 
It  has  previously  been  shown  that  induction  of  the  diabetic  state  causes  a 
decrease  in  the  liver  weight  (Rouer  and  Leroy,  1980),  and  that  this  may  be  due  to  a 
decreased  plasma  insulin  level  resulting  in  a  decrease  in  hepatic  lipid  and  glycogen 
storage  (Pugazhenthi  and  Khandelwal,  1990).  This  would  also  result  in  an  increase  in 
liver  protein  content,  since  if  lipid  and  glycogen  storage  was  decreased  and  there  was 
therefore  a  decrease  in  liver  weight,  there  would  be  an  increase  in  the  amount  of  protein 
in  each  gram  of  tissue.  The  results  shown  here  are  consistent  with  previous  findings. 
The  change  in  liver  weight  was  reversed  by  treatment  with  Artemisia  extract. 
It  has  previously  been  shown  that  the  metabolism  of  various  drugs  is  strikingly 
altered  by  the  diabetic  state  (Defeng  et  al.,  1993).  Induction  of  the  diabetic  state  caused 
a  marked  change  in  the  enzyme  activity  of  certain  forms  of  cytochrome  P450.  These 
were  cytochrome  P4502E1,  which  was  increased,  and  the  cytochromes  P450  of  the  2B 
and  2C  subfamilies,  which  were  decreased.  The  induction  of  the  diabetic  state  inhibits 
the  microsomal  oxidation  of  drugs  such  as  aminopyrine  by  a  marked  decreased  in  the 
activity  of  the  cytochromes  P450  of  the  2B  and  2C  subfamilies  but  increases  the 
oxidation  of  aniline  (Defeng  et  al.,  1993),  which  is  known  to  be  an  effective  substrate 
for  cytochrome  P4502E1.  It  is  possible  to  measure  the  enzyme  activity  of  these  3  forms 
of  cytochrome  P450  as  described  by  Gibson  and  Skett  (1994).  By  using  the  assay  of 
aniline  4-hydroxylase  activity  described  earlier,  it  is  possible  to  measure  the  enzyme 
activity  of  the  2E1  form  of  cytochrome  P450.  The  assay  of  aminopyrine  N-demethylase 
used  was  that  described  by  Nash  in  1953  to  measure  the  formation  of  formaldehyde  and 
is  a  function  of  the  enzyme  activity  of  the  2B  and  2C  subfamilies  of  cytochrome  P450. 
The  overall  metabolism  of  the  steroid,  androst-4-ene-3,17-dione  has  been  shown 
to  be  decreased  in  diabetic  animals  (Reinke  et  al.,  1978)  although  there  are  reports  of 
increases  in  some  specific  enzyme  activities  (Skett  and  Joels,  1985).  The  results 
presented  here  are  consistent  with  those  found  earlier  although  the  increase  in  7a. 
hydroxylase  and  5a-reductase  seen  in  earlier  work  are  not  seen  here.  Artemisia  extract 
treatment  of  the  diabetic  animals  reversed  or  partially  reversed  the  effects  of  diabetes  on 
aniline,  aminopyrine  and  androst-4-ene-3,17-dione  metabolism.  The  addition  of 
Artemisia  extract  directly  to  microsomes  gave  some  unexpected  results  with  a 
92 significant  increase  in  aminopyrine  N-demethylation  and  androst-4-ene-3,17-dione 
metabolism  indicating  that  some  of  the  effects  of  the  Artemisia  extract  may  be  direct  on 
the  microsomal  enzymes  whereas  the  other  effects  may  be  indirect  (e.  g.  that  on  aniline 
metabolism).  The  nature  of  the  active  principles  of  the  Artemisia  extract  giving  these 
effects  is  /  are  at  present  unclear. 
93 5.  Clinical  Experiments 
The  following  results  were  obtained  from  a  small  series  of  patients  examined  at  the  Al- 
Afia  Houn  Hospital.  Each  patient  was  treated  individually  as  noted  and  blood  glucose 
was  assayed  by  the  technique  described  in  the  Materials  and  Methods. 
Patient  1"A  man  (43  years)  with  mild  diabetes  of  5  years  duration.  This  patient  had 
undergone  therapy  with  Artemisia  judaica  and  Marrubium  vulgare  with  a  controlled 
diet  for  approximately  three  years.  The  patient  was  asked  to  stop  his  own  treatment 
with  Artemisia  judaica  and  Marrubium  vulgare  extract  for  the  period  of  the  study.  His 
blood  glucose  levels  varied  from  162-180  mg/ml  before  treatment  with  Artemisia 
extract  and  135-159  mg/ml  after  a  2-7  day  period  of  treatment  with  Artemisia  extract 
(Figure  5.1(1)) 
Patient  2:  A  man  of  20  years  who  had  been  treated  with  insulin  injection  (40  Lu.  once 
daily).  The  patient  was  then  given  Artemisia  extract  as  described  three  times  daily 
together  with  the  pre-existing  insulin  therapy.  On  insulin  alone  the  blood  glucose 
concentration  was  180-192  mg/ml,  which  fell  to  160  mg/ml  after  6  days  treatment  and 
107  mg/ml  after  9  days  treatment  with  Arlemisia  extract.  The  insulin  dose  was 
subsequently  reduced  to  20  i.  u.  /day  and  the  blood  glucose  level  rose  to  150-152  mg/ml 
(Figure  5.1  (2)). 
Patient  3:  A  man  (age  17  years)  who  had  been  treated  with  plant  extracts  (one  of  them 
being  Artemisia  judaica)  since  being  a  juvenile.  He  had  stopped  using  the  Arlemisia 
because  when  he  took  it  he  suffered  from  bradycardia.  He  had  asked  the  doctor  to 
replace  his  treatment  with  lente  insulin  injection.  The  patient  was  given  40  i.  u.  /day 
insulin.  We  asked  the  patient  to  use  Artemisia  extract  with  insulin.  The  patient  had 
polyuria,  polydipsia  and  polyphagia  with  insulin  treatment  alone.  Blood  glucose  levels 
varied  between  180  and  210  mg/ml  without  Artemisia  extract  and  declined  from  200  to 
158  mg/ml  over  a5  day  treatment  period  with  Artemisia  extract  (Figure  S.  1(3)). 
94 Patient  4:  A  man  (aged  24  years)  with  diabetes  of  one  year  duration,  He  had  been 
treated  with  diet  restriction  and  insulin  (30  i.  u.  am.  and  20  i.  u.  pm).  This  was  the  first 
time  he  had  used  Artemisia  extract  but  he  knew  that  the  plant  is  widely  used  by 
diabetics.  Prior  to  taking  the  Artemisia  extract  his  blood  glucose  levels  were  231-371 
mg/ml  and  continued  to  varying  widely  during  a  10  day  treatment  with  the  extract  (  310 
mg/ml  on  day  3  of  treatment,  104  mg/ml  on  day  5,327  mg/ml  on  day  8  and  53  mg/ml 
on  day  10)  (Figure  5.1(4)). 
Patient  5:  A  woman  of  55  years  with  diabetes  mellitus  of  eight  years  duration.  She  had 
used  hypoglycaemic  agents  (Daonil®)  and  used  Artemisia  and  other  plants  at  some 
times.  This  patient  was  asked  to  stop  the  self-administration  of  these  plants  for  the 
duration  of  the  study.  Her  blood  glucose  levels  varied  from  288-325  mg/ml  before 
administration  of  Artemisia  extract  and  was  reduced  to  205  mg/ml  after  2  days 
treatment  with  the  extract.  Her  blood  glucose  level  continued  to  fall  to  180  mg/ml  at 
day  5  and  168  mg/ml  on  day  7  of  treatment  (Figure  5.1(5)). 
Patient  6:  A  man  of  60  years  with  mild  diabetes  of  20  years  duration.  He  had  used 
Artemisia  judaica  extracts  for  a  long  time  but  at  irregular  intervals  and  he  did  not  feel 
any  side  effects  of  the  treatment.  His  blood  glucose  levels  were  unchanged  by  treatment 
with  Artemisia  extract  (174-228  mg/ml  before  and  170-250  mg/ml  after)  (Figure 
5.1(6)). 
95 Figure  S.  1  Effect  of  treatment  on  blood  glucose  levels. 
1=  Patient(1),  2=  patient(2),  3=  patient(3), 
4=  patient(4),  5=  patient(s)  &6=  patient(6) 
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Several  diabetic  patients  in  Libya  have  reported  benefit  to  their  diabetic 
symptoms  of  polyuria  and  polydipsia  and  a  gain  in  body  weight  upon  daily  consumption 
of  the  aqueous  extract  of  Artemisia  judaica.  It  is  well  known  to  most  diabetic  patients 
and  grows  in  several  countries  such  as  Libya 
, 
Egypt,  other  parts  of  Africa  and  the 
Middle  East  as  well  as  the  United  States. 
Due  to  the  long  history  of  use  of  this  plant  and  its  efficacy  and  safety,  we  were 
encouraged  to  perform  an  evaluation  of  the  effects  of  Artemisia  judaica  on  blood 
glucose  in  diabetic  patients  and  also  to  see  whether  the  extract  caused  any  side  effects. 
The  results  showed  that  Artemisia  judaica  had  a  potent  therapeutic  value  in 
treating  some  patients  with  diabetes  as  it  significantly  reduced  blood  glucose  to  near  the 
normal  level  (80-120  mg/ml).  Patients  1,2  and  4  responded  well  to  Ariemisia  extract 
but  patient  3  had  no  response  after  2  weeks  of  treatment  showing  little  reduction  in 
blood  glucose  levels.  Patient  4  responded  to  Ariemisia  judaica  except  on  day  17  where 
a  significant  increase  to  317  mg/ml  in  blood  glucose  concentration  was  seen.  Patient  6 
had  no  response  to  the  treatment  with  Artemisia  extract. 
The  extract  seemed  to  have  no  side  effects  except  in  patient  3  who  still  suffered 
from  bradycardia  but  all  of  the  diabetic  symptoms  had  disappeared 
. 
These  results  suggest  that  Artemfsia  judaica  contains  material  capable  of 
reducing  blood  glucose  and  improving  diabetic  symptoms  but  this  is  only  a  small-scale 
clinical  trial  and  much  more  work,  including  a  full-scale  clinical  trial,  needs  to  be 
performed  before  it  can  be  said  that  Artemisia  judaica  extract  is  a  worthwhile  treatment 
for  diabetes  mellitus. 
97 6.  In-Vitro  Experiments  (Isolated  Hepatocytes) 
6.1  Androst-4-ene-3,  I7-dione  Metabolism 
6.1.1  The  effects  of  insulin  and  crude  extracts  of  Artemisia  judatca 
The  assay  for  the  metabolism  of  androst-4-ene-3,17-dione  allows  the 
measurement  of  five  different  enzyme  activities:  the  7a-hydroxylase,  60-hydroxylase, 
16c  -hydroxylase,  17-oxosteroid  oxidoreductase  (OHSD)  and  the  5a-reductase.  The 
data  in  the  tables  are  expressed  as  a  percentage  of  relevant  control  values  for  each 
experiment  as  the  control  values  can  vary  depending  on  the  animal  from  which  the  cells 
were  taken.  To  avoid  this  inter-experiment  variation,  control,  and  insulin-treated  cells 
were  assayed  in  all  experiments  to  compare  to  extract-treated  cells.  The  results  of  the 
first  experiment  (1/2  hour  &1  hour)  in  experiment  two  are  shown  in  Tables  6.1  and 
6.2. 
It  is  seen  that  neither  insulin  (at  10-6  and  10-9M)  nor  the  crude  extract  of 
Artemisia  judaica  had  very  much  effect  on  steroid  metabolism.  There  were  some 
decreases  in  5a-reductase  activity  with  10-9M  insulin  (p<0.001)  and  in  7a-,  6p-  and 
16a-hydroxylase  activities  with  Artemisia  extract  and  Artemisia  extract  with  insulin  (10' 
6M)  (p<0.05),  but  Artemisia  extract  with  insulin  (10'9M)  had  no  effect  on  steroid 
metabolism.  This  result  is  in  stark  contrast  to  those  of  Hussin  &  Skett  (1986)  who 
found  marked  increases  in  the  metabolism  of  androst-4-ene-3,17-dione  in  the  presence 
of  insulin.  The  reason(s)  for  this  discrepancy  were,  thus,  investigated. 
6.1.2  Effect  of  animal  weight  /  age 
The  first  difference  noticed  between  the  experiments  described  here  and  those  of  Hussin 
&  Skett  (1986)  was  the  age  (size)  of  the  animals  used.  Hussin  &  Skett  (1986)  used 
smaller  animals  (200-250g).  The  experiment  was,  thus,  repeated  using  the 
98 Table  6.1:  The  effect  of  insulin  (10-6M  &  10-9M)  and  Arlemisia  judaica 
(A10=0.02g/ml,  A.  j=0.2g/ml)  on  the  7a-,  60-,  and  16cc-,  hydroxylase,  17a(p)- 
hydroxysteroid  dehydrogenase  and  5a-reductase  after  1/2  hour  of  preincubation  in 
hepatocytes  obtained  from  normal  rat,  p  values  relative  to  control  values  were  obtained 
by  ANOVA  followed  by  Dunnet's  test  *=  p<0.05,  ***-  p<0.001. 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  ±  s.  d.,  (n=5). 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7a-0H  6ßOH  16a-0H  17-01SD  5a-Red. 
Control  100±18.14  100115.8  100±13.8  100±20.6  100±30.0 
Insulin  10-6  M  85.9±19.6  96.6±15.7  85.6±15.9  102.4113.7  86.5±9.80 
Insulin  10'9M  72.0±22.5  87.5±43.2  96.3±52.5  94.7±8.60  49.6±8.03*** 
A10  85.3±10.4  105.0±16.2  105.0±18.2  103.7±19.8  87.6±25.3 
A10  +  10-6M  88.2±21.9  103.2126.3  100±28.4  92.8±25.6  85.7±27.0 
A10+  10'9M  91.6±34.7  95.4130.1  87.4±25.6  92.5±32.3  95.1±28.5 
A.  j  61.9±24.4*  70.9±19.9*  65.2±25.3*  99.2±38.7  84.5±42.8 
A.  j  +  I'M  66.31±13.8*  76.3±8.20*  67.95±18.5*  90.3±23.6  75.2±17.1 
A.  j  +  r9M  88.0±14.0  104.7119.9  95.1±19.9  106.9±31.6  106.0±44.4 
99 Table  6.2:  The  effect  of  insulin  (10,6M  &  10"9M)  and  Artemisia  judaica  (A.  j=0.2, 
A10=0.02,  A100=0.002,  A1000=0.0002  g/  ml)  on  the  7a-,  60-  and  16a-,  hydroxylase, 
17a(ß)-  hydroxysteroid  dehydrogenase  and  5a-reductase  after  1  hour  of  preincubation 
in  hepatocytes  obtained  from  normal  rat,  p  values  relative  to  control  values  were 
obtained  by  ANOVA  followed  by  Dunnet's  test  *=p<0.05. 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  f  S.  D,  (n=5). 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7a-OH  600H  16a-OH  17-OHSD  5(x-Red. 
Control  100±28.7  100±27.0  100±24.1  100±22.2  100±40.1 
Insulin(r6M)  110.9±29.7  102.6±40.7  121.2±14.7  119.7±24.4  104.3±76.6 
Insulin(r9M)  105.0±32.4  106.2±27.5  85.4±11.9  109.3±24.8  102.4±36.0 
A10  107.518.50  114.41  12.7  108.8±5.68  116.0±9.26  82.91  15.4 
A10  +  I-6M  104.8±22.1  95.2±20.6  81.6113.9  132.0±49.1  94.2±39.8 
A10  +  r9M  84.1±26.3  82.1±35.3  76.0122.4  92.9±45.3  71.9±42.3 
A100  132.1±10.7  135.0±4.74  116.7±  17.3  130.0±20.3  111.0±40.8 
A100  +  I-6M  169.7±107.2  77.96±36.0  65.3±25.8  127.6±77.3  126.2±88.4 
A100+I'9M  117.3±26.1  100.9±9.03  97.0±26.1  121.9±39.3  95.9±29.5 
A1000  141.5±53.1  135.4152.4  152.0±53.9  200.8-+112.8  100.1±66.7 
A  1000+  14M  100±19.6  110.6±20.5  98.2±21.0  108.6121.0  88.44:  23.6 
A1000  +r9M  99.2±35.9  91.1±32.8  88.5±32.5  97.6±25.2  81.3±37.0 
100 Table  6.3:  The  effect  of  insulin  (10'6M  &  10  9M) 
andArtemisiaJudaica  (A.  j  0.2,  A10=0.02, 
A100=0.002,  A1000=0.0002  g/  ml)  on  the  7a-,  6ß-  and  16oc-,  hydroxylase.  170t(ß-  hydroxysteroid 
dehydrogenase  and  Sat-reductase  after  1/2  hour  of  preincubation  in  hepatocytes  obtained  from  normal 
(weighed  200g)  rat,  p  values  relative  to  control  values  were  obtained  by  ANOVA  followed  by  Dunnct's 
test  p<0.05.  Results  are  expressed  as  percentage  of  the  relevant  control  and  meant  S.  D.  (n-5). 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7a-0H  60OH  16a-OH  17-OHSD  5a-Red. 
Control  100±14.2  100±6.74  100±9.00  100±11.6  100114.1 
Insulin(I-6M)  142.5±31.3  122.4±44.2  147.7±48.1  155.1±60.2  154.8±76.8 
Insulin(I"9M)  111.016.11  107.2±1.84  120.2±19.9  105.2±14.2  97.9±15.3 
A10  169.4±30.8  119.2±58.8  133.4±75.3  94.1144.9  112.0±78.8 
A10  +  1-6M  101.7±25.9  83.1±21.6  84.6±25.6  75.1±12.1  73.5±13.8 
A10  +  1-9M  119.1±30.1  114.5±23.7  113.2±42.3  75.1±12.8  73.5±13.8 
A100  139.9±39.4  110.3±22.6  124.7±20.9  104.916.56  100.5±15.0 
A100  +  1-6M  154.8±30.6*  1423±32.5  146.9132.0  150.7±30.2  74.7±10.9 
A100  +  I-9M  133.3±18.8  126.1±27.9  166.5±24.2  131.3±21.3  144.2±15.0 
A1000  124.5±14.7  96.1±14.2  115.4124.0  76.8±13.7  91.3±47.8 
A1000+I-6M  149.1131.8  126.5±14.1  142.3±30.9  95.4±22.3  89.4111.6 
A1000+1-9M  125.9±30.1  79.9±17.0  82.7125.6  97.6±10.1  94.6116.2 
101 hepatocytes  obtained  from  a  200g  male  rat  as  shown  in  Table  6.3.  As  is  seen,  there  is 
still  very  little  effect  of  insulin  or  the  Artemisia  extract  except  that  the  trend  towards  an 
increase  in  7a-hydroxylase  activity  in  the  presence  ofArlenilsia  extract  has  now  become 
significant  when  10-6M  insulin  is  added  as  well.  The  age  of  the  animal  is,  thus,  of  little 
importance. 
6.1.3  Effect  of  different  insulin  preparations 
The  next  suggestion  was  that  the  insulin,  as  stored  in  aliquots  in  the  freezer  at  - 
20°C,  had  degraded.  A  fresh  batch  of  insulin  was  made  and  used  directly  for  addition. 
As  can  be  seen  in  Table  6.4,  there  was  still  no  significant  effect  of  insulin  at  either 
concentration.  There  was  very  little  effect  of  the  Artemisia  extract  except  for  a 
significant  increase  in  60-hydroxylase  activity  in  the  presence  of  10-9M  insulin.  It  is 
unlikely,  therefore,  that  the  insulin  stability  was  at  fault.  In  the  experiments  of  Hussin  & 
Skett  (1986),  a  porcine  insulin  preparation  from  Novo  (Denmark)  and  Neulente®Zinc 
insulin  (Wellcome,  U.  K.  )  was  used  whereas  in  these  experiments  a  similar  preparation 
from  the  Sigma  Chemical  Co.  (U.  K.  )  was  used.  Could  this  be  the  difference?  The 
various  insulin  preparations  and  different  times  were  tried  in  one  experiment  and  the 
results  shown  in  Tables  6.5a-e.  None  of  the  insulin  preparations  tested  had  any 
significant  effect  on  androst-4-ene-3,17-dione  metabolism. 
6.1.4  Effect  of  Different  Culture  Media 
The  above  experiments  were  performed  in  Ham's  F"10  medium  but  recent 
experiments  in  this  laboratory  have  indicated  that  this  is  not  the  best  medium  for  the 
maintenance  of  liver-specific  functions  in  isolated  rat  hepatocytes  (Skett,  1994).  It  was, 
thus,  decided  to  test  the  effects  of  insulin  and  Artenmisia  extract  in  Williams'  E  medium 
and  in  Ham's  F-10  in  the  absence  of  albumin  (in  case  the  insulin  was  binding  to  the 
albumin  and  being  inactivated).  As  shown  in  Tables  6.6  and  6.7,  neither  of  these 
changes  altered  the  lack  of  effect  of  insulin  or  Artemisia  extract.  Although  there  were 
some  trends  to  increases  and  decreases,  there  was  no  significant  change  in  the  activities 
measured. 
102 Table  6.4:  The  effect  of  insulin  (10,6M  &  10'9M)  and  Artemisia  judaica  (A10=0.02  g 
/  rnl)  on  the  7a-,  60-  and  16a-,  hydroxylase,  17a(ß)-  hydroxysteroid  dehydrogenase 
and  5a-reductase  after  1/2  hour  of  preincubation  in  hepatocytes  obtained  from  normal 
rat,  p  values  relative  to  control  values  were  obtained  by  ANOVA  followed  by  Dunnet's 
test  (*  =p<0.05). 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  ±  S.  D,  (n=5) 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7(x-OH  6AOH  16a-OH  17-OIISD  5a-Red. 
Control  100114.1  100±9.71  100±  15.7  10017.28  10014.94 
Insulin(I6M)  116.9±41.4  90.2±14.6  99.8±14.1  95.6±3.84  93.4±21.4 
Insulin(I'9M)  132.6±16.8  117.3±7.81  116.1±7.83  107.7±7.90  90.9113.7 
A10  135.9±31.3  116.7±20.2  110.2±13.1  96.6±3.84  92.4±6.60 
A10  +  I6M  115.4±9.70  110.9±4.30  117.2±2.42  98.4±7.82  92.9±6.10 
A10  +  r9M  137.9±13.7*  120.7±7.85;  100.1±4.86  101.6±7.60  100.0±20.9 
103 Table  6.5:  The  effect  of  different  types  of  insulin  (IP=isophane  porcine  insulin, 
Blnew=bovin  insulin  new  stock  &  BIold=bovin  insulin  old  stock)  on  the  7a-,  6ß-,  and 
16a-,  hydroxylase,  17a(ß)-  hydroxysteroid  dehydrogenase  and  Sa-reductase  after 
a=5min.,  b=l0min.,  c=l5min.,  d=20min.,  e=1/2hour  of  preincubation  in  hepatocytes 
obtained  from  normal  rat,  p  values  relative  to  control  were  obtained  by  ANOVA 
followed  by  Dunnet's 
. 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  f  S.  D,  (n=S) 
a) 
Enzyme  Activity  (  expressed  %  of  control) 
GROUP  7a-OH  60OH  16a-0H  17-OIISD  5a-Rcd. 
Control(1/21u)  100±19.3  100±14.1  100±17.8  100126.6  100±21.5 
IP  (10-6M)  89.0±14.8  93.8112.2  102.3120.5  113.1±13.3  102.0122.7 
Blnew,  10.6M  77.1±14.1  78.4119.5  94.0±24.3  100.5±19.0  98.4±19.9 
BIold,  10.6M  76.7±22.9  80.7±24.8  92.4125.3  98.0116.3  91.6±14.9 
104 b) 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7a-OH  600H  16a-0H  17-OIISD  Sa-Red. 
Control(1/2hr)  100±13.96  100±2.24  100±5.64  100±20.1  100±5.99 
IP  (10-6M)  106.1±11.4  80.9±9.49  75.2±3.39  89.8111.9  87.6±7.06 
Blnew,  10-6M  118.8±9.94  109.0±4.61  91.1±19.5  99.5119.0  113.2±13.4 
BIold,  10-6M  107.7±20.7  101.6±25.7  90.4±22.3  108.616.35  110.6±12.1 
C) 
Enzyme  Activity  (expresscd  as  %  of  control 
GROUP  7a-OH  600H  16a-OH  17-OHSD  Sa-Red. 
Control(1/2hr)  100±14.3  100±24.5  100±21.4  100140.8  100129.8 
IP  (10-6M)  95.9±16.4  109.9±9.20  100.6±6.29  102.4±13.9  95.0±17.6 
BInew,  106M  103.6±16.7  100.0±20.3  106.2±22.4  113.7±16.99  96.8±7.97 
BIold,  10'6M  117.4±27.8  121.2±34.3  124.7±40.4  89.6±23.9  89.3±14.2 
105 d) 
GROUP 
Control(1/2hr) 
7a-OH 
100±28.6 
Enzyme  Activity  (expressed  as  %  of  control) 
6ßOH  16a-0H  17-OHSD 
100±23.8  100±20.7  100±20.3 
5a-Red. 
100±22.5 
IP  (10-6M)  72.99±6.46  85.5±23.9  79.75±11.9  81.3±17.9  94.8±10.1 
BInew,  10'6M  82.8±22.75  87.2±22.5  73.1±18.9  81.9±8.43  88.37±17.5 
BIold,  10"6M  116.3±40.6  87.8±34.6  94.9±31.5  87.0±6.42  81.5±2.95 
e) 
Enzyme  Activity  (  expressed  as  %  of  control  ) 
GROUP  7a-OH  6ßOH  16a-0H  17-0IISD  5a-Rcd. 
Control(1/21u)  100±19.3  100±14.1  100±17.8  100±26.6  100±21.5 
IP  (10'6M)  89.0±14.8  93.8±12.2  102.3±20.5  113.1113.3  102.0122.7 
BInew,  10'6M  77.1±14.1  78.4±19,5  94.0±24.3  100.5±19.0  98.4±19.9 
BIold,  10'6M  76.7±22.9  80.7±24.8  92.4±25.3  98.0116.3  91.6±14.9 
106 Table  6.6:  The  effect  of  insulin  (10'6M)  and  Artemisia  judaica  (A.  j=0.2,  A10=0.02, 
A100=0.002,  A1000=0.0002,  A10000=0.00002  g/  ml)  on  the  7a-,  60-  and  16a-, 
hydroxylase,  17a(ß)-  hydroxysteroid  dehydrogenase  and  Sa-reductase  after  1/2  hour  of 
preincubation  in  hepatocytes  obtained  from  normal  rat  in  Ham's  F-10  medium,  p  values 
relative  to  control  values  were  obtained  by  ANOVA  followed  by  Dunnet's  test  *P 
<0.05 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  :kS.  D,  (n=5). 
Enzyme  Activity  (  expressed  as  %  of  control) 
GROUP  7a-OH  6ßOH  16a-OH  17-OHSD  5a-Red. 
Control  100±4.40  100±1.89  100±6.43  100±9.81  100±8.76 
Insulin(f6M)  120131.3  104.5±20.6  110.8±32.2  83.4±8.60  92.9±9.98 
Aj  103.7±18.3  67.2±7.99  83.4±17.7  97.0±20.1  78.0±20.5 
A10  104.9±30.5  92.6±0.87  105.3±3.91  98.1113.9  86.8±2.30 
A100  130.0±21.3  82.6±17.0  99.3±20.7  92.0113.9  99.8±19.7 
A1000  135.6±  16.4  104.5±44.8  123.3±50.2  75.218.75  91.3±4.10 
A10000  120.4t11.2*  75.4±5.20*  91.4±1.59  71.7±10.9*  89.2±8.90 
A  100  +  1-6M  119.7±9.20  96.7±6.70  111.7±11.9  104.3±14.1  90.0±7.42 
A.  j  +  1-6M  116.0±11.4  68.5±6.70*  74.6±1.40*  92.5±12.2  77.2±3.78* 
107 Table  6.7:  The  effect  of  insulin  (10-6M  &  10-9M)  and  Artemisia  judaica  (A.  j=0.2, 
A10=0.02  g/  ml)  on  the  7a-,  60-  and  16a-,  hydroxylase,  17a(ß)-  hydroxysteroid 
dehydrogenase  and  5a-reductase  after  1/2  hour  of  preincubation  in  hepatocytes 
obtained  from  normal  rat  in  William's  E  medium,  p  values  relative  to  control  values 
were  obtained  by  ANOVA  followed  by  Dunnet's  test  *P  =  <0.05. 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  ±  S.  D,  (n=5) 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7a-OH  60OH  16a-OH  17-0HSD  5a-Red. 
Control  100127.99  100±30.1  100±27.2  100±12.1  100±7.20 
Insulin(i61v1)  79.98±9.50  86.1±2.53  94.8±6.28  101.4±10.8  79.713.20 
Insulin(r9M)  92.6±27.9  109.2141.3  108.7±18.8  121.2±9.68  110.211.35 
A10  76.1±21.4  73.97±18.02  85.014.92  88.5±8.71  78.1±15.0 
Aj  86.5±39.2  73.2±9.56*  89.0±3.64  120.8±13.4  103.4±10.6 
108 6.1.5  Effect  of  different  periods  of  pre-incubation 
In  the  study  of  Hussin  &  Skett  (1986),  it  was  found  that  the  effect  of  insulin 
seen  depended  on  the  period  during  which  the  cells  had  been  exposed  to  the  hormone. 
The  greatest  effect  had  been  seen  at  '/2  hour  but  had  disappeared  at  1  hour.  The  timing 
of  the  experiment  could,  therefore,  be  crucial.  The  effect  of  insulin  and  Artemisia 
extract  was  tested  at  periods  ranging  from  1/2  to  72  hours.  No  effect  of  insulin  was  seen 
at  any  of  the  time  points  investigated  (Tables  6.8-6.12).  The  time-dependent  effects  of 
Artemisia  extract  were,  however,  more  complex.  At  %hr  with  a  10x  diluted  extract 
(0.02  g/ml),  there  was  no  effect  as  noted  previously  and  this  lack  of  effect  continued 
until  4  hours  (with  a  small,  though  significant,  reduction  in  60-hydroxylase  activity  at  1 
hour)  (table  6.8).  With  a  more  concentrated  extract  (0.2  g/ml),  there  was  still  no  effect 
at  1/2hr  but  by  1  hour  a  significant  elevation  of  16a-hydroxylase  and  Sct-reductase 
activity  was  seen  (table  6.9).  At  2  hours  post-treatment  there  was  a  significant  increase 
in  7a-hydroxylase  activity.  All  of  these  effects  had  disappeared  at  4  hours.  A  repeat  of 
this  experiment  with  a  different  cell  preparation  gave  substantially  similar  results  (Table 
6.10)  with  significant  increases  in  6p-  and  16a-hydroxylases  and  5a-reductase  activities 
at  times  after  1  hour.  Extension  of  the  period  of  pre-incubation  with  Artemisia  extract 
up  to  72  hours  did  not  result  in  any  enhancement  of  the  action  of  the  extract  and  insulin 
(Tables  6.11  and  6.12).  There  were  some  significant  increases  noted  (at  24  hours  with  a 
x10  diluted  extract  on  17-OHSD  and  5a-reductase  activities)  but  the  most  significant 
feature  was  a  marked  decrease  in  enzyme  activities  at  72  hours  post-treatment  (down  to 
50%  of  control  for  the  5a-reductase).  The  length  of  time  during  which  the  cells  are  in 
contact  with  the  Artemisia  extract  can,  thus,  have  some  bearing  on  the  effects  seen  but 
there  is  still  no  consistent  effect  noted. 
6.1.6  Effects  of  Storage  ofArtemisia  extract 
The  crude  aqueous  extract  of  Ariemisia  judaica  was  stored  frozen  at  -20°C  in 
5ml  aliquots.  These  aliquots  were  defrosted  before  addition  to  the  cells.  Could  the 
freeze-thawing  process  have  inactivated  the  extract  by  destroying  the  active  ingredient? 
It  was  decided  to  test  the  effects  of  a  fresh  and  a  frozen  extract  in  the  same  experiment. 
109 Table  6.8:  The  effect  of  insulin  (I10'6M)  and  Artemisia  judaica  (A10=0.02  g/  ml)  on 
the  7a-,  60-  and  16a-,  hydroxylase,  17a(ß)-  hydroxysteroid  dehydrogenase  and  5a- 
reductase  after  1/2,1,2  &4  hour  of  preincubation  in  hepatocytes  obtained  from  normal 
rat  in  Ham's  F-10  medium,  p  values  relative  to  control  values  were  obtained  by 
ANOVA  followed  by  Dunnet's  test  *p  <0.05. 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  ±  S.  D  (n=5) 
Enzyme  Activity  (as  expressed  of  %  of  control) 
GROUP  7a-OH  60OH  16a-0H  17-OIISD  5a-Red. 
Control(1/2hr)  100±14.4  100±7.45  100±9.74  100±12.4  100±14.3 
A10(1/2hr.  )  99.9±11.1  98.6±1.46  93.4±9.80  88.8±9.18  88.7116.5 
Control  (Ihr)  100±17.7  100114.9  100±6.28  100±5.26  100±13.3 
Insulin(r6M) 
lhr 
86.9±19.6  102.4±13.7  90.5±9.9  112±20.0  106±12.3 
A10  (ihr.  )  82.34±18.3  75.8±12.8*  88.4±31.3  91.1117.6  83.5±22.5 
Control  (2hr.  )  100120.2  100119.2  100±23.8  100±4.80  100±22.7 
A10  (2hr)  123.1±19.0  119.5±3.70  109.4110.8  113.618.25  97.6±30.7 
Control  (4hr.  )  100±16.9  100±8.82  100±19.5  100±10.3  100±30.9 
A10  (4hr.  )  93.7114.96  121.9±18.5*  128.4±24.5  108.6±7.48  90.8±11.8 
110 Table  6.9:  The  effect  of  insulin  (10-6M)  and  Ariemisia  jridaica  (  A.  j=0.2  g/  ml)  on  the 
7a-,  60-  and  16a-,  hydroxylase,  17a(ß)-  hydroxysteroid  dehydrogenase  and  Sa- 
reductase  after  1/2,1,2  &4  hour  of  preincubation  in  hepatocytes  obtained  from  normal 
rat,  in  Ham's  F-10  medium,  p  values  relative  to  control  values  were  obtained  by 
ANOVA  followed  Dunnet's  test  *=p<0.05,  **  *=p<0.001- 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  f  S.  D,  (n=5) 
Enzyme  Activity  (  expressed  as  %  of  control) 
GROUP  7a-OH  600H  16a-OH  17-OIISD  5a-Red. 
Control(1/2hr)  100±17.0  100±11.7  100±2.22  10018.71  100±5.21 
Insulin(I4M) 
1/2hr. 
107.2±2.73  112.0±6.11  105.2±14.2  99.6±12.3  97.9±15.3 
A  j(1/2hr.  )  82.4±10.3  99.2±9.10  102.2±9.20  104.2±8.70  102.4±5.50 
Control  (Ihr)  100±2.50  100±12.2  100±22.7  10014.70  100±16.2 
A.  j  (I  hr.  )  102.1±11.4  114.11:  3.40  132.5±10.9*  108.718.80  128.9±15.8* 
Control  (2hr.  )  100±8.10  100±7.80  100±10.5  100±14.8  100117.3 
Insulin(r6M)  105.5±32.4  109.2±24.8  103.2±26.5  102.5±36.0  85.4±11.9 
A.  j  (2hr) 
(2hr.  ) 
137±13.3***  119.5±33.3  139.6±33.0*  110.8110.4  103.7±25.0 
Control  (4hr.  )  100±18.0  100±7.30  100±26.4  10013.13  100119.2 
A.  j  (4hr.  )  115.0±13.6  107.8±23.3  76.7±23.3  99.3±7.00  133.7±39.6 
III Table  6.10:  The  effect  of  Insulin  (10'6M)  and  Artemisia  judaica  (A.  j=0.2  g/  ml)  on 
the  7a-,  60-,  and  16a-,  hydroxylase,  17a(ß)-  hydroxysteroid  dehydrogenase  and  50C- 
reductase  after  1/2,1,2  &4  hour  of  preincubation  in  hepatocytes  obtained  from  normal 
rat  in  William  `E  medium,  p  values  relative  to  control  values  were  obtained  by  ANOVA 
followed  by  Dunnet's'  test,  *=p0.05,  **  *=p<0.001. 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  ±  S.  D,  (n=5). 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7a-OH  6ßOH  16a-OH  17-OHSD  5a-Red. 
Control(1/2hr)  100±16.8  100±12.1  10017.70  100±7.81  100±12.6 
A.  j(1/2hr.  )  122.7±25.2  111.1±10.4  110.7±9.80  100±6.0  123.0±17.8 
Control  (Ihr)  100±9.52  100±12.1  100±18.8  100±16.4  100±23.4 
Insulin  (ihr)  102.7123.0  110.3±11.4  100.7113.80  89±7.0  113.0±7.8 
A.  j  (Ilu.  )  109.1±18.9  140.8±7.5***  129.7±12.8*  113.1±18.5  126.8±18.7* 
Control  (2hr.  )  100±21.6  100±3.36  100±9.34  100±11.28  100±11.0 
Insulin  (2hr)  110.1±9.04  85.8±9.47  103.9±7.3  92.7±13.0  104.0±20.5 
Aj  (21u)  112.1±6.04  95.8±3.47  143.9.  +4.3***  112.7±23.5  104.0±17.5 
Control  (4hr.  )  100±8.17  100±21.1  100±3.0  100±21.0  100+18.0 
Insulin  (4hr)  10.2±16.8  85.9±14.7  112.9±9.30  121.7±19.5  100.4±6.7 
A.  j  (4hr.  )  112.0±46.96  85.49±24.7  120.9±4.26  112.7±23.5  133.1±2.7** 
112 Table  6.11:  The  effect  of  Insulin  (10-6M)  and  Artemisiajudaica  (  Al0=0.02  g/  ml)  on 
the  7a-,  60-,  and  16a-,  hydroxylase,  17a(ß)-  hydroxysteroid  dehydrogenase  and  Sa- 
reductase  after  24,48  &  72  hour  of  preincubation  in  hepatocytes  obtained  from  normal 
rat,  p  values  relative  to  control  values  were  obtained  by  ANOVA  followed  by  Dunnet's 
test  *  *=p<0.01  and  p<0.001. 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  f  S.  D,  (n=5). 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7a-OH  6AOH  16a-OH  17-OHSD  Sa-Rcd. 
Control(24hr)  100±20.1  100±18.1  100128.6  100112.6  100±8.16 
Insulin  (24hr)  116.4±5.6  100.7±15.2  101.0111.5  109.8±17.6  99.0±10.1 
A10  (24hr.  )  106.0±6.57  116.7±11.3  111.  ±10.9  133.8±10.9**  163.0±19.0** 
Control  (48hr)  100±37.8  100112.2  100±6.44  100±13.3  100±12.1 
A10  (48hr.  )  80.69±23.8  127.3±4.20**  110.8±23.1  103.9±5.70  126.0±33.7 
Control  (72hr)  100±30.1  100±9.90  100±22.7  100±9.15  100±20.8 
A10  (72hr)  66.1±28.9  55.9±7.18***  83.2±10.5  64.0±5.50***  51.7±11.9** 
113 Table  6.12:  The  effect  of  Insulin  (10'M)  and  Artemisia  judaica  (  A.  j=0.2  g/  ml)  on  the 
7a-,  60-  and  16a-,  hydroxylase,  17a(ß)-  hydroxsteroid  dehydrogenase  and  5a- 
reductase  after  24,48  &  72  hour  of  preincubation  in  hepatocytes  obtained  from  normal 
rat,  p  values  relative  to  control  values  were  obtained  by  ANOVA  followed  by  Dunnet's. 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  ±  S.  D,  (n=5). 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7a-OH  6ßOH  16a-OH  17-OIISD  5a-Red. 
Control(24hr)  100112.1  100±10.5  100±11.8  100±4.30  100±16.5 
Insulin  (24hr)  106.1±5.60  90.5±15.8  99.5.17.20  96.4±8.58  98.5±11.3 
A.  j  (24hr.  )  86.0±2.50  92.5±7.80  87.4.18.20  88.3±2.85  88.9±10.6 
Control  (48hr)  100±11.2  100±9.40  100±15.1  100113.2  100±10.7 
Aj  (48hr.  )  85.7±5.40  86.5±6.30  105.5±12.3  94.715.60  98.817.20 
Control  (721u)  100±57.1  100±16.1  100±14.7  100±1.80  10015.30 
A.  j  (72hr)  86.3±8.70  91.4±2.90  101.3118.8  119.9±23.1  90.7±7.40 
114 The  results  are  shown  in  Table  6.13.  There  are  no  significant  changes  in  any  of  the 
enzyme  activities  tested  with  either  the  fresh  or  the  frozen  extract.  The  result  of  this 
experiment  is,  thus,  inconclusive. 
The  overall  outcome  of  this  series  of  experiments  is  disappointing.  It  was 
impossible  to  reproduce  the  results  of  Hussin  &  Skett  (1986)  with  respect  to  the  effects 
of  insulin  on  androst-4-ene-3,17-dione  metabolism.  The  reasons  for  this  are  unclear  and 
require  further  examination.  This  means  that  the  results  obtained  with  the  crude  aqueous 
extract  of  Artemisia  judaica  are  difficult  to  interpret.  We  cannot  compare  the  effects  of 
the  extract  to  that  of  insulin  if  the  insulin  itself  is  not  giving  the  expected  effect. 
6.1.7  The  effect  of  Preincubation  with  Marrubiun:  vulgare  extract  : 
Exposure  of  the  hepatocytes  to  different  concentrations  of  a  crude  aqueous 
extract  of  Marrubium  vulgare  gave  little  change  in  the  metabolism  of  androst-4-ene- 
3,17-dione  except  at  high  concentration  (0.2  g/ml)  where  a  significant  decrease  in 
enzyme  activities  of  the  7a-,  60-  and  16a-hydroxylases  was  seen  at  1  hour  and  smaller 
effect  at  1/2  hour.  (Table  6.14). 
6.1.8  The  effect  of  Pre-incubation  with  Anvillea  carcinil  : 
Table  6.15  shows  the  effect  of  a  crude  extract  of  Anvillea  carcinil  on  the 
metabolism  of  androst-4-ene-3,17-dione  in  isolated  rat  hepatocytes.  It  is  seen  that  there 
is  no  change  when  different  concentrations  ofAnvillea  extract  are  used  except  that  after 
1  hour  Anvillea  extract  at  a  concentration  of  0.02  g/ml  caused  a  significant  decrease  in 
all  enzyme  activities.  By  4  hours  post-treatment,  the  effects  had  either  disappeared  or 
reversed  with  significant  increases  in  17-OHSD  and  5a-reductase  activities  (Table 
6.15). 
115 Table  6.13:  The  effect  of  Artemisia  judaica  (  A10=0.02,  A,  j=0.2  g/  ml)  on  the  7a-, 
60-,  and  16a-,  hydroxylase,  17a(ß)-  hydroxysteroid  dehydrogenase  and  Sa-reductase 
after  1/2  hour  of  preincubation  in  hepatocytes  obtained  from  normal  rat,  p  values 
relative  to  control  values  were  obtained  by  ANOVA  followed  by  Dunnet's  test 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  ±  S.  D,  (n=5) 
Enzyme  Activity  (expressed  as  %  of  control) 
GROUP  7a-OH  6ßOH  16(x-OH  17-OHSD  5a-Red. 
Control  100123.5  100±29.3  100±34.8  100±24.6  100±37.8 
A10  (fresh)  81.4±15.3  77.6±15.0  80.3±12.7  95.2111.1  77.4±12.7 
A10  (frozen)  82.4±19.9  90.8±22.7  92.7±14.5  93.4±21.4  79.8±23.8 
A.  j  (fresh)  86.5±17.8  119.3±32.8  95.9125.7  105.9117.5  89.4±24.0 
Aj  (frozen)  100±26.7  92.7±18.1  96.8±13.8  115.3±23.8  79.7117.20 
116 Table  6.14:  The  effect  of  Marrubium  vulgare  (M=0.2,  M10=0.02,  M100=0.002, 
M1000=0.0002,  M10000=0.00002  g/  ml)  on  the  7a-,  60-,  and  16a-,  hydroxylase, 
17a(ß)-  hydroxysteroid  dehydrogenase  and  Sa-reductase  after  1/2  hour  of 
preincubation  in  hepatocytes  obtained  from  normal  rat,  p  values  relative  to  control 
values  were  obtained  by  ANOVA  followed  by  Dunnet's  *  =P<O.  05  and  ***  -p<0.001. 
Results  are  expressed  as  percentage  of  the  relevant  control  and  mean  ±  S.  D,  (n=5). 
Enzyme  Activity  (  expressed  as  %  of  control  ) 
GROUP  7a-OH  6ßOH  16a-011  17-OHSD  5a-Red. 
Control(1/21ir)  100±14,1  100±14.6  100±12.7  100±11.8  100111.8 
M(1/2hr.  )  91.6±11.8  63.318.60**  68.7±8.40**  101.3±17.3  120.1124.9 
M10  (1/2hr.  )  100.9±25.3  100.4±13.3  110.4±10.9  103.6±13.3  102.8±10.0 
M100(1/2hr)  107.6±14.71  102.918.92  110.3±11.3  110.6121.2  105.9112.8 
M1000(1/2hr)  99.3±18.6  99.4±12.5  100.97±11.58  110.6124.6  90.8±1.95 
M10000(I/2hr  127.9±14.8  114.814.00  129.9±6.90  128.8±28.2  118.5123.1 
Control  (Ihr.  )  100±42.1  100±39.8  100133.9  100±11.24  100120.5 
M  (I  hr.  )  40.97±8.85**  26.6917.35**  22.17±2.43**  65.714.73  120.1136.3 
M10  (1  fir.  )  76.6113.6  34.5813.50  34.4±9.80  86.8±16.3  110.3125.5 
Control(4hr.  )  100±18.0  100±21.2  100±18.6  100113.3  100±24.7 
M  (4hr.  )  115.4123.97  87.6122.1  113.4118.2  121129.67  108.915.98 
M10  (4hr.  )  101.3±19.8  96.6±13.8  88.2±8.25  115.6±7.90  96.3123.9 
117 Table  6.15:  The  effect  of  Anvillea  carcinii  (  V=0.2,  V10=0.02,  V100=0.002, 
V1000=0.0002,  V10000=0.00002  g/  ml)  on  the  7a-,  6ß-,  and  16a-,  hydroxylase, 
17a(ß)-  hydroxysteroid  dehydrogenase  and  Sa-reductase  after  1/2  hour  of 
preincubation  in  hepatocytes  obtained  from  normal  rat,  p  values  relative  to  control 
values  were  obtained  by  ANOVA  followed  by  Dunnet's  test,  **  -p<0.01  and 
=p<0.001.  Results  are  expressed  as  percentage  of  the  relevant  Control  and  Mean  +  S.  D, 
(n=5) 
Enzyme  Activity  (  expressed  as  %  of  control) 
GROUP  7a-OH  6ßOH  16a-011  17-OIISD  5a-Red. 
Control(1/2hr)  100±14.1  100±14.6  100±12,7  100±11.8  100±11.8 
V(1/2hr.  )  109.8±85.4  85.4±6.30  97.8±7.85  107.6±17.1  108.4±17.7 
VIO  (1/2hr.  )  108.9±14.2  93.3±6.61  112.4±9.01  114.0±38.3  107.9±12.6 
V100(1/2hr)  106.2±15.5  115.8117.5  111.3±13.8  113.4±23.7  105.9±12.8 
V1000(1/2hr)  104.0±15.5  89.2±16.2  92.7±13.4  120.9±3.30  97.7±17.0 
V10000(1/2hr  111.1±11.3  97.9±9.22  101.7±6.30  112.9±23.4  105.9±5.13 
Control  (Ihr.  )  100±42.1  100:  39.8  100±33.9  100±11.24  100+20.5 
V  (ihr.  )  86.3±20.7  88.1±23.8  87.7±20.6  101.9±29.6  85.3±18.2 
VIO  (ihr.  )  39.4±I2.4***  30.0±7.81***  32.2±3.09***  53.2±11.4**  38.116.20*** 
Control(41u.  )  100±18.0  100±21.2  100±18.6  100±13.3  100±24.7 
V  (41u.  )  95.7±0.66  93.1±17.2  123.1±24.4  193.7±33.4**  178.8±32.7* 
V10  (41w.  )  110±26.9  67.4±15.7  85.6±41.2  111.5163.9  123.9±57.3 
118 6.2  Discussion  of  steroid  metabolism 
In  1986,  Skett  found  that  STZ-induced  diabetes  mellitus  could  affect  steroid 
metabolism  in  the  rat  liver  and  that  this  effect  could  be  reversed  by  insulin  administration 
to  the  diabetic  animals.  Steroid  metabolism  is  closely  related  to  drug  metabolism  in  the 
rat  liver  by  the  enzymes  involved  and  by  an  apparent  common  control  mechanism, 
thought  to  be  mediated  via  the  pituitary  gland  (Skett  et  al.,  1984).  As  it  was  not  certain 
how  diabetes  affected  liver  function  in  this  case  (e.  g.  directly  via  changes  in  blood 
insulin  levels  or  indirectly  via  the  pituitary  gland  as  above),  it  was  decided  to  study  the 
effect  of  insulin  on  androst-4-ene-3,17-dione  metabolism  in  primary  culture  of  rat 
hepatocytes.  As  the  biological  effects  of  insulin  vary  in  their  time  of  onset  from  very 
rapid  responses  (seconds  to  minutes)  to  quite  slow  modulations  of  cell  proliferation,  that 
may  take  hours  to  be  expressed  the  experiments  were  conducted  over  a  time  period 
ranging  from  1/2  hour  to  72  hours. 
Androst-4-ene-3,17-dione  was  used  as  a  substrate  in  these  experiments  because 
it  has  a  sex-dependent  metabolism  which  is  well  characterized  (Stenberg,  1976)  and  also 
because  it  has  commonly  been  used  in  this  laboratory  and  its  metabolites  are  well- 
defined  and  are  easily  separated  and  its  labelled  and  unlabelled  forms  are  easily  available. 
Only  male  rats  were  used  in  all  of  the  experiments  because  it  was  found  that  the  effect 
of  diabetes  mellitus  on  steroid  metabolism  was  sex-dependent  i.  e.  only  seen  in  the  male. 
It  was  thought  that  diabetes  interfered  with  the  androgenic  stimulation  of  drug 
metabolism  in  the  male  (Dixon  et  at,  1961;  Skett,  1986)  and,  therefore,  drug 
metabolism  would  be  unaffected  by  the  same  treatment  in  the  female  (Skett,  1986).  It 
was  decided  to  use  the  same  hepatocytes  approach  in  our  studies  because  of  the  above. 
It  was  also  thought  appropriate  as  the  hepatocytes  can  be  obtained  in  high  yields  and 
one  can  do  more  and  long  term  hormonal,  studies.  This  is  in  contrast  to  the  perfused 
liver  where  only  one  or  two  preparations  may  be  run  at  one  time,  the  technique  requires 
a  high  degree  of  skill  and  the  preparations  can  only  be  kept  viable  for  a  few  hours. 
We  used  Ham's  F-10  supplemented  with  0.1%  bovine  serum  albumin  as  a 
nutrient  medium  because  it  was  found  that  the  enzyme  activities  were  well  maintained 
and  that  steroid  metabolising  enzyme  activities  returned  to  control  level  after  2  days  in 
119 culture  (Hussin  &  Skett,  1986).  We  used  insulin  10-6M  in  most  of  the  experiments 
because  Hussein  was  found  the  maximum  effect  was  reached  at  this  concentration. 
Insulin  has,  been  demonstrated  to  affect  the  metabolism  of  androst-4-ene-3,17- 
dione  in-vivo  (Skett,  1986)  and,  in  1988,  Hussin  &  Skett  showed  that  insulin  had  a 
direct  effect  on  steroid  metabolism  in  rat  hepatocytes  by  increasing  the  activity  of  all 
enzymes,  unlike  in-vivo  where  selective  increases  in  enzyme  activities  were  seen.  Insulin 
(10-6M)  was  used  in  most  of  the  experiments  as  Hussin  &  Skett  (1988)  had  found  the 
maximum  effect  was  reached  at  this  concentration. 
The  initial  purpose  of  the  present  study  was  to  test  if  extracts  of  the  plants, 
Artemisia  judaica,  Marrubiran  vulgare  and  Anvil/ea  carcinil,  which  are  used  as 
antidiabetics  in  Libya,  could  have  the  same  effect  as  insulin  on  hepatocytes  isolated  from 
normal  rats. 
Initially,  after  1/2  an  hour  exposure  to  insulin  at  concentrations  of  10-6  and  10- 
9M,  Artemisia  extract  and  Artemisia  extract  with  insulin,  there  was  no  significant 
increase  in  any  of  the  enzyme  activities  studied  and,  indeed,  a  significant  decrease  was 
found  with  Artemisia  extract  with  insulin.  This  data  is  not  in  agreement  with  the  results 
of  Hussin  &  Skett  (1988),  who  found  that  there  was  a  significant  increase  in  all  of  the 
enzyme  activities  at  all'concentrations  of  insulin. 
Attempts  to  ascertain  the  reason(s)  for  this  discrepancy  in  the  results  by  a  close 
examination  of  the  methods  of  Hussin  &  Skett  (1986:  1988)  and  comparison  with  the 
techniques  used  in  this  study  have  proved  inconclusive.  Changing  the  pre-incubation 
period,  testing  the  preparations  of  insulin  and  extract  used,  changing  the  incubation 
medium  and  altering  the  weight/age  of  the  animals  made  very  little  difference.  The  basis 
of  the  discrepancy  between  the  results  of  this  study  and  those  of  Russin  &  Skett  remains 
unresolved. 
When  we  did  not  find  any  positive  results  with  Artc'misia  extract,  we  used  other 
plant  extracts,  from  Marrubium  vulgare  and  An  villea  carcinil  in  different  concentration 
and  different  times.  Neither  of  these  extracts  caused  any  significant  increases  in  enzyme 
activity  although,  rarely,  significant  decreases  were  seen  at  some  concentrations  of 
extract. 
120 The  assay  of  hepatic  metabolism  of  androst-4-ene-3,17-dione  does  not, 
therefore,  seem  to  be  of  use  in  detecting  insulin-like  activity  in  the  system  employed  in 
this  study. 
6.3  Glycogen  Phosphorylase  a 
6.3.1  Effect  of  crude  extracts  of  medicinal  plants  on  the  activity  of  glycogen 
phosphorylase  a  in  hepatocytes  isolated  from  normal  rat  hepatocytes: 
The  graphs  (Figure  6.1  and  6.2)  and  tables  (Tables  6.17-6.26)  show  the  effects 
of  tested  compounds  (insulin,  glucagon  and  crude  extracts  of  plants  (Artemisia  judaica, 
Anvillea  carcinii  &  Marrubium  vulgare)  on  glycogen  phosphorylase  a  activity  in 
isolated  rat  hepatocytes.  In  these  experiments  insulin  and  glucagon  were  used  as 
standards  to  compare  to  the  activity  of  the  crude  plant  extracts  to  see  any  insulin-like  or 
glucagon-inhibiting  activity.  Results  are  expressed  as  percentage  change  from  control. 
Figure  6.1  a  shows  that  insulin  had  little  effect  on  glycogen  phosphorylase  a  activity  in 
hepatocytes  isolated  from  control  animals  at  all  different  concentrations  except  at  10- 
5M,  which  significantly  decreased  the  activity  (p<0.001).  As  shown  in  Figures  6.1b-d 
, 
the  presence  of  insulin  (10-6M),  which  itself  did  not  decrease  enzyme  activity,  with 
different  concentrations  of  crude  plant  extracts  significantly  decreased  the  glycogen 
phosphorylase  a  activity  in  virtually  all  cases.  The  plant  extracts  alone  were  less  able  to 
decrease  glycogen  phosphorylase  a  activity  although  significant  decreases  were  seen 
with  Artemisia  extract  (2x  10-1  and  2x  10-4g/ml),  Anvillea  extract  (2x  10-6  104g/ml) 
and  Marrubium  extract  (2x  10-4g/ml).  The  crude  plant  extracts  alone  were  never  as 
potent  as  the  insulin  and  plant  extract  mixture  except  for  the  highest  dose  of  Artemisla 
121 extract.  Under  similar  experimental  conditions  the  presence  of  glucagon  (10-6  -  10- 
I  OM)  had  a  biphasic  effect  on  glycogen  phosphorylase  a  activity  (Figure  6.2a).  At  10- 
10  -  10-9M,  glucagon  decreased  glycogen  phosphorylase  a  activity  whereas  at  10-8  - 
10-7M  a  marked  increase  was  seen.  At  10-6M  glucagon,  a  return  to  a  significant 
decrease  was  seen.  If  crude  plant  extracts  alone  were  tested  (Figures  6.2b-d),  it  is  seen 
122 Figure  6.1:  Dose-response  curves  for  the  of  ectinsulin  and  extracts  of  Arlemisia 
judaica  (b);  Marrublum  vulgare  (c)  and  Anvillea  carcinii  (d)  on  glycogen 
phosphorylase  a  (a)  in  isolated  rat  hepatocytes  preincubated  for  30  min  in  Krebs- 
Ilenseleit  medium  and  the  effect  of  3  min  exposure  to  the  extracts  and  hormone  on  the 
enzyme  activity  measured,  compared  to  basal  phosphorylase  activity  *=  p<0.05,  ** 
p<0.01,  ***  -  p<0.001,  and  t=  p<0.05,  tt  =  p<0.01,  ttt  =  p<0.001  compared  to 
respective  dose  of  extract  alone,  p  were  obtained  by  ANOVA  followed  by  Dunnet's 
test. 
Results  are  expressed  as  mean  ±  s.  d.  (n=3). 
o-  Insulin,  Arlemisla,  Marrubhun  &  Anvillea  alone 
"-  Arlemisla,  Marrublum  or  Anvillea  +  insulin  (10-6M) 
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LOO  CONC.  (mg/ml)  LOG  CONC.  (mg/ml) Figure  6.2:  Dose-response  curves  for  the  effect  glucagon  and  extracts  ofArtemisia 
judaica  (b);  Marrtublum  vulgare  (c)  and  Anvillea  carcürü  (d)  on  glycogen 
phosphorylase  a  (a)  in  isolated  rat  hepatocytes  preincubated  for  30  min.  in  Krebs- 
i  ienseleit  medium  and  the  effect  of  3  min  exposure  to  the  extracts  and  hormone  on  the 
enzyme  activity  measured,  compared  to  basal  phosphorylase  activity  *=  p<0.05,  ** 
p<0.01,  +**  -  p<0,001  and  t-  p<0.05,  tt  -  p<0.01,  ttt  =  p<0.001  compared  to 
respective  dose  of  extract  alone,  p  were  obtained  by  ANOVA  followed  by  Dunnet's 
test. 
Results  are  expressed  as  mean  ±  s.  d.  (n=3). 
o-  Glucagon,  Arlemisla,  Marnibium  &  Auvillea  alone 
"-  Arlc'misla,  Marrubliun  or  Anv!!  lea  +  glucagon  (10'7M) 
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LOG  CONC.  (mg/ml) that  there  is  a  general  decrease  in  enzyme  activity  except  at  very  high  concentration  of 
Artemisia  (2x10-2  g/ml)  or  low  concentrations  ofMarrublum  (2x10-7g/ml).  This  does 
not  fully  agree  with  the  results  in  the  previous  experiment.  The  reason  for  this  is  unclear 
but  will  be  discussed  later.  If  the  effects  of  the  crude  extracts  are  tested  in  the  presence 
of  glucacon  (10-7M),  which  increases  enzyme  activity,  then  all  extracts  antagonize 
glucagon  action  (i.  e.  the  increase  in  activity  expected  with  10-7M  glucagon  is  not  seen 
and,  indeed,  in  some  cases  a  marked  decrease  in  activity  is  observed  compared  to 
control  levels). 
At  this  stage  the  crude  extract  of  Arlemisia  judaica  was  fractionated  to  give  an 
aqueous  (water-soluble)  extract  and  an  alcoholic  (ethanol-soluble)  extract  as  described 
in  Materials  and  Methods. 
6.3.2  Effect  of  insulin  and  glucagon  on  the  activity  of  glycogen 
phosphorylase  a  in  hepatocytes  isolated  from  normal  and  STZ  diabetic  rats. 
Tables  6.17  and  6.18  show  the  effect  of  different  concentrations  of  insulin  and 
glucagon  alone  on  glycogen  phosphorylase  a  in  normal  and  diabetic  rats.  Insulin  did  not 
decrease  enzyme  activity  in  hepatocytes  isolated  from  normal  or  diabetic  rats  except  at 
104M,  which  significantly  increased  the  activity  (p<0.001  &  p<0.01  in  cells  from 
normal  and  diabetic  animals  respectively).  Under  similar  conditions,  glucagon  in 
different  concentrations  significantly  increased  enzyme  activity  (p<0.001)  in  normal  and 
diabetic  rats. 
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°ý 6.3.3  Effect  of  an  aqueous  extract  ofArtemistaJudaica  and  insulin  on  the 
activity  of  glycogen  phosphorylase  a  in  hepatocytes  isolated  from  normal  rat. 
The  data  in  Table  6.19  shows  the  effects  of  different  concentrations  of  an  aqueous 
extract  of  Artemisia  alone  or  in  the  presence  of  different  concentrations  of  insulin  on 
glycogen  phosphorylase  a  activity.  Incubation  of  control  rat  hepatocytes  with  an 
aqueous  extract  of  Arlemisia  in  different  concentrations  resulted  in  decreased  glycogen 
phosphorylase  a  activity  at  concentrations  of  extract  of  2x10-2,2x10-3,2x10-5  and 
2x10-6  g/I  (25%,  35%,  37%,  and  51%  respectively  as  compared  to  control  (p<0.01)) 
but  concentrations  of  2x10-1  and  2x10-4  g/l  had  no  significant  eft'ect.  The  result  at 
2x10-4  g/l  looks  out  of  place  and  may  be  a  false  negative  as  this  concentration  of  extract 
has  shown  effects  previously  (see  Figure  6.2b).  The  highest  concentration  ofArtemisia 
extract  has,  however,  tended  to  be  inactive.  When  the  hepatocytes  were  incubated  with 
different  concentrations  of  aqueous  extract  of  Artemisia  with  insulin  (104M),  a 
significant  decrease  was  found  at  concentrations  of2x10-1  g/ml  (p<0.01),  2x10-2  g/ml 
(p<0.001)  and  2x10-5  g/ml  (p<0.001)  compared  to  the  effects  of  insulin  or  Artemisia 
extract  alone.  At  other  concentrations,  there  was  no  synergistic  effect  of  aqueous 
extract  of  Artemisia  and  insulin  and,  indeed,  at  2x10-6  g/l  Arletnisia  extract,  insulin 
inhibited  the  activity. 
Insulin  alone  in  different  concentrations  (10-9-10-6NI)  was  less  able  to  decrease 
glycogen  phosphorylase  a  activity  in  this  experiment  and  this  agrees  with  the  results 
from  previous  experiments. 
In  general,  a  similar  pattern  of  changes  in  glycogen  phosphorylase  a  activity  was 
seen  for  the  other  concentrations  of  insulin  used  (10-9-10-7M)  with  synergistic  effects 
being  noted  (i.  e.  the  effect  of  insulin  plus  the  aqueous  extract  ofArtendsiajudaica  being 
more  potent  than  either  component  alone).  It  is  interesting  to  note  the  combinations  that 
have  antagonistic  effects,  however.  At  the  highest  concentration  of  insulin  used  (10- 
6M),  an  antagonistic  effect  is  noted  with  the  most  potent  concentration  of  Arlemisia 
extract  (2x10-6  g/I).  As  the  concentration  of  insulin  used  falls.  the  antagonistic  effect 
shifts  towards  the  less  potent  concentrations  of  Arlemisia  extract  (e.  g.  insulin  10'7M 
and  Artemisia  2x10-5  g/l;  insulin  10-814  and  Arlemisia  2x104  g/I  and  insulin  10-9M 
and  Artemisia  2x  10-3  g/1).  The  significance  of  this  is  unclear  at  present. 
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Q  CC  - 6.3.4  Effect  of  an  aqueous  extract  of  Artemisia  judaica  and  glucagon  on  the 
activity  of  glycogen  phosphorylase  a  in  hepatocytes  isolated  from  normal  and 
diabetic  rat. 
Table  6.20  illustrates  the  significant  rise  in  glycogen  phosphorylase  a  activity 
when  different  concentrations  of  glucagon  (10-4  -  10-9  M)  were  added  to  isolated 
hepatocytes. 
As  described  above,  the  addition  of  an  aqueous  extract  of  Artemisia  judaica  to 
the  cells  caused  a  significant  fall  in  the  activity  of  glycogen  phosphorylase  a  at  most 
concentrations.  If  glucagon  at  concentrations  of  10-6  -  10-9  M  was  added  to  the  cells  at 
the  same  time  as  different  concentrations  of  Artemisia  extract,  we  found  that  the  effect 
of  the  glucagon  could  be  modified.  At  a  concentration  of  10-6M,  which  increases 
glycogen  phosphorylase  a  by  248%  of  control,  all  concentrations  of  an  aqueous  extract 
of  Artemisia  diminished  the  action  of  the  glucagon  though  the  activity  of  the  glycogen 
phosphorylase  a  was  still  significantly  higher  than  their  respective  control.  Aqueous 
extracts  ofArtemisia  had,  thus,  a  partial  antagonistic  effect  on  the  effect  (p<0.001  at  all 
concentrations).  Similar  effects  were  seen  with  glucagon  at  concentrations  of  10-7  and 
10-8  M  and  the  same  observation  was  seen  in  hepatocytes  isolated  from  STZ  diabetic 
rat  (Table  6.21). 
6.3.5  The  effect  of  an  aqueous  extract  of  Artemisia  judaica  and  insulin  on  the 
activity  of  glycogen  phosphorylase  a  in  hepatocytes  isolated  from  STZ 
diabetic  rat. 
The  effect  ofArtemisiajudaica  and  glucagon  on  glycogen  phosphorylase  a  were 
further  studied  by  analyzing  their  effects  in  hepatocytes  isolated  from  diabetic  rats. 
Table  6.22  shows  that,  Artemisia  extract  in  the  concentrations  range  2x10-2  to 
2x  10-6  g/ml  gave  no  significant  change  in  the  activity  but  at  a  concentration  of  2x  10-1 
g/ml  the  activity  decreased  to  35%  of  control  (p<0.001). 
The  addition  of  different  concentrations  of  aqueous  extract  of  Artemisia  judaica  to 
insulin  (10-6M)  caused  a  decrease  at  all  concentrations  from  2x10-1  to  2x10-5  g/ml 
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t except  at  a  concentration  of  2x  10-2  g/ml  which  had  no  effect.  Maximum  effect  was  seen 
at  a  concentration  of  3x  10-3  g/  ml  (32  %  of  control  ).  Insulin  at  a  concentration  of  10- 
7M  with  different  concentrations  of  aqueous  extract  ofArtemisiaJudaica  decreased  the 
activity  of  the  enzyme  activity  significantly  more  than  insulin  (10-6M)  with  different 
concentrations  of  aqueous  extract.  Insulin  (10-8M)  decreased  the  activity  significantly 
with  concentrations  of  Artemisia  extract  at  2x10-2,2x10-3  and  20x-5  g  /ml  but  no 
effect  at  a  concentration  of  2x  10-2  and  2x  10-4  g/H. 
6.3.6  The  effect  of  an  ethanolic  extract  of  Artemisia  judatca  and  insulin  on 
the  activity  of  glycogen  phosphorylase  a  in  hepatocytes  isolated  from  normal 
rat. 
The  data  of  Table  6.23  shows  that  an  ethanolic  extract  of  Artemisia  judaica 
alone  had  little  effect  on  glycogen  phosphorylase  a  activity  except  at  concentrations  of 
2x  10-1  and  2x  10-3  g/1  ,  which  showed  a  significant  fall  in  activity  (p<0.01).  The 
ethanolic  extract  is,  thus,  less  effective  than  the  aqueous  extract  by  itself. 
As  noticed  previously,  insulin  had  little  effect  on  glycogen  phosphorylase  a 
activity  except  in  high  concentration  which,  in  this  experiment,  activated  glycogen 
phosphorylase  a. 
The  addition  of  insulin  (10-6M)  together  with  different  concentrations  of  an 
ethanolic  extract  of  Artemisia  gave  no  significant  change  in  glycogen  phosphorylase  a 
activity  except  at  the  lowest  concentration  of  Artemisia  extract  (2x  10-5  g/1)  where  a 
reduction  was  seen  which  was  statistically  significant  (p<0.001).  Neither  insulin  nor 
Artemisia  extract  at  these  concentrations  gave  any  significant  reduction  and,  thus,  this 
indicates  a  synergism  of  effect  at  these  concentrations  on  the  activity  of  glycogen 
phosphorylase  a.  The  of  ect  of  the  ethanolic  extract  of  Artemisia  with  10-7M  insulin 
was  to  significantly  decrease  glycogen  phosphorylase  a  activity  (p<0.001)  at  all 
concentrations  of  the  ethanolic  extract,  the  maximum  decrease  (63%  of  control)  was 
seen  at  the  high  concentration  . 
Insulin  (10-8  and  10-9M)  together  with  different  concentrations  of  the  ethanolic 
extract  ofArtemisia  gave  a  similar  effect  to  that  seen  for  insulin  (10-7M)  with  marked 
synergistic  action  of  the  two  additions. 
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V  '" 6.3.7  Effect  of  an  ethanolic  extract  of  Artemisia  judaica  and  insulin  on  the 
activity  of  glycogen  phosphorylase  a  in  hepatocytes  isolated  from  STZ 
diabetic  rat. 
In  the  same  set  of  cells  isolated  from  diabetic  rats,  the  effect  of  an  ethanolic 
extract  of  Artemisia  judaica  and  insulin  on  glycogen  phosphorylase  a  was  studied 
(Table  6.24).  Ethanolic  extract  of  Artemisia  judaica  at  2x10-1  g  /ml  alone  and  with 
different  concentrations  of  insulin  range  (10-6  to  10-8M)  and  ethanolic  extract  of 
Artemisia  judaica  (2x  10-2  g/ml)  with  insulin  (10-6M  and  10x  10-8  M)  decreased  the 
enzyme  activity  to  49%,  73%,  27%,  67%,  48%  and  23%  respectively  compared  to 
control  (  p<0.001).  The  addition  of  different  concentrations  of  insulin  with  different 
concentrations  of  aqueous  extract  of  Artemisia  judaica  (2x  10-3  to  2x  10-6  g/  ml)  had 
little  effect  on  the  activity  of  glycogen  phosphorylase  a. 
6.3.8  Effect  of  an  ethanolic  extract  of  Artemisia  judaica  and  glucagon  on  the 
activity  of  glycogen  phosphorylase  a  in  hepatocytes  isolated  from  normal  and 
STZ  diabetic  rat. 
As  noticed  above,  glucagon  again  exhibited  a  significant  activation  of  glycogen 
phosphorylase  a  in  normal  and  diabetic  at  all  concentrations  (see  Tables  6.17  &  6.18). 
The  ethanolic  extract  of  Artemisia  alone  had  little  effect  on  glycogen  phosphorylase  a 
activity  but  completely  counteracted  the  effects  of  glucagon  on  the  activity  of  glycogen 
phosphorylase  a  at  all  concentrations  (p<0.001)  in  normal  and  diabetics  (Table  6.25  & 
6.26). 
6.3.9  The  effects  of  artemisinin  and  santonin  on  the  activity  of  glycogen 
phosphorylase  a  in  hepatocytes  isolated  from  normal  rat. 
As  shown  in  Figures  6.3  and  6.4,  artemisinin  and  santonin  had  no  significant 
effects  alone  on  glycogen  phosphorylase  a  activity  in  isolated  rat  hepatocytes  except  for 
a  marked  increase  in  activity  with  artemisinin  at  high  concentrations  (104M)  and  some 
small  increases  with  santonin  at  various  concentrations.  Treatment  of  cells  with 
137 artemisinin  and  insulin  (10-7M)  gave  a  marked  increase  in  glycogen  phosphorylase  a 
activity  at  concentrations  above  10'7M.  Artemisinin,  however,  does  appear  to  inhibit  the 
action  of  glucagon  (10-7M)  at  all  concentrations.  The  action  of  santonin  on  the  effect  of 
insulin  (10-7M)  is  rather  complex  giving  a  stimulation  of  glycogen  phosphorylase  a 
activity  at  low  concentrations  (10-9-10-8M)  and  an  inhibition  at  higher  concentrations 
(104M).  Santonin  at  higher  concentrations  (10-5.10-4M)  also  seemed  to  inhibit 
glucagon  action  on  glycogen  phosphorylase  a  activity. 
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01  bi Figure  6.3  Dose-response  curves  of  glycogen  phosphorylase  a  to  insulin  (a);  artemisinin 
(b)  and  santonin  (c)  in  isolated  rat  hepatocytes  preincubated  for  30  min  in  Krebs- 
Henseleit  medium  and  the  effect  of  3  min  exposure  to  the  compounds  and  hormone  on 
the  enzyme  activity  measured,  compared  to  basal  phosphorylase  activity  *=  p<0.05,  ** 
=  p<0.01,  ***  =  p<0.001  and  t=  p<0.05,  tt  =  p<0.01,  ttt  p<0.001  compared  to 
respective  dose  of  extract  alone,  p  values  were  obtained  by  ANOVA  followed  by 
Dunnet's  test. 
Results  are  expressed  as  mean  ±  s.  d.  (n=6). 
°=  Insulin,  Artemisinin  or  santonin  alone 
9  Artemisinin  or  santonin  +  insulin  (10-7M). 
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LOG  [INSULIN]  (M) Figure  6.4  Dose-response  curves  of  glycogen  phosphorylase  a  to  glucagon  (a); 
artemisinin  (b)  and  santonin  (c)  in  isolated  rat  hepatocytes  preincubated  for  30  min  in 
Krebs-Henseleit  medium  and  the  effect  of  3  min  exposure  to  the  compounds  and 
hormone  on  the  enzyme  activity  measured,  compared  to  basal  phosphorylase  activity  * 
=  p<0.05,  **  =  p<0.01,  ***  =  p<0.001,  and  t=  p<0.05,  tt  =  p<0.01,  ttt  =  p<0.001 
compared  to  respective  dose  of  extract  alone.  P  values  were  obtained  by  ANOVA 
followed  by  Dunnet's.  Test. 
Results  are  expressed  as  mean  ±  s.  d.  (n=6). 
°=  Insulin  or  Artemisinin  or  santonin 
"  Artemisinin  or  santonin  +  insulin  (10-7M). 
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The  liver  is  an  important  site  for  insulin  and  glucagon  action  in  the  regulation  of 
mammalian  glucose  homeostasis.  Liver  glycogen  phosphorylase  a  is  the  rate-limiting 
enzyme  of  glycogenolysis  and  exists  in  two  forms  as  an  active  a  form  and  inactive  b 
form  (Hems  &  Whitton,  1980).  The  present  investigation  looked  at  the  effects  of 
extracts  of  Artemisia  judaica,  Anvillea  carcinii,  and  Marrubium  vulgare,  which  are 
widely  used  in  Libyan  folk  medicine  for  the  treatment  of  diabetes  mellitus,  on  glycogen 
phosphorylase  a  activity  in  hepatocytes  isolated  from  control  male  rats  to  see  if  any  of 
the  plants  contained  substances  which  could  mimic  insulin  or  counteract  the  effects  of 
glucagon  on  this  activity. 
We  found  that  insulin  in  different  concentrations  when  incubated  with  control 
hepatocytes  produced  little  change  in  glycogen  phosphorylase  a  activity.  This  result  is  in 
agreement  with  reports  suggesting  that  insulin  alone  has  little  effect  on  glycogen 
phosphorylase  a  activity  in  liver  (Andrew  et  al.,  1985).  A  crude  extract  of  Artemisia 
judaica  alone  decreased  glycogen  phosphorylase  a  activity  but  when  insulin  was  added 
together  to  crude  extract,  the  activity  of  glycogen  phosphorylase  a  was  decreased  more 
than  with  the  extract  of  Artemisia  alone.  The  same  observations  were  seen  with  crude 
extracts  ofMarrubium  vulgare  or  Anvillea  carcinii.  These  three  medicinal  plants,  thus, 
contain  (a)  substance(s)  which  can  act  synergistically  with  insulin  to  decrease  glycogen 
phosphorylase  a  activity  in  the  liver.  This  could  account  for  some  of  the  proposed 
hypoglycaemic  actions  of  these  plants. 
Although  the  mechanism  of  action  of  the  biguanides  (e.  g.  metformin)  is  not 
completely  understood,  the  presence  of  insulin  is  required  for  metformin  to  exert  many 
of  its  effects  (Hermann,  1979;  Lucis,  1983).  The  plant  extracts  could,  therefore,  be  said 
to  show  a  biguanide-like  action,  potentiating  the  action  of  insulin.  In-vivo,  the  blood 
glucose  lowering  capacity  of  metformin  does  not  result  from  an  increase  in  insulin 
secretion,  but  is  rather  attributed  to  a  combination  of  actions  in  peripheral  insulin  target 
tissues  involving  both  enhanced  glucose  metabolism  and  improved  insulin  action  (Shen 
&  Bressier,  1977).  Several  in-vivo  and  in-vitro  studies  have  pointed  out  one  possible 
mode  of  action  of  the  drug  at  the  cell  surface  -  its  ability  to  increase  insulin  binding  to  its 
receptor  in  various  cell  types  like  erythrocytes  (Holle  et  al.,  1981),  rat  hepatoma  cells 
144 (Goldfine  et  al.,  1984),  human  breast  cells  (Pezzino  et  al.,  1982)  and  rat  adipocytes 
(Fantus  &  Brosseau,  1986).  Can  the  plant  extracts  tested  here  affect  insulin  binding?  A 
question  for  a  future  study.  Recent  studies  have  also  demonstrated  that  metformin 
improves  insulin-mediated  [14C]-glucose  incorporation  into  glycogen  in  cells  isolated 
from  the  liver  and  this  may  represent  one  of  the  mechanisms  by  which  biguanides  exerts 
their  hypoglycemic  action  (Melin  et  al.,  1990),  So  biguanides  are  known  to  improve  the 
effect  of  insulin  in  some  types  of  diabetes  and  the  presence  of  insulin  is  required  for  the 
biguanides  to  exert  some  of  their  hypoglycemic  action  (Muntoni,  1974).  Insulin  alone,  in 
several  reports,  has  shown  little  effect  on  glycogen  synthase  or  phosphorylase  a  in  liver 
cells  (Andrew  et  al.,  1985).  The  extracts  of  Artemisia  judaica,  Anvillea  carcinil  and 
Marrubium  vulgare  may,  thus,  have  a  similar  mechanism  of  action  to  the  biguanides 
although  the  extracts  can  have  some  effect  in  the  absence  of  insulin  unlike  the 
biguanides. 
With  respect  to  the  action  of  glucagon  on  glycogen  phosphorylase  a  activity,  it 
is  seen  that  glucagon  alone  significantly  increased  glycogen  phosphorylase  a.  However, 
when  glucagon  was  added  with  the  crude  extracts  of  Artemisia  judaica,  Anvillea 
carcinii  and  Marrubium  vulgare,  the  effect  of  glucagon  was  completely  abolished.  The 
plant  extracts,  thus,  contain  (a)  substance(s)  which  antagonises  glucagon  action  on 
glycogen  phosphorylase  a  activity  in  isolated  hepatocytes.  This  again  could  account  for 
some  of  their  hypoglycaemic  actions. 
Glucagon  activates  glycogen  phosphorylase  a  through  an  elevation  of 
intracellular  cAMP  levels,  which  leads  to  the  activation  of  a  cAMP-dependent  kinase 
and  activation  of  phosphorylase  kinase  (Sutherland  &  Robinson,  1979).  Insulin  on  the 
other  hand  reduces  the  glucagon-stimulated  elevation  of  cAMP  and  activation  of 
phosphorylase  (Exton  et  al.,  1971;  Siddle  et  al.,  1973).  There  is  general  agreement 
that  insulin  is  effective  in  antagonizing  the  action  of  certain  glycogenolytic  hormones 
such  as  glucagon  and  alpha1-adrenergic  agonists  (Andrew  et  al.,  1985).  It  can  therefore 
be  inferred  from  the  data  on  glycogen  phosphorylase  a  that  the  crude  extracts  of 
Artemisia  judaica,  Anvillea  carcinii  and  Marrubium  vulgare  may  have  insulin-like 
activity  in-vitro  and  perhaps  some  of  the  same  actions  as  biguanides  as  discussed  above. 
As  previously  discussed,  we  found  that  the  crude  extract  ofArtemisia  contains  a 
substance  which  reacts  in  the  glucose  assay  but  is  unlikely  to  be  glucose  itself.  If  we 
145 consider  the  mechanism  of  action  of  glucose  in  liver  (Stalmans  et  al  1990),  we  find  that 
it  activates  glycogen  synthase  and  inhibits  glycogen  phosphorylase  by  the  following 
steps:  (1)  glucose  binds  to  glycogen  phosphorylase  as  a  better  substrate,  the  glycogen 
phosphorylase  is  dephosphorylated  and  inactivated  (Carabaza  et  al.,  1992).  (2)  The 
dephosphorylation  of  the  phosphorylase  releases  the  inhibitory  effect  of  active 
phosphorylase  on  the  hepatic  phosphatase  which  now  is  able  to  activate  glycogen 
synthase  (Carabaza  et  al.,  1992).  Glucose  is  thus  a  physiological  regulator  of  hepatic 
glycogen  metabolism  that  promotes  inactivation  of  glycogen  phosphorylase  (Stalmans  et 
al.,  1974)  and  acts  synergistically  with  insulin  (Martin,  et  al.,  1991).  Could  the  crude 
extract  of  Artemisia  have  the  same  action  as  glucose?  What  component  of  the  extract 
gives  the  effects?  These  are  questions  requiring  an  answer. 
If  a  first  step  at  a  fractionation  is  performed  and  the  crude  extract  is  split  into  an 
aqueous  and  an  alcoholic  fraction  as  described  in  Materials  and  Methods,  then  it  is  seen 
that  the  aqueous  fraction  can  enhance  the  effects  of  insulin  but  is  poor  at  inhibiting  the 
actions  of  glucagon  whereas  the  alcoholic  fraction  completely  abolishes  glucagon  action 
and  enhances  to  a  certain  extent  insulin  action.  The  glucagon-inhibiting  action  of  the 
extract,  thus,  resides  primarily  in  the  ethanol-soluble  fraction  whereas  the  insulin- 
enhancing  substance(s)  are  split  between  the  water-  and  ethanol-soluble  fractions, 
although  more,  perhaps,  in  the  water-soluble  fraction.  The  water-soluble  fraction  has 
recently  been  shown  to  contain  inositol-like  sugars  (Professor.  J.  Connolly,  Department 
of  Chemistry,  University  of  Glasgow;  personal  communication)  but  the  exact  nature  of 
these  is  not  known.  This  would  fit  in  with  the  detection  of  a  glucose-like  substance  in 
our  assays  and  the  effects  of  glucose  on  glycogen  phosphorylase  a  activity  discussed 
above. 
Two  compounds,  artemisinin  and  santonin,  known  to  be  found  in  extracts  of 
Artemisia  judaica  (Abdalla  et  at,  1987),  also  showed  activity  in  our  assay  but  the 
activity  was  the  opposite  of  that  seen  with  the  crude  extract  -  an  increase  in  glycogen 
phosphorylase  a  activity  in  the  presence  of  insulin.  Santonin  alone  also  increased 
glycogen  phosphorylase  a  activity.  It  is  unlikely,  therefore,  that  either  of  these  known 
components  of  Artemisia  judaica  can  account  for  the  effects  seen. 
146 7.  General  discussion: 
Non-insulin-dependent  diabetes  mellitus  is  one  of  the  most  frequent  metabolic 
disorder  in  world.  As  the  WHO  study  group  stated  in  1985:  Its  impact  is  often  not  fully 
acknowledged  and  should  attract  more  attention  from  health  care  professionals  and 
planners.  Patient  with  this  disease  often  do  not  receive  optimal  care  resulting  in  impaired 
quality  of  life,  excess  mortality  and  enormous  health  care  costs.  So  the  causes,  effects 
and  treatment  of  diabetes  mellitus  have  been  the  subject  of  a  great  deal  of  scientific 
research  over  the  years  but  despite  this  there  is  still  controversy  over  them  and  the 
condition  and  its  implications  are  still  not  fully  understood.  Sulphonylureas  or 
biguanides  have  been  widely  used  for  treatment  of  NIDDM  over  the  past  30  years.  In 
addition  to  their  stimulatory  effect  on  insulin  secretion,  these  compounds  seem  to 
possess  extra  pancreatic  effects  (Prato  et  al.,  1991)  and  this  has  raised  questions  over 
their  effectiveness  in  treating  symptoms  other  than  the  hyperglycaemia,  which  has 
resulted  in  a  failure  to  reduce  mortality  associated  with  diabetes.  Insulin  therapy  should 
not  be  used  in  NIDDM  patient  so  long  as  blood  glucose  can  be  maintained  within  the 
individual  target  range  by  correction  of  overweight,  diet  and  or  exercise  but  short-term 
insulin  therapy  may  be  necessary  in  some  NIDDM  patients  during  periods  of  illness.  It  is 
clear,  therefore,  that  current  treatments  of  diabetes  mellitus,  particularly  of  the  non- 
insulin-dependent  type  are  not  ideal  and  involve  drugs  that  have  no  defined  mechanism 
of  action.  Even  the  apparently  straightforward  treatment  of  insulin-dependent  diabetes 
mellitus  with  insulin  is  not  without  its  drawbacks  such  as  the  continual  necessity  for 
injections  of  the  hormone.  Clearly  work  needs  to  continue  to  find  alternative  treatments 
for  these  conditions  that  have  a  clearer  mechanism  of  action  and  are  easier  to 
administer.  Arabic  folk  medicine  contains  a  number  of  herbal  extracts  said  to  combat  the 
symptoms  of  diabetes  mellitus,  chief  amongst  these  are  extracts  of  Artemisia  judaica, 
Marrubium  vulgare  and  Anvillea  carcinii.  Little  is  known  of  their  actions,  however, 
other  than  empirical  work  suggesting  a  reduction  in  serum  glucose  levels  on  taking  the 
extracts.  Interestingly,  these  treatments  are  aqueous  infusions  of  the  herbs  taken  by 
mouth  and,  thus,  could  represent  a  source  of  novel  therapeutic  agents  for  the  treatment 
of  diabetes  mellitus  that  are  easier  to  take  for  the  patient. 
147 The  study  of  diabetes  is  made  complex  by  the  fact  that  neither  the  in-vivo  nor  in- 
vitro  animal  models  can  provide  a  true  representation  of  the  range  of  the  human  diabetic 
conditions.  The  model  used  here,  the  STZ-induced  diabetic  rat,  has  been  put  forward  as 
an  animal  model  of  IDDM  in  humans  although  STZ  is  known  to  produce  some  NIDDM 
symptoms  such  as  pronounced  insulin  resistance  in  the  target  tissues.  Such  a  model  may 
provide  some  evidence  of  action  of  drugs  against  both  non-insulin-  and  insulin- 
dependent  diabetes  mellitus. 
In  order  to  study  the  potential  of  drugs  to  combat  diabetes  mellitus  and  to  obtain 
a  handle  on  the  possible  mechanisms  of  action  of  the  drugs,  it  is  necessary  to  look  for 
processes  that  are  controlled  by  the  hormones  involved  in  the  development  of  the 
disease  -  the  most  likely  candidates  being  insulin  and  glucagon.  Many  processes  of 
intermediary  metabolism  are  controlled  to  a  greater  or  lesser  extent  by  these  hormones 
including  carbohydrate,  protein  and  lipid  metabolism.  The  major  symptom  of  diabetes 
mellitus  is,  however,  a  raised  serum  glucose  level  and,  thus,  carbohydrate  metabolism 
could  be  considered  as  the  most  important  regulatory  process.  One  enzyme  involved  in 
carbohydrate  metabolism  is  glycogen  phosphorylase  a,  a  key  enzyme  in  the  regulation  of 
glycogen  metabolism,  has  been  shown  to  be  decreased  in  diabetic  rats  (Miller  et  al. 
1986).  In  STZ-diabetic  liver,  phosphorylase  (a  &  total  activities)  were  significantly 
lower  than  those  seen  in  the  normal  animals.  cAMP-dependent  protein  kinase  and 
phosphorylase  kinase  activities  also  show  substantial  reduction  during  the  fasted  to 
refed  transition  (Pugazhenthi  &  Khandelwal,  1991)  but  the  enzyme  activities  were 
restored  to  control  values  by  insulin  therapy  (Roester  &  Khandelwal,  1987,  Stude  & 
Ganeas,  1989).  In  an  in  vitro  study  it  was  clearly  demonstrated  that,  in  hepatocytes 
cultured  in  serum-free  medium,  insulin  decreased  the  activity  of  glycogen  phosphorylase 
(Hartmann,  et  al.  1987,  Lawrence  &  Zhag,  1994)  Glycogen  phosphorylase  a  activity  is, 
thus,  an  insulin-sensitive  enzyme  activity  and  can  be  used  to  measure  insulin-like 
activity.  In  this  study,  extracts  of  Artemisia  judaica,  Marrubium  vulgare  and  Anvillea 
carcinii  were  examined  for  their  potential  anti-diabetic  effects  in  the  STZ-diabetic  rat 
model,  on  isolated  rat  hepatocytes  using  glycogen  -  phosphorylase  a  activity  and 
metabolism  of  androst-4-ene-3,17-dione  (two  insulin-sensitive  enzyme  systems)  and  in 
diabetic  human  subjects.  Time  restraints  meant  that  most  work  was  concentrated  on 
Artemisia  judaica.  The  extract  of  Artemisia  judaica  was  give  to  the  animal  in  their 
148 drinking  water,  body  weight,  urine  volume  and  urine  glucose  and  food  and  fluid  intake 
were  monitored  daily.  In  normal  rat  treated  with  Artemisia  judaica  food  and  fluid  intake 
and  body  weight  were  not  changed  by  11  days  treatment  with  extract  of  Artemisia  but 
urine  volume  was  found  to  increase  suggesting  that  Artemisia  judaica  itself  acting  as  a 
mild  diuretic  which  may  be  due  to  the  presence  of  a  glucose-like  substance  in  the  urine 
of  normal  animals  following  exposure  to  Artemisia  extract  in  the  first  6  rats.  This  may 
be  the  substance  in  the  Artemisia  extract  that  reacts  in  the  glucose  assay  which  is  not 
reabsorbed  by  kidney.  Assay  of  Artemisia  extract  gives  glucose  readings  but  the  nature 
of  the  actual  substance  is  unknown  at  present. 
In  diabetic  rats  treated  with  Arterrmisia  judaica,  diabetes  was  induced  by 
administration  of  STZ  and  was  associated  with  the  characteristic  development  of 
hyperglycaemia,  hyperphagia,  polydipsia  and  loss  of  body  weight  and  after  treatment 
with  Artemisia  judaica  the  urine  glucose  level  was  decreased.  The  decrease  in  the 
presence  of  ketones  suggested  that  there  is  an  improvement  in  the  handling  or 
catabolism  of  lipids,  both  of  which  are  beneficial  in  diabetes.  From  the  results  of  the 
present  study  it  can  be  said  that  the  extract  exhibits  significant  anti-diabetic  effects  when 
administered  orally.  Similar  results  were  obtained  from  the  small  clinical  evaluation 
performed  in  this  project. 
Artemisia  extract  treatment  of  the  diabetic  animals  reversed  or  partially  reversed 
the  effects  of  diabetes  on  aniline,  aminopyrine  and  androst-4-ene-3,17-dione 
metabolism.  The  addition  of  Artemisia  extract  directly  to  microsomes  gave  some 
unexpected  results  with  a  significant  increase  in  aminopyrine  N-demethylation  and 
androst-4-ene-3,17-dione  metabolism  indicating  that  some  of  the  effects  of  the 
Artemisia  extract  may  be  direct  on  the  microsomal  enzymes  whereas  the  other  effects 
may  be  indirect  (e.  g.  that  on  aniline  metabolism).  It  is  reported  that  the  diabetic 
condition,  probably  via  generation  of  ketone  bodies,  can  elevate  aniline  metabolism.  The 
fact  that  Artemisia  treatment  reverses  this  effect  suggests  again  that  Artemisia  contains 
a  substance  or  mixture  of  substances  that  reverse  the  perturbation  of  intermediary 
metabolism  brought  about  by  diabetes  mellitus. 
Overall  the  in  vivo  experiments  show  that  crude  aqueous  extracts  of  Artemisia 
judaica  had  significant  anti-diabetic  properties  both  when  measured  as  effects  on  serum 
glucose  and  ketone  bodies  and  when  examining  the  changes  in  xenobiotic  and  steroid 
149 metabolism  known  to  occur  in  diabetes  mellitus.  These  results  suggested  that  it  was 
worth  examining  the  possible  mechanism  of  action  of  these  extracts  to  try  and  ascertain 
how  they  achieved  their  effects. 
It  is,  however,  very  difficult  to  examine  the  mechanism  of  action  of  drugs  at  the 
whole  animal  level  and,  thus,  a  better,  more  controllable  system  was  sought.  One  such 
system  that  has  been  well  studied  in  this  laboratory  when  looking  at  the  action  of 
hormones  is  the  isolated  rat  hepatocyte  model.  Here  hepatocytes  are  separated  from  the 
liver  and  kept  in  suspension  or  culture  for  up  to  12  days.  Potentially  active  substances 
can  be  added  to  the  cells  at  precise  concentrations  and  for  precise  periods  of  time,  thus 
allowing  a  greater  control  of  the  experimental  conditions.  By  measuring  the  activity  of 
some  insulin-sensitive  enzymes,  it  should  be  possible  to  examine  if  the  herbal  extracts 
have  any  insulin-like  activity.  To  this  end  glycogen  phosphorylase  a  and  androst-4-ene- 
3,17-dione  metabolism  were  examined  in  isolated  hepatocytes  treated  with  the  various 
plant  extracts. 
In  the  present  study  Artemisia  judaica,  Anvillea  carcinii  and  Marrubium 
vulgare  were  used  and  tested  for  their  ability  to  decrease  glycogen  phosphorylase  a  in 
normal  and  streptozotocin-induced  diabetes  rat  hepatocytes  as  a  measure  of  their 
insulin-like  action.  In  hepatocytes  isolated  from  normal  rats,  a  crude  extract  of 
Artemisia  judaica,  Anvillea  carcinii  and  Marrubium  vulgare  inhibited  the  activity  on 
glycogen  phosphorylase  a  but  when  insulin  was  added  together  with  crude  extracts  of 
Artemisia  judaica,  Anvillea  carcinii  and  Marrubium  vulgare,  the  activity  of  glycogen 
phosphorylase  a  was  decreased  more  than  with  the  extracts  alone,  These  three  plants, 
thus,  contain  (a)  substance(s)  which  can  act  synergistically  with  insulin  to  decrease 
glycogen  phosphorylase  a  activity  in  the  liver.  If  the  same  experiments  are  repeated  with 
hepatocytes  isolated  from  diabetic  rats  then  it  is  seen  that  the  cells  are  less  responsive  to 
hormones  and  to  the  plant  extracts  although  some  synergistic  effects  of  insulin  and  the 
plant  extracts  are  still  seen. 
If  the  crude  extract  of  Artemisia  judaica  is  sub-fractionated  by  extraction  with 
ethanol,  it  is  seen  that,  of  the  two  fractions,  the  water-soluble  fraction  retains  insulin-like 
actions  whilst  the  alcohol-soluble  fraction  shows  a  marked  glucagon  antagonistic  action 
and  little  insulin-like  activity.  There  are,  thus,  at  least  two  active  substances  in  the  crude 
extract  of  Artemisia  judaica.  More  work  needs  to  be  done  here  to  further  fractionate 
150 the  extract  and  eventually  arrive  at  an  active  fraction  with  one  (or  a  limited  number)  of 
constituent(s). 
It  is  seen  that  glucagon-inhibiting  action  of  the  extract,  thus,  residues  primarily 
in  the  ethanolic-soluble  fraction,  whereas  the  insulin-enhancing  substance(s)  are  split 
between  the  water-and  ethanolic-soluble  fractions,  which  suggested  future  work  to 
continue  by  trying  to  purify  the  active  ingredients  from  the  aqueous  and  ethanolic 
extracts. 
The  results  from  the  androst-4-ene-3,17-dione  assay  were  disappointing  given 
that  Hussin  &  Skett.  (1987)  had  previously  shown  a  marked  effect  of  insulin  on  these 
enzymes.  No  effect  of  insulin,  Artemisia  judaica  and  insulin  with  Artemisia  extract  was 
seen  on  any  steroid  metabolisms  enzyme  activity  studied  and,  indeed,  a  significant 
decrease  was  seen  with  Artemisia  judaica  and  insulin.  Changing  the  preincubation 
period,  changing  the  incubation  medium,  testing  different  types  of  insulin  with  extract 
and  altering  the  weight  and  age  of  the  animals  gave  no  different  results.  We  did  not  find 
any  positive  results  with  Artemisia  extract  or  the  other  plant  extract,  Marrubium 
vulgare  and  Anvillea  carcinii  in  different  concentration  and  at  different  times.  The  very 
limited  clinical  studies  possible  during  this  time  period  were  encouraging  showing  that 
the  crude  extract  of  Artemisia  judaica  appeared  to  reduce  the  amount  of  insulin  needed 
to  maintain  a  steady  serum  glucose  level  and,  in  some  cases,  could  replace  more 
conventional  anti-diabetic  treatment.  Much  more  in  the  way  of  clinical  studies,  including 
double-blind  testing  of  plant  extracts  would  be  necessary,  however,  before  any  definite 
conclusions  could  be  drawn  about  the  potential  of  these  plant  extracts  to  be  used  as 
treatments  of  diabetes  mellitus. 
In  summary,  this  project  has  shown  that  traditional  herbal  treatments  of  diabetes 
mellitus  in  use  in  Libya  today  (and  over  many  years)  do  have  some  basis  in  scientific 
fact.  The  extracts  do  appear  to  be  beneficial  in  diabetic  patients  as  claimed  and  do  have 
some  anti-diabetic  effects  in  a  rat  model  system  of  diabetes  mellitus  although  the  results 
are  not  as  striking  in  this  study  as  they  were  in  a  previous  unpublished  study  from  this 
laboratory.  On  examining  some  insulin-sensitive  enzymes  in  the  isolated  rat  hepatocytes, 
it  was  found  that  extracts  of  Artemisia  judaica,  Marrubium  vulgare  and  Anvillea 
carcinii,  all  contained  substances  that  either  mimicked  insulin,  antagonised  glucagon  or 
acted  synergistically  with  insulin  in  affecting  the  enzymes  studied.  The  extracts,  thus, 
151 have  many  possible  ways  in  which  they  could  be  acting  as  anti-diabetics,  remembering 
that  these  studies  only  involved  the  examination  of  liver  enzymes. 
Future  work  must  concentrate  in  a  number  of  areas;  one,  isolation  and 
identification  of  the  active  principle(s)  of  the  extracts,  two,  closer  investigation  of  the 
mechanism  of  action  of  the  extracts  on  the  liver  to  give  anti-diabetic  effects  including 
where  in  the  cells  the  substances  act  (at  the  receptor,  at  the  level  of  the  second 
messenger(s)  or  directly  on  the  target  enzymes)  and  three,  do  these  extracts  have  any 
potential  anti-diabetic  effects  on  any  other  insulin-  or  glucagon-sensitive  tissue.  A  start 
has  been  made  to  examine  these  potentially  life-saving  herbal  plants  but  a  great  deal 
more  needs  to  be  done  before  they  can,  perhaps,  realise  their  potential  as  a  new  breed  of 
treatments  for  diabetes  mellitus. 
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